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SUMMARY	 5	
SUMMARY		The	 hepatic	 serum	 glycoprotein	 fetuin-A	 plays	 a	 role	 in	 mineralized	 matrix	metabolism.	It	prevents	unwanted	ectopic	calcification	by	stabilizing	the	amorphous	phase	of	calcium	phosphate	and	facilitating	excess	mineral	clearance.	Fetuin-A	is	one	of	 the	most	highly	abundant	non-collagenous	proteins	 in	bone.	As	Ahsg-/-	mice	have	shortened	 femoral	 bones,	 fetuin-A	 plays	 an	 important	 role	 in	 endochondral	ossification.	However,	 the	underlying	mechanisms	are	yet	unknown.	Earlier	 studies	explained	 the	 shortened	 femora	 as	 a	 lack	 of	TGF-β	 antagonization	or	 as	 premature	growth	plate	mineralization.		In	 this	 study,	 I	 first	 hypothesized	 that	 fetuin-A	 regulates	 endochondral	ossification	 through	 retinoic	 acid	 signaling,	 as	 retinoic	 acid	 intoxication	 leads	 to	growth	plate	closure,	especially	in	the	femur.	Using	a	postnatal	bone	culture	system,	the	 effect	 of	 fetuin-A	 and	 all-trans-retinoic	 acid	 (ATRA)	 on	 bone	 growth	 was	investigated.	 Treatment	 of	 bones	 with	 ATRA	 alone	 led	 to	 growth	 plate	 cartilage	degradation;	a	combination	of	ATRA	and	fetuin-A	led	to	an	increased	degradation	to	the	 point	 of	 cartilage	 detachment.	 This	 indicated	 that	 fetuin-A	might	 play	 a	 role	 in	cartilage	 degradation,	 but	 it	was	not	 clear	 how,	 if	 at	 all,	 fetuin-A	 regulated	 retinoic	acid	signaling	in	cartilage.		In	 histological	 sections	 from	 cultured	 bones,	 I	 discovered	 that	 bones	 from	fetuin-A	 deficient	 mice	 had	 elongated	 hypertrophic	 zones	 in	 their	 growth	 plates.	Histological	 sections	 of	 eight	 weeks	 old	 mice	 showed	 that	 growth	 plates	 of	
Ahsg-/-	 mice	 were	 grossly	 disordered	 and	 deformed.	 In	 order	 to	 gain	three-dimensional	 information	 of	 growth	 plate	morphology,	 bones	 were	measured	using	 µCT.	 Three-dimensional	 reconstructions	 of	 bones	 from	 eight	weeks	 old	mice	revealed	that	the	distal	 femora	were	displaced	and	deformed	and	the	growth	plates	showed	an	angular	deformation.	Histological	 examination	 of	 bones	 from	 mice	 of	 different	 ages	 showed	 that,	starting	 from	 three	 weeks	 of	 age,	 growth	 plates	 of	 both	 homo-	 and	 heterozygous	fetuin-A	deficient	mice	had	lesions	and	were	invaded	by	foreign	cells.	At	eight	weeks	of	age,	lesions	in	the	growth	plates	of	Ahsg-/-	mice	had	healed,	partially	by	bone	bridge	formation,	 and	 growth	 plate	 architecture	 was	 distorted.	 Interestingly,	 in	heterozygous	 Ahsg+/-	mice,	 growth	 plates	 were	 either	 inconspicuous,	 or	 contained	cavities	 which	 were	 lined	 with	 cellular	 infiltrate,	 although	 Ahsg+/-	 mice	 never	developed	the	dysplasia.		A	 microarray	 analysis	 of	 growth	 plates	 from	 13	 days	 old	 mice	 revealed	 a	 strong	immune	response	in	Ahsg-/-	mice.	A	comparison	to	the	Interferome	database	showed,	that	a	huge	amount	of	the	upregulated	genes	were	regulated	through	either	a	type	I	or	a	type	II	interferon	response.	I	therefore	hypothesize	that	fetuin-A	plays	an	anti-inflammatory	role	in	endochondral	ossification	 and	 the	 dysplasia	 in	 Ahsg-/-	mice	 is	 a	 consequence	 of	 an	 inflammatory	response	 in	 the	 growth	 plate,	 which	 leads	 to	 cellular	 infiltration,	 mechanical	weakening	 of	 growth	 plate	 cartilage	 and	 angular	 deformation	 of	 the	 distal	 femoral	growth	plate.	
	 	
ZUSAMMENFASSUNG	 7	
ZUSAMMENFASSUNG		Das	 hepatische	 Serum-Glykoprotein	 Fetuin-A	 spielt	 eine	 wichtige	 Rolle	 im	Metabolismus	mineralisierter	Matrix.	Durch	Stabilisierung	der	amorphen	Phase	von	Kalziumphosphat	 begünstigt	 es	 die	 Clearance	 von	 überschüssigem	 Mineral	 und	verhindert	 somit	 ektope	 Kalzifizierungen.	 Im	 Knochen	 ist	 Fetuin-A	 eines	 der	häufigsten	 Nichtkollagen-Proteine.	 Da	 Ahsg-/-	Mäuse	 verkürzte	 Femora	 aufweisen	Fetuin-A,	 ist	wichtig	 für	 die	 enchondrale	 Ossifikation.	 Der	 hier	 zu	 Grunde	 liegende	Mechanismus	ist	 jedoch	noch	unbekannt.	Frühere	Studien	haben	sowohl	mangelnde	TGF-β-Antagonisierung,	 als	 auch	 vorzeitige	 Wachstumsfugen-Mineralisierung	 als	Gründe	für	die	Verkürzung	der	Femora	in	Ahsg-/-	Mäusen	genannt.	In	der	hier	vorliegenden	Studie	habe	ich	zunächst	die	Hypothese	aufgestellt,	dass	Fetuin-A	 das	 Knochenwachstum	 durch	 den	 Retinsäure-Signalweg	 reguliert,	 da	 eine	Retinsäure-Intoxikation	 zu	 vorzeitiger	 Schließung	 der	 Wachstumsfugen,	 besonders	im	 Femur,	 führt.	 Der	 Effekt	 von	 all-trans-Retinsäure	 (ATRA)	 und	 Fetuin-A	 auf	 das	Knochenwachstum	wurde	mit	Hilfe	 von	Knochenkultur	untersucht.	Die	Behandlung	der	Knochen	mit	ATRA	führte	zu	einer	Degradierung	des	Wachstumsfugen-Knorpels	und	 diese	 Degradierung	wurde	 sichtbar	 stärker	 bei	 einer	 zusätzlichen	 Behandlung	mit	 Fetuin-A.	 Dies	 ließ	 darauf	 schließen,	 dass	 Fetuin-A	 die	 Knorpel-Degradierung	reguliert.	Es	 ließ	sich	allerdings	nicht	 feststellen,	ob	und	auf	welche	Weise	Fetuin-A	den	Retinsäure-Signalweg	im	Knorpel	reguliert.		Histologisch	wiesen	neugeborene	Ahsg-/-	Mäuse	verlängerte	hypertrophe	Zonen	auf.	 Histologische	 Schnitte	 von	 Femora	 acht	 Wochen	 alter	 Mäuse	 zeigten	 stark	deformierte	 und	 ungeordnete	 Wachstumsfugen.	 Um	 die	 Morphologie	 der	Wachstumsfugen	drei-dimensional	zu	beurteilen,	wurden	µCT	Analysen	der	Femora	durchgeführt.	Rekonstruktionen	acht	Femora	alter	Knochen	zeigten,	dass	der	distale	Femur	disloziert	und	Wachstumsfugen	deformiert	waren.		Weitere	histologische	Untersuchungen	zeigten,	dass	bereits	in	drei	Wochen	alten,	sowohl	 Ahsg-/-	 	 als	 auch	 Ahsg+/-	 	 Mäusen,	 die	 Wachstumsfugen	 Läsionen	 aufwiesen	und	 von	 fremden	 Zellen	 infiltriert	 waren.	 Bei	 acht	 Wochen	 alten	 Ahsg-/-	Mäusen	waren	 die	 Läsionen	 verheilt	 und	 die	 Wachstumsfugen	 waren	 ungeordnet	 und	teilweise	 verknöchert.	 Interessanterweise	 waren	 die	 Wachstumsfugen	 von	 acht	Wochen	 alten	 Ahsg+/-	 Mäusen	 entweder	 unauffällig,	 oder	 sie	 enthielten	 große	Kavitäten	welche	mit	Zell-Infiltrat	ausgekleidet	waren,	obwohl	Ahsg+/-	Mäuse	niemals	eine	Dysplasie	entwickelten.		Eine	Microarray-Analyse	 der	Wachstumsfugen	 13	 Tage	 alter	Mäuse	 zeigte	 eine	starke	Immunreaktion	in	Ahsg-/-	Mäusen.	Ein	Abgleich	mit	der	Interferome	Database	verdeutlichte,	dass	 ein	großer	Teil	 der	hochregulierten	Gene	durch	eine	Typ	 I	 oder	Typ	II	Interferon-Antwort	reguliert	werden.		Fetuin-A	 spielt	 daher	 vermutlich	 eine	 anti-inflammatorische	 Rolle	 in	 der	enchondralen	Ossifikation	und	die	Dysplasie	 in	Ahsg-/-	Mäusen	ist	das	Resultat	einer	Inflammatorischen	Reaktion	in	der	Wachstumsfuge,	welche	zur	zellulären	Infiltration,	mechanischen	Schwächung	und	Deformierung	der	Wachstumsfuge	im	distalen	Femur	führt.	
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! INTRODUCTION	
 
1.1 Fetuin-A		During	 a	 study	 on	 serum	 fractionation	 in	 ./00,	 Kai	 Pedersen	 discovered	 a	 globular	protein,	 which	 was	 highly	 abundant	 in	 serum	 from	 newborn	 calves	!.	 	 As	 its	concentration	 decreased	 with	 the	 age	 of	 the	 animal,	 Pedersen	 concluded	 that	 this	protein	 was	 associated	 with	 developmental	 processes	 and	 had	 its	 highest	concentration	in	the	fetus.	Consequently,	he	dubbed	this	protein	“fetuin”.	The	human	homologue	of	fetuin	was	discovered	in	5678/75	by	Heremans	!	and	independently	 by	 Schmid	 and	 Bürgi	!	 but	 its	 homology	 to	 bovine	 fetuin	 was	 not	identified	 until	 *++,	!.	 Human	 fetuin	 was	 named	α!-Heremans-Schmid-glycoprotein	(α!-HS)	 in	 honor	 of	 its	 discoverers.	 Its	 name	 also	 indicates	 that	 fetuin	 co-migrates	with	the	α!-fraction	of	serum	proteins	in	electrophoresis.	Accordingly,	the	gene	name	for	fetuin	is	Ahsg	in	mice	and	AHSG	in	humans.	Until	now,	several	fetuin	homologues	have	been	described	in	reptiles,	fish,	birds,	marsupials,	and	mammals	!.	Since	 the	 year	 ,---	 scientists	 distinguish	 between	 two	 structurally	 similar,	 yet	functionally	unrelated	fetuins,	namely	fetuin-A	and	fetuin-B	!.	Both	fetuins	belong	to	the	cystatin	superfamily	of	proteins	!	and	the	genes	for	fetuin-A	and	B	are	located	next	to	 each	 other	 in	 all	 mammalian	 genomes.	 Due	 to	 structural	 similarities,	 fetuin-A	and	-B	co-purified	as	a	mixture,	and	thus	may	be	confused	 in	 literature	before	'()*,	when	 this	phenomenon	was	 first	described	 !.	Female	 fetuin-B	deficient	mice,	which	were	 established	 in	 our	 group,	 are	 fully	 infertile	!.	 Fetuin-B	 is	 an	 inhibitor	 of	 the	astacin	 protease	 ovastacin.	 Ovastacin	 cleaves	 the	 zona	 pellucida	 sperm-binding	protein	 )	 (ZP))	 of	 the	 oocyte	 and	 in	 this	manner	 induces	definitive	 zona	 pellucida	hardening	after	fertilization.	Premature	zona	pellucida	hardening	in	fetuin-B	deficient	female	 mice	 prevents	 sperm	 penetration	 into	 the	 oocyte	 and	 therefore	 leads	 to	infertility.	 Fetuin-A	 however,	 has	 no	 role	 in	 fertilization	 biology	 and	 acts	 through	different	molecular	mechanisms,	which	are	not	yet	fully	understood.	Fetuin-A	is	expressed	by	liver	hepatocytes	at	high	concentrations,	secreted	into	the	bloodstream	and	is	hence	present	in	all	vascularized	tissues	!.	The	normal	serum	
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fetuin-A	concentration	in	human	adults	is	around	(.*	to	(.,	mg/ml	!".	In	young	mice,	the	serum	fetuin-A	concentration	amounts	up	to	&	mg/ml	and	decreases	with	age	!!.	The	fetuin-A	protein	consists	of	two	cystatin	domains	D3,	D5	and	a	third	domain	D!.	Fetuin-A	belongs	to	the	type	!	cystatin	superfamily	together	with	fetuin-B,	histidin	rich	 glycoprotein	 (HRG)	 and	 kininogen	 (KNG)	!.	 Domain	 D)	 contains	 a	 cluster	 of	mainly	 negatively	 charged	 amino	 acid	 residues,	 which	 enables	 binding	 to	 calcium	phosphate	mineral.	 Amino	 acid	 residues	 001-!"#	 contain	 a	 TGF-β	binding	 loop	with	sequence	 similarities	 to	 the	 TGF-β	 receptor	 II	 (TGFβRII)	!".	 Fetuin-A	 undergoes	several	 post-translational	 modifications:	 complex	 glycosylation	!",!$,	phosphorylation	!"–!"	and	sulfation	!",$%.	The	human	fetuin-A	homologue	α!-HS	consists	of	 two	 chains,	 a	 heavy	A	 chain	 and	 a	 light	 B	 chain,	which	 are	 connected	 through	 a	disulfide	 bridge.	 Human	 fetuin-A	 is	 proteolytically	 processed,	 whereby	 a	 so-called	connecting	peptide	is	released	from	the	heavy	chain	!",!!.	Both	chains	are	derived	from	a	single	mRNA	!".	The	human	AHSG	gene	is	localized	on	chromosome	!	!".	The	fetuin-A	homologues	 of	 all	 other	 species	 including	 mouse,	 consist	 of	 a	 single	 peptide.	 The	mouse	fetuin-A	gene	is	located	on	chromosome	12.		The	 fetuin-A	gene	contains	C/EBP	(CCAAT/enhancer-binding	protein)	and	NF0	(nuclear	 factor	 -)	 binding	 sites	 for	 basal	 transcription	!"	 and	 a	 steroid	 control	 unit	mediating	 glucocorticoid	 induced	 upregulation	 of	 mRNA	 transcription	!".	Downregulation	of	 fetuin-A	occurs	upon	 inflammatory	 cues	!",!$.	Hepatocyte	 growth	factor	(HGF)	increases	fetuin-A	expression	in	vitro	and	in	vivo	!".	Single	 nucleotide	 polymorphisms	 (SNPs)	 in	 the	 human	 fetuin-A	 gene	 were	utilized	for	genetic	and	forensic	studies	!"–!!.	Two	common	polymorphisms	have	been	identified,	 dubbed	AHSG*0	 and	AHSG*2,	 and	 several	 other	 rare	 variants	 exist	!".	 The	AHSG*&	 phenotype	 is	 characterized	 by	 ACG	 (Thr)	 at	 position	 ;<=	 and	 ACC	 (Thr)	 at	position	()*,	while	 the	AHSG*(	phenotype	 is	 associated	with	ATG	 (Met)	 at	position	!"#	 and	 AGC	 (Ser)	 at	 position	 !"5.	 The	 SNPs	 in	 AHSG*!	 phenotype	 result	 in	 the	formation	of	a	SacI	and	an	NlaIII	restriction	site.	Also,	several	other	SNPs	were	found	in	the	human	AHSG	gene.	Most	notably,	the	SNP	rs##$%&'(	in	the	promoter	region	of	the	AHSG	gene	was	shown	to	aﬀect	AHSG	gene	expression	levels	and	serum	fetuin-A	concentration	 !".	 Also,	 SNPs	 in	 rs./01	 and	 rs./04	 have	 previously	 been	 associated	with	differences	in	α!-HS	protein	levels	!".	
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Many	 different	 biological	 roles	 have	 been	 proposed	 for	 fetuin-A.	 The	 following	paragraphs	 summarize	 the	 existing	 literature	 on	 the	 most	 important	 functions	 of	fetuin-A.	Figure	(	shows	a	schematic	overview	of	the	biological	roles	of	fetuin-A.		
	
Figure	!:	Multiple	proposed	roles	of	fetuin-A.	TGF-β/BMP	binding	has	been	demonstrated	in	vitro	!".	Recently	it	was	 reported	 that	 fetuin-A	 is	 associated	 with	 lipid-induced	 insulin	 resistance	!".	 Fetuin-A	 binds	 lipids	 and	increases	 lipid	 uptake	 and	 signaling	 in	 cells	!"–!".	 Calciprotein	 particles	 (CPPs)	 are	 cleared	 by	 liver	 and	 spleen	macrophages	!",!$.	 Fetuin-A	 alone	 can	 also	 be	 internalized	 by	 cells,	 for	 instance	 by	 VSMC	!",!$.	 Reproduced	 from	Brylka	et	al.	!!.		
1.1.1 Fetuin-A	and	the	Immune	System		Fetuin-A	 is	 a	 negative	 acute	 phase	 protein	 in	 humans,	 rats	 and	 mice	!".	 It	 is	downregulated	 by	 inflammatory	 cytokines	 such	 as	 interleukin	 %	 (IL%)	 and	 tumor	necrosis	 factor	α	 (TNF-α)	!"	 through	 a	 cytokine-responsive	 element	 in	 the	 fetuin-A	promoter	!".	Opsonic	properties	of	human	fetuin-A	were	first	described	in	&'()	by	van	Oss	
et	al.	!"	 after	 the	 authors	 discovered	 that	 fetuin-A	 levels	 were	 lowered	 in	 trauma	patients.	They	showed	that	human	fetuin-A	significantly	enhanced	the	phagocytosis	of	
E.	coli	and	S.	aureus	by	human	neutrophils	 in	vitro.	 Others	 also	 reported	 enhancing	properties	 of	 fetuin-A	 on	 the	 uptake	 of	 latex	 particles	!"	 and	 apoptotic	 cells	!",	although	 the	 uptake	 of	 latex	 particles	 was	 shown	 not	 to	 occur	 through	 classic	opsonization	!".	Other	studies	showed	that	fetuin-A	acted	as	a	chemotactic	agent	for	
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human	monocytes	!",$%,	 and	might	 thus	 play	 a	 role	 in	 the	 recruitment	 of	 osteoclast	precursor	cells	to	bone.	A	study	by	Wang	and	colleagues	demonstrated	that	fetuin-A	suppressed	TNF-α	released	 from	 lipopolysaccharide	 (LPS)	 stimulated	 macrophages	 by	 facilitating	 the	uptake	of	spermine	by	macrophages	!".	Spermine	is	a	ubiquitous	polyamine	released	from	 dying	 or	 injured	 cells	 and	 bound	 to	 the	 sialic	 acid	 residues	 on	 fetuin-A.	 The	resulting	 fetuin-spermine	 complex	 inhibited	 TNF-α	 production	 by	 macrophages	!".	This	mechanism	might	be	 important	during	pregnancy;	both	 fetuin-A	and	spermine	are	 present	 in	 the	 fetus	 at	 high	 abundance	 and	 fetuin-A	 would	 attenuate	 TNF-α	release	 during	 pregnancy	 and	 thus	 decrease	 the	 likelihood	 of	 abortion.	 Indeed,	fetuin-A	administration	to	pregnant	rats	could	prevent	LPS-induced	abortion	!".	Wang	
et	 al.	 demonstrated	 that	 fetuin-A	 mediated	 the	 uptake	 of	 the	 cationic	macrophage-deactivating	molecule	CNI-!"#$	and	concluded	that	fetuin-A	is	important	for	 the	 opsonization	 of	 cationic	 molecules,	 both	 endogenous	 (spermine)	 and	pharmacologic	 (CNI-!"#$).	 Furthermore,	 in	 an	 LPS-independent	 model	 of	carrageenan-induced	 inflammation	 in	 the	 paws	 of	 rats,	 fetuin-A	 administration	attenuated	 paw	 edema	 development	 and	 TNF-α	 production	!".	 A	 recent	 study	 on	D-galactosamine/LPS-induced	 liver	 failure	 showed	 that	 intraperitoneal	 injection	 of	fetuin-A	prior	to	induction	of	liver	failure	attenuated	TNF-α	and	IL-!	production	and	improved	 liver	 function	!!.	 Li	 and	 colleagues	demonstrated	 the	 attenuation	of	 lethal	systemic	 inflammation	 by	 fetuin-A	!".	 Genetic	 ablation	 of	 the	 fetuin-A	 gene	 reduced	survival	rates	of	mice	upon	lethal	systemic	inflammation	or	endotoxemia.	Conversely,	supplementation	of	fetuin-A	increased	survival	rates.	Fetuin-A	supplementation	led	to	decreased	 levels	 of	 circulating	 High-Mobility-Group-Protein	 B*	 (HMGB*).	 HMGB*	 is	released	by	macrophages	or	necrotic	cells	and	 functions	as	a	 late	mediator	of	 lethal	systemic	 inflammation.	 Elevated	 HMGB+	 levels	 can	 be	 found	 in	 patients	 with	sepsis-induced	 organ	 failure	 but	 also	 in	 synovial	 fluid	 of	 rheumatoid	 arthritis	patients	!",!$.	Notably,	the	administration	of	fetuin-A	as	a	treatment	for	lethal	systemic	inflammation	in	mammals	was	patented	!".		
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1.1.2 The	Role	of	Fetuin-A	in	Insulin	Resistance		Recently,	a	publication	by	Pal	et	al.	proposed	a	molecular	mechanism	for	the	role	of	fetuin-A	in	insulin	resistance	!".	The	study	claimed	that	fetuin-A	enables	the	binding	of	free	 fatty	acids	 to	 toll-like	 receptor	&	 (TLR&),	 leading	 to	 lipid-induced	 inflammation	and	consequently	reduced	insulin	sensitivity.	A	 connection	 between	 fetuin-A	 and	 insulin	 resistance	 had	 already	 been	established	 previously.	 In	 4565,	 Auberger	 et	 al.	 discovered	 pp+,,	 a	 rat	 protein	 that	inhibited	the	insulin	receptor	tyrosine	kinase	(IRTK)	in	vitro	!".	The	protein	pp,-	was	then	 identified	 as	 the	 rat	 homologue	 of	 fetuin-A	!".	 Subsequently,	 also	 the	 human	fetuin-A	homologue	α!-HS	was	found	to	be	an	inhibitor	of	the	IRTK	 in	vitro	!".	 It	was	shown	that	recombinant	human	fetuin-A	did	only	aﬀect	mitogenic,	but	not	metabolic	eﬀects	 of	 the	 insulin	 receptor	!",!$.	 In	 another	 study	 using	 recombinant	 human	fetuin-A,	 insulin	 autophosphorylation	 was	 decreased	 by	 23	%	 in	 fibroblasts	overexpressing	 the	 rat	 insulin	 receptor	!".	 Additionally,	 injection	 of	 recombinant	human	 fetuin-A	 through	 the	 portal	 vein	 in	 rats	 inhibited	 insulin-stimulated	 IRTK	autophosphorylation	 in	 liver	 and	 hindlimb	muscle.	 The	 recombinant	α!-HS	used	 in	this	 and	other	 studies	was	produced	via	baculovirus	 in	 insect	 cells.	Kalabay	et	al.	!"	showed	that	baculoviral	fetuin-A	from	insect	cells	was	phosphorylated	and	possessed	a	 connecting	peptide	between	 the	A	 and	B	 chain.	 In	 contrast,	 fetuin-A	 from	normal	human	plasma	was	 only	 partially	 phosphorylated	 and	did	 not	 contain	 a	 connecting	peptide	!",$%.		In	rat	adipocytes,	overexpression	of	human	fetuin-A	did	not	lead	to	inhibition	of	 IRTK	 phosphorylation,	 however	 an	 inhibition	 of	 insulin-stimulated	 and	 basal	phosphorylation	of	elk-!	was	observed	!!,	which	points	to	a	decreased	IRTK	activity.	In	!""#,	 also	 mouse	 fetuin-A	 was	 shown	 to	 inhibit	 IRTK	 autophosphorylation	!".	Consequently,	in	fetuin-A	deficient	mice,	IRTK	phosphorylation	was	increased	in	liver	and	skeletal	muscle	!",!$.	Additionally,	these	mice	had	a	higher	insulin	sensitivity	and	glucose	clearance.	On	a	high	fat	diet,	they	were	resistant	to	weight	gain,	had	lower	fat	and	remained	insulin	sensitive.	A	large	number	of	clinical	studies	also	showed	a	positive	correlation	between	fetuin-A	 blood	 levels	!"–!",	 and	 certain	 fetuin-A	 polymorphisms	!",$$–!"	 with	 insulin	
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resistance	and	the	risk	of	diabetes	type	!.	In	contrast	to	most	cell,	animal	and	clinical	correlation	studies	claiming	a	role	for	 fetuin-A	 in	 insulin	 sensitivity,	 our	 laboratory	 could	 never	 reproduce	 the	 finding	that	 fetuin-A	inhibits	IRTK	autophosphorylation	and	that	 fetuin-A	deficient	mice	are	protected	from	insulin	resistance	!".		
1.1.3 Fetuin-A	and	Lipid	Transport		Kumbla	 et	 al.	 demonstrated	 that	 fetuin-A	 from	 commercial	 preparations	 was	associated	with	a	variety	of	lipids,	mainly	cholesterol,	cholesteryl	ester,	triglycerides,	and	 free	 fatty	acids	!".	Using	ultracentrifugation,	 a	 fraction	could	be	detected,	which	contained	the	majority	of	the	lipids	associated	with	fetuin-A.	This	fraction	was	in	the	density	range	of	high-density	lipoprotein	(HDL).	Fetuin-A	 increased	 the	 uptake	 of	 fatty	 acids	 into	 fetal	 rabbit	 aortic	 smooth	muscle	 cells	 and	 human	 fetal	 skin	 fibroblasts	 in	 vitro	!".	 Furthermore,	 fetuin-A	containing	 lipoprotein-like	 particles	 caused	 a	 significant	 eﬄux	 of	 cholesterol	 from	cells	in	the	same	magnitude	as	HDL	!".	Intriguingly,	apolipoprotein	E	(ApoE)	/	fetuin-A	double	deficient	mice	on	a	high-fat	Mediterranean	diet,	in	contrast	to	single	deficient	
ApoE-/-	control	mice,	developed	severe	dyslipidemia,	corroborating	a	role	of	fetuin-A	in	lipid	metabolism	!".		
1.1.4 Fetuin-A	Is	a	Mineral	Chaperone	and	a	Systemic	Inhibitor	of	
Calcification			Fetuin-A	is	one	of	the	most	abundant	non-collagenous	proteins	in	bone	and	dentine,	enriched	)*	to	-**-fold	with	respect	to	other	plasma	proteins	!".	This	accumulation	is	due	 to	 the	 high	 aﬃnity	 of	 fetuin-A	 to	 calcium	phosphate	mineral.	 Triﬃtt	 et	al.	 first	demonstrated	 this	 by	 investigating	 the	 binding	 of	 serum	 fetuin-A	 to	 precipitates	 of	calcium	 phosphate	 in	 vitro	!".	 All	 serum	 fetuin-A	 completely	 bound	 to	 the	 calcium	phosphate	precipitates	and	fetuin-A	was	found	to	be	concentrated	up	to	123-fold	with	respect	to	albumin.	Our	group	studied	fetuin-A	in	osteoblast	mineralization	in	vitro,	to	investigate	 its	 role	 in	 cell-mediated	 bone	 mineralization	!".	 While	 osteoblasts	
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produced	 mineralized	 bone	 nodules	 in	 the	 presence	 of	 fetuin-A,	 in	 its	 absence	dystrophic	calcification	led	to	massive	apoptosis.	This	study	was	the	first	to	indicate	that	fetuin-A	regulates	the	de	novo	formation	of	calcium	phosphate	mineral.	To	 confirm	 the	 in	 vivo	 relevance	 of	 the	 role	 of	 fetuin-A	 in	 biomineralization,	fetuin-A	 deficient	 Ahsg-/-	 mice	 were	 generated.	 For	 technical	 reasons,	 the	 fetuin-A	knockout	was	first	created	on	a	mixed	!"#/Sv	x	C*+BL/.	genetic	background	!!.	In	the	serum	of	these	mice,	the	inhibition	of	apatite	formation	was	severely	decreased,	and	some	homozygous	Ahsg-/-	female	ex-breeders	developed	ectopic	microcalcifications	in	soft	tissues,	corroborating	a	role	for	fetuin-A	in	systemic	calcification	inhibition.	In	 $%%&,	 the	 underlying	 mechanism	 of	 mineralization	 inhibition	 by	 fetuin-A	was	discovered.	 Fetuin-A	 sequesters	 calcium	phosphate	prenucleation	 clusters	with	its	 acidic	β-sheet	!",	which	 leads	 to	 the	 formation	 of	 so	 called	 calciprotein	 particles	(CPPs).	 Formation	 and	 biological	 role	 of	 CPPs	 are	 discussed	 in	 more	 detail	 in	section	!.!.#.	Fetuin-A-deficient	 mice	 were	 backcrossed	 to	 two	 pure	 genetic	 backgrounds,	C"#BL/'	 and	 DBA/.,	 as	 the	 latter	 is	 known	 to	 be	 prone	 to	 develop	 ectopic	calcifications.	On	a	C./BL/3	background,	Ahsg-/-	mice	calcified	only	when	challenged	with	 heminephrectomy	 and	 a	 high	 mineral	 diet	!",!!.	 On	 the	 calcification	 sensitive	DBA/%	 background,	 Ahsg-/-	 mice	 spontaneously	 developed	 severe	 soft	 tissue	calcifications	!"".	 Ectopic	 calcifications	 first	 appeared	 in	 the	 brown	 adipose	 tissue,	later	also	in	lung,	heart,	tongue,	skin,	kidney,	and	the	reproductive	organs.	We	now	know,	that	the	calcification	proneness	of	DBA/7	mice	 is	a	compound	phenotype	caused	by	fetuin-A	deficiency,	a	hypomorphic	mutation	of	the	Abcc$	(ATP-binding	 cassette	 sub-family	 C	 member	 ,)	 gene,	 and	 a	 magnesium	 handling	 defect	caused	by	the	TRPM0	magnesium	channel	(unpublished	work).	In	the	Abcc$	gene,	a	missense	 mutation	 results	 in	 an	 alternative	 splice	 variant	 and	 consequently	 only	about	half	of	 the	Abcc)	protein	 is	expressed	!"!–!"#.	A	mutation	 in	 the	ABCC$	gene	 in	humans	 is	 responsible	 for	 pseudoxanthoma	 elasticum	 (PXE),	 leading	 to	 the	calcification	of	elastic	fibers	!"#.	ABCC!	is	a	putative	transport	protein	with	unknown	ligand,	and	 its	absence	results	 in	soft	 tissue	calcification	!"#.	 Interestingly,	 soft	 tissue	calcification	 in	ABCC!-deficient	mice	could	be	 rescued	by	hepatic	overexpression	of	fetuin-A	!"#.	Notably,	a	clinical	study	showed	that	fetuin-A	serum	levels	were	reduced	
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in	 PXE	 patients	 compared	 to	 their	 unaﬀected	 relatives	!"#.	 Additionally,	 DBA/0	mice	have	 lowered	 blood	magnesium	 levels	!"".	 Magnesium	 can	 substitute	 for	 calcium	 in	calcium	 phosphate	minerals,	 thus	 inhibiting	mineral	 precipitation.	Accordingly,	 low	magnesium	 blood	 levels	 are	 associated	 with	 increased	 cardiovascular	 mortality	 in	CKD	 patients	!"#.	 To	 sum	 up,	 the	 combination	 of	 fetuin-A	 deficiency	 with	 reduced	levels	 of	 other	 systemic	 calcification	 inhibitors,	 in	 this	 case	ABCC6	and	magnesium,	leads	 to	 extensive	 soft	 tissue	 calcifications,	 corroborating	 the	 role	 of	 fetuin-A	 as	 a	systemic	inhibitor	of	ectopic	calcification	(unpublished).	Recently,	we	discovered	that	calcifications	in	DBA/8-Ahsg-/-	mice	first	 form	as	precipitates	 the	 lumen	of	microvessels	 (unpublished)	which	 contradicts	 the	general	notion	 in	 the	 biomineralization	 field	 that	 ectopic	 calcification	 is	 primarily	 a	cell-mediated	process	reminiscent	of	bone	formation.	A	 role	 for	 fetuin-A	 in	 pathological	 mineralization	 in	 the	 context	 of	cardiovascular	pathologies,	especially	atherosclerosis,	has	been	found	in	both,	in	vitro	and	clinical	studies.	Reynold	et	al.	demonstrated	 that	 fetuin-A	 inhibited	calcification	of	vascular	 smooth	muscle	 cells	 (VSMC)	 in	vitro	!",!$.	Under	mineralizing	 conditions,	VSMC	mineralization	 was	 mediated	 through	 shedding	 of	 mineralization	 competent	matrix	 vesicles	 and	 vesicles	 from	 apoptotic	 cells.	 Fetuin-A	 was	 detected	 inside	vesicles	 shed	 by	 VSMCs,	 indicating	 cellular	 uptake	 of	 fetuin-A	 from	 the	 cell	 culture	medium.	 Fetuin-A	 prevented	 uncontrolled	 mineralization	 of	 VSMCs	 by	 inhibiting	mineral	precipitation	inside	intracellular	vesicles,	which	could	play	a	role	in	patients	with	disturbed	mineral	homeostasis,	for	instance	in	chronic	kidney	disease	(CKD).	Ectopic	vascular	calcification	due	to	an	imbalance	in	the	mineral	homeostasis	is	a	common	complication	in	CKD	and	end	stage	renal	disease	(ESRD)	patients.	Loss	of	 renal	 function	 decreases	 the	 clearance	 of	 phosphate	 from	 the	 blood	 leading	 to	dysregulation	of	FGF23	and	PTH	and	thus	disturbance	of	bone	turnover	(see	section	!.#.!).	Also,	uremia	due	to	loss	of	kidney	function	might	be	an	additional	risk	factor	for	ectopic	calcification	and	a	major	cause	of	calciphylaxis	!"#,!!",	which	is	characterized	by	ectopic	 calcification	 of	 vessel	 walls	 and	 subcutaneous	 fat,	 leading	 to	 necrotic	 skin	lesions.	Several	 clinical	 studies	 on	 the	 correlation	 of	 fetuin-A	 blood	 levels	 and	calcification	severity	 in	patients	shows	 that	high	 levels	of	 fetuin-A	are	beneficial	 for	
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clinical	outcomes	!!!–!!".	As	an	example,	clinicians	from	the	Aachen	University	Clinics	in	collaboration	 with	 our	 group,	 studied	 fetuin-A	 levels	 in	 a	 cohort	 of	 hemodialysis	patients	 !!".	 They	 showed	 that	 these	 patients	 had	 overall	 lower	 fetuin-A	 levels	compared	 to	 healthy	 subjects,	 which	 was	 in	 agreement	 with	 other	 studies	 !!!–!!".	Furthermore,	 low	 fetuin-A	 concentrations	 were	 associated	 with	 increased	 levels	 of	C-reactive	protein	(CRP),	an	inflammatory	marker,	and	increased	cardiovascular	and	all-cause	 mortality.	 Sera	 from	 patients	 on	 long-term	 dialysis	 with	 low	 AHSG	concentrations	 had	 an	 impaired	 capacity	 to	 inhibit	 the	 precipitation	 of	 calcium	phosphate	in	vitro	!!".		
	
Figure	 !:	 Hypothetical	 roles	 of	 fetuin-A	 in	 cell	 and	 matrix	 mineralization.	 Fetuin-A	might	 be	 involved	 in	vesicle-mediated	cartilage	mineralization	!!",!!$.	Recently,	mitochondria	have	been	shown	to	provide	at	 least	some	mineral	 for	osteoblast	mineralization	of	collagen	 I	!!".	Fetuin-A	was	shown	to	regulate	mineralization	 in	cultured	osteoblasts	!".	 Pathological	 calcification	 in	 VSMCs	 was	 equally	 inhibited	 by	 fetuin-A	!",!$.	 Figure	 modified	 from	Brylka	et	al.	!!.	In	conclusion,	fetuin-A	is	a	systemic	inhibitor	of	ectopic	calcification	and	plays	a	protective	role	when	mineral	homeostasis	is	disturbed.	Figure	(	shows	a	schematic	overview	of	the	roles	of	fetuin-A	in	physiological	and	pathological	mineralization.		
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1.1.5 The	Molecular	Mechanism	of	Calcification	Inhibition	by	
Fetuin-A:	Calciprotein	Particles			Calcification	 inhibition	 by	 fetuin-A	 is	 mediated	 by	 a	 cluster	 of	 acidic	 amino	 acid	residues	forming	an	outward	facing	five-pleated	β-sheet	on	domain	D-	!".	This	acidic	β-sheet	 has	 a	 high	 aﬃnity	 to	 crystalline	 and	 amorphous	 calcium	 phosphate	 and	calcium	 phosphate	 prenucleation	 clusters.	 In	 2345,	 Posner	 postulated	 that	 calcium	phosphate	ions	arrange	in	Ca!(PO!)!	prenucleation	clusters	with	a	size	of	about	/	nm,	the	 so-called	 Posner’s	 clusters	!!".	 Notably,	 a	 recent	 cryo-transmission	 electron	microscopic	(cryo-TEM)	investigation	of	calcium	phosphate	mineralization	in	solution	suggested	that	such	a	prenucleation	cluster	has	the	composition	Ca!(HPO!)!	!-	!!".		Estimations	 from	 small-angle	 neutron	 scattering	 (SANS)	 measurements	suggested,	 that	one	fetuin-A	molecule	binds	up	to	012	±	12	Posner’s	clusters	!"#.	One	fetuin-A	molecule	with	bound	prenucleation	clusters	is	called	a	calciprotein	monomer	(CPM)	and	 is	considered	the	building	block	of	 the	calciprotein	particle	 (CPP).	When	CPMs	 aggregate,	 CPPs	 are	 formed	 and	 they	 undergo	 a	 two-stage	 ripening	 process.	Primary	CPPs	are	about	/00	nm	in	size	and	have	a	spherical	shape.	They	consist	of	a	homogeneous	 mixture	 of	 fetuin-A	 and	 amorphous	 calcium	 phosphate.	 Over	 time,	depending	on	 temperature	and	 supersaturation	 level,	 CPPs	become	more	elongated	and	more	mineralized.	 In	 transmission	 electron	microscopy	 (TEM),	 they	 appear	 as	ovoid	structures	consisting	of	aggregated	apatite	platelets.	As	the	calcium	phosphate	of	 the	 CPPs	 starts	 to	 crystallize,	 fetuin-A	 protein	 is	 extruded	 from	 the	mineralized	core,	forming	an	envelope	around	the	particle.	The	so	formed	outer	layer	of	fetuin-A	protein	 provides	 solubility,	 thus	 secondary	 CPP	 form	 a	 colloidal	 dispersion	 in	solution	!"!.	 Through	 CPP	 formation,	 fetuin-A	 stabilizes	 the	 amorphous	 phase	 of	calcium	phosphate	and	delays	the	precipitation	of	crystalline	mineral.	Studies	on	the	formation,	composition	and	stability	of	CPMs	and	CPPs	were	all	based	on	particles	 generated	 in	 supersaturated	 solutions	 of	 calcium	and	phosphate	ions	in	vitro.	Only	in	one	case	we	could	successfully	isolate	CPPs	from	the	ascites	of	an	ESRD	patient	with	calcifying	peritonitis	!"!.	Although	several	groups	have	reported	the	isolation	 of	 CPPs	 from	 serum	 or	 other	 bodily	 fluids	 of	 either	 rats	!"",!"$	 or	 CKD	patients	!"#–!"#,	we	 have	 never	 been	 able	 to	 isolate	 or	 detect	 endogenous	 CPPs	 from	
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neither	mice	nor	men	and	could	not	reproduce	any	of	the	experimental	findings	in	the	studies	reporting	on	endogenous	CPPs.	We	assume	that	under	physiological	and	also	pathological	conditions,	CPPs	are	quickly	and	eﬃciently	cleared	from	the	system	and	are	 thus	 very	 hard	 to	 isolate.	 Thus,	 we	 hypothesize	 that	 CPPs	 aid	 to	 clear	 excess	calcium	and	phosphate	from	the	circulation.	To	investigate	CPP	clearance,	researchers	from	our	group	 injected	 fluorescent	 in	vitro	generated	CPPs	 into	mice	and	analyzed	their	 tissue	 distribution	 after	 diﬀerent	 time	 points.	 In	 wildtype	 mice,	 CPP	 were	cleared	 by	 liver	 Kupﬀer	 cells	 and	 by	 spleen	 marginal	 zone	 macrophages	 and	 the	clearance	was	mediated	 by	 scavenger	 receptor-A	!".	 These	 findings	 indicated	 a	 role	for	fetuin-A	in	the	clearance	of	excess	mineral	from	the	circulation.	A	depiction	of	the	formation,	clearance	and	biological	role	of	CPPs	is	shown	in	Figure	).		
	
Figure	 !:	 A	 schematic	 overview	 of	 the	 theoretical	mechanisms	 of	 calciprotein	 particle	 (CPP)	 formation,	
clearance	 and	 contribution	 to	 pathological	 calcification.	 Due	 to	 high	 fetuin-A,	 calcium	 and	 phosphate	concentrations	 in	 bone,	 CPPs	 might	 be	 formed,	 especially	 during	 bone	 resorption.	 CPPs	 derived	 from	 bone	 or	formed	in	blood	and	tissue	are	most	likely	cleared	through	macrophages	in	the	liver	and	spleen	!".	Excess	calcium	phosphate	 in	 the	 form	 of	 CPPs	 is	 taken	 up	 by	 these	macrophages	 and	 eventually	 leaves	 the	 body	 through	 the	kidney.	 In	chronic	kidney	disease,	 this	clearing	mechanism	is	 impaired.	Thus,	blood	calcium	and	phosphate	rise,	leading	to	CPP	formation.	This	might	also	occur	in	other	disease	states,	which	results	in	increased	blood	calcium	and	phosphate	levels.	Figure	modified	from	Brylka	et	al.	!!.		Making	 use	 of	 the	 formation	 of	 CPPs	 in	 a	 supersaturated	 solution	 of	 calcium	 and	phosphate,	 our	group	 developed	 an	 assay	 to	 determine	 the	 propensity	 of	 serum	 to	inhibit	 calcification	!"#.	 When	 in	 vitro	 generated	 primary	 CPPs	 ripen	 to	 secondary	CPPs,	there	is	a	sudden	change	in	the	turbidity	of	the	solution	due	to	a	change	in	size	and	 solubility	 of	 the	 particles.	 Using	 a	 nephelometer,	 the	 transition	 point	 from	primary	to	secondary	CPPs	can	be	determined.	The	later	this	transition	point	occurs,	the	 higher	 is	 the	 ability	 of	 the	 solution	 to	 prevent	 mineral	 precipitation.	 Adding	serum,	 which	 contains	 endogenous	 mineralization	 inhibitors	 like	 fetuin-A,	 to	 a	
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supersaturated	 calcium	 and	 phosphate	 solution,	 delays	 the	 transition	 point	 from	primary	to	secondary	CPP.	The	time-point	of	the	transition	is	called	T./,	and	thus	this	assay	 was	 dubbed	 T+,	 test.	 The	 calcification	 propensity	 of	 the	 serum	 reflects	 the	calcification	proneness	of	the	patient	and	thus	the	T23	test	can	be	used	to	assess	the	risk	of	a	patient	to	develop	soft	tissue	calcifications	!"!.	Furthermore,	the	T-.	assay	can	be	 utilized	 to	 develop	 individual	 therapeutic	 strategies	 to	 prevent	 ectopic	calcification	!"#.	 For	 instance,	 a	 very	 recent	 publication	 showed	 the	 improvement	 of	T"#	values	of	sera	from	CKD	patients	after	treatment	with	high	flux	hemodialysis	!"".		
1.1.6 Fetuin-A	in	Bone	Metabolism		The	 systemic	 calcification	 inhibitor	 fetuin-A	 accounts	 for	 about	 -.	%	 of	 the	non-collagenous	 proteins	 in	 bone	!",$%&–!"#,	 suggesting	 a	 role	 for	 fetuin-A	 in	 bone	mineralization	and	metabolism.	Szweras	et	al.	 first	described	the	bone	phenotype	of	fetuin-A	 deficient	 mice	 on	 a	 mixed	 .!"/Sv	 x	 C)*BL/-	 background	!"#.	 The	 authors	reported	shorter	 femoral	bones	with	an	 increased	cortical	 thickness,	while	all	other	bones	 appeared	 normal	 (see	 Figure	 ().	 The	 epiphyseal	 plates	 of	 Ahsg-/-	mice	 were	disordered	 and	 fragmented	 and	 unresorbed	 cartilage	 islands	 were	 found	 in	 the	metaphyses.	A	reduced	number	of	hypertrophic	chondrocytes	in	Ahsg-/-	growth	plates	was	 attributed	 to	 defective	 growth	 plate	 chondrocyte	 maturation.	 Fetuin-A	 was	previously	 established	 as	 an	 inhibitor	 of	 TGF-β	 and	 BMP	 signaling	 in	 vitro,	antagonizing	 cytokine	 receptor	 binding	!".	 Therefore,	 the	 mechanism	 behind	 the	femoral	 dysplasia	 in	 the	 absence	 of	 fetuin-A	 was	 explained	 as	 lack	 of	 TGF-β	antagonization.	 BMP-containing	 capsules	 were	 implanted	 into	 the	 hindlimbs	 of	
Ahsg-/-,	Ahsg+/-	and	wildtype	mice	 to	 investigate	whether	 fetuin-A	had	an	 impact	on	BMP-induced	 bone	 formation	 !"#.	 BMP	 induced	 the	 formation	 of	 bone-like	 tissue,	so-called	 ossicles,	 in	 the	 hindlimbs.	 Ahsg-/-	 mice	 showed	 a	 higher	 bone	 formation	capacity	compared	to	wildtype	mice.	Surprisingly,	heterozygous	Ahsg+/-	mice	showed	the	 highest	 bone	 formation	 capacity	 concerning	 ossicle	 size	 and	 bone	 mineral	content.		
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Figure	 !:	 Shortened	 femora	 in	
Ahsg-/-	 mice.	X-ray	 photographs	 of	a	 C$%BL/)	 wildtype	 and	 an	
Ahsg-/-	 mouse	 separated	 by	 a	 red	line.	 Red	 arrows	 indicate	 femora.	Note	the	visibly	shortened	femur	of	the	Ahsg-/-	mouse.		The	 bone	 phenotype	 of	 fetuin-A	 deficient	 mice	 was	 re-evaluated	 following	 the	availability	 of	 mice	 on	 two	 pure	 genetic	 backgrounds,	 namely	 C9:BL/>-Ahsg-/-	 and	DBA/%-Ahsg-/-	!"",!$%.	 Because	 extensive	 soft	 tissue	 calcifications	 in	 DBA/#	 fetuin-A	deficient	mice	established	fetuin-A	as	a	systemic	inhibitor	of	ectopic	calcification,	the	investigation	of	fetuin-A	in	bone	growth	was	recapitulated	with	a	new	focus	on	bone	mineralization	!"#.	As	mice	on	a	DBA/,	background	may	develop	bone	disorders	due	to	 secondary	 hyperparathyroidism	 as	 a	 result	 of	 kidney	 calcification,	 mice	 on	 the	genetic	 background	 C01BL/5	were	 used	 for	 the	 bone	 phenotype	 study.	These	mice	also	 had	 shorter	 femora.	 However,	 no	 diﬀerences	 on	 micro-mechanical,	micro-structural	 and	 cellular	 levels	 were	 found	 in	 Ahsg-/-	 mice,	 although	mineralization	 inhibitors	 are	 known	 to	 be	 crucial	 for	 proper	 collagen	mineralization	!"#.	 Consequently,	 other	 proteins	 take	 over	 the	 role	 of	 the	mineralization	 inhibitor	 in	Ahsg-/-	mice.	However,	 an	 increased	mineral	 content	was	discovered	 in	 the	 femoral	 growth	 plate	 remnants	 of	 adult	 Ahsg-/-	 mice	!"#.	 This	suggested	 a	 role	 for	 fetuin-A	 in	 the	 prevention	 of	 unwanted	 calcification	of	growth	plate	 cartilage.	 Accordingly,	 the	 decreased	 length	 of	 the	 femora	 was	 explained	 by	premature	mineralization	of	the	growth	plates.	Although	the	localization	and	biological	function	of	fetuin-A	strongly	suggests	a	role	in	bone	mineralization,	the	function	of	calciprotein	particles	(CPPs)	in	bone	is	yet	 poorly	 understood.	 Research	 groups	 from	 the	 Weizmann	 Institute	 in	 Rehovot,	Israel	 use	 elaborate	 imaging	 techniques	 to	 unravel	 the	 earliest	 steps	 in	biomineralization.	 They	 published	 various	 studies	 in	which	 they	 describe	 roundish	particles,	 in	 the	 size	 range	 of	 CPPs,	 containing	 calcium	 and	 phosphate,	 which	contribute	to	bone	tissue	mineralization	!"!–!"".	It	may	very	well	be	that	these	particles	contain	fetuin-A	and	are	similar	or	identical	to	CPPs.	
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The	 role	 of	 fetuin-A	 in	 bone	 mineralization	 and	 metabolism	 was	 also	 assessed	 in	clinical	studies.	The	concentration	of	fetuin-A	in	human	bone	was	shown	to	vary	with	age	!"#.	Bones	from	children	had	a	higher	fetuin-A	content	compared	to	adults,	which	might	reflect	age-dependent	variations	in	fetuin-A	serum	levels	!",	and	indicate	a	role	for	 fetuin-A	 in	bone	 turnover.	Diﬀerent	AHSG	phenotypes	 also	have	an	 influence	on	bone.	 A	 study	 in	 postmenopausal	 women	 suggested	 an	 association	 between	 AHSG	phenotypes	 and	 serum	 estrogen	 concentration,	 whereby	 the	 AHSG*:	 allele	 was	associated	 with	 lower,	 and	 the	 AHSG*5	 allele	 with	 increased	 estrogen	 levels.	 They	suggested	 that	 the	 AHSG	 phenotype	might	 influence	 weight,	 which	 in	 turn	 aﬀects	estrogen	 serum	 levels	 and	 bone	 density	!"#.	 A	 diﬀerent	 study	 on	 postmenopausal	women	did	not	show	any	correlation	between	fetuin-A	phenotype	and	bone	density,	however	 an	 association	 between	 fetuin-A	 phenotype	 and	 height	 was	 suggested	!"#;	increased	height	was	 associated	with	 the	 AHSG*1	 phenotype.	 Zmuda	 et	al.	 found	 a	relationship	 between	 genetic	 variation	 in	 the	 AHSG	 gene	 and	 calcaneal	 broadband	ultrasound	 attenuation	 (BUA),	 a	 predictor	 of	 bone	 fractions	!"#.	 They	 found	 no	significant	association	of	AHSG	polymorphism	to	hip,	lumbar	spine,	or	calcaneal	bone	mineral	 density.	 However,	 the	 study	 showed	 that	 the	 AHSG*9	 phenotype	 was	correlated	 with	 increased	 height	 and	 increased	 fracture	 risk	 in	 postmenopausal	women.	 Other	 studies	 investigating	 the	 association	 between	 AHSG	 phenotype	 and	bone	 mineral	 density	 led	 to	 inconsistent	 results	!"#–!"#.	 In	 one	 study,	 a	 positive	correlation	between	fetuin-A	serum	levels	and	BMD	was	found	for	elderly	women,	but	not	 men	!"#,!"%.	 Although	 lowered	 fetuin-A	 levels	 were	 reported	 in	 postmenopausal	women	suﬀering	from	osteoporosis	compared	to	age	matched	healthy	controls	!"",	no	correlation	 between	 AHSG	 levels	 and	 fracture	 risk	 in	 community	 dwelling	 older	people	could	be	established	!"#.		Fetuin-A	 was	 also	 studied	 in	 the	 context	 of	 certain	 bone	 pathologies	 with	contradicting	 results.	 In	 patients	with	 Paget’s	 disease	 of	 bone,	 two	 studies	 showed	decreased	!",$"%	serum	fetuin-A	levels,	while	another	study	reported	elevated	fetuin-A	concentrations	 in	 bone	!"#.	 In	 osteogenesis	 imperfecta	 (OI),	 one	 study	 stated	abnormally	 high	 serum	 fetuin-A	 concentrations	 in	 ,,	 of	 ./	 patients	!"#	and	 elevated	fetuin-A	levels	in	OI	bone	were	reported	!"#,!%&.		
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1.2 Endochondral	Ossification		The	 skeletal	 system	 is	unique	 and	 remarkable	 in	 combining	mechanical	 properties	and	endocrine	function.	While	its	shape	and	its	mechanical	strength	provide	mobility,	support	 and	 protection	 of	 vital	 organs,	 it	 is	 also	 a	 niche	 for	 bone	 marrow,	 where	hematopoiesis	 takes	place	and	where	a	vital	portion	of	 the	 immune	system	resides.	The	shape	and	size	of	the	skeletal	structures	need	to	be	carefully	coordinated	in	order	to	 fulfill	 their	 functions.	 Although	 rigid	 in	 its	 nature,	 bone	 is	 constantly	 remodeled	upon	mechanical	cues.	During	adolescence,	bone	tissue	is	mainly	anabolically	active,	in	adulthood	it	can	adapt	to	diﬀerences	in	mechanical	loading,	but	is	mainly	inactive,	and	 in	 old	 age,	 bone	 mass	 decreases	 due	 to	 hormonal	 changes,	 leading	 to	mostly	catabolic	activity	!"!.	Local	paracrine	regulators	as	well	as	endocrine	hormones	 from	the	bloodstream	control	the	development	and	lifelong	remodeling	of	bone.	Bones	 can	 be	 divided	 into	 two	 classes.	 Long	 bones,	 which	 compose	 our	appendicular	skeleton,	like	the	bones	of	arms	and	legs,	and	the	vertebrae	of	the	spine.	Most	bones	are	long	bones	and	develop	through	endochondral	ossification	(Figure	().	The	craniofacial	bones,	 like	 the	skull	and	 the	mandible	belong	 to	 the	 flat	bones	and	develop	 through	 intramembranous	 ossification.	 Also,	 a	 mixture	 of	 both	 bone	development	mechanisms	might	occur,	for	instance	in	the	scapula	or	the	clavicle.	Bone	 development	 starts	 when	 mesenchymal	 precursor	 cells	 condense	 into	clusters	!"#.	During	 the	development	of	 a	 flat	 bone	 like	 the	 skull,	mesenchymal	 cells	diﬀerentiate	 directly	 into	 bone-forming	 osteoblasts,	 which	 deposit	 bone	 matrix	consisting	predominantly	of	collagen	type	I.	This	process	 is	called	 intramembranous	ossification.	 In	 long	 bone	 development,	 for	 instance	 the	 formation	 of	 the	 femur,	mesenchymal	cells	diﬀerentiate	 into	chondrocytes,	 forming	a	cartilaginous	model	of	the	future	bone.	Cells	at	the	border	of	the	cartilage	model	create	the	perichondrium.	Chondrocytes	 secrete	 an	 extracellular	matrix	 rich	 in	 type	 II	 collagen	 and	 aggrecan.	The	 cartilage	 model	 expands	 through	 proliferation	 and	 matrix	 production.	Chondrocytes	at	the	center	of	the	cartilage	model	stop	proliferating	and	mature	into	hypertrophic	chondrocytes;	they	enlarge	and	express	a	matrix	rich	in	collagen	type	X.		Hypertrophic	chondrocytes	attract	blood	vessels	trough	the	secretion	of	vascular	endothelial	 growth	 factor	 (VEGF).	 Vascularization	 is	 an	 important	 factor	 in	
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endochondral	ossification	as	invading	blood	vessels	transport	mineral	ions	in	order	to	mineralize	 the	 hypertrophic	 cartilage,	 and	 allow	 for	 the	 invasion	 of	 osteoblast	precursors.	 Recently,	 a	 new	 type	 of	 bone	 capillary	 was	 discovered	 located	 at	 the	metaphysis	!"#.	 As	 this	 vessel	 type	 expressed	 high	 levels	 of	 endomucin	 and	 platelet	endothelial	cell	adhesion	molecule	!	(PECAM#	or	CD"#)	it	was	called	type	H	vessel	(H	for	 high).	 Type	H	 vessels	 are	 crucial	 for	 endochondral	 ossification	 as	 they	 actively	recruit	 precursor	 cells	 into	 the	 primary	 spongiosa.	 They	 are	mainly	 present	 during	active	bone	growth	and	their	number	gradually	decreases	with	age.	
		
Figure	 !:	 Endochondral	 ossification.	 A)	 Mesenchymal	 progenitor	 cells	 condense	 (B)	 and	 diﬀerentiate	 into	chondrocytes	 (C),	 forming	 the	 cartilaginous	 bone	 template.	 D)	 Cells	 at	 the	 center	 of	 the	 future	 bone	 become	hypertrophic.	E)	Hypertrophic	chondrocytes	attract	bone	vessels,	leading	to	matrix	mineralization.	Chondrocytes	at	the	periphery	become	osteoblasts,	forming	the	bone	collar	(bc).	F)	Osteoblasts	appear	in	the	center	of	the	bone,	forming	the	primary	ossification	center	(poc).	G)	Proliferation	of	chondrocytes	 leads	to	 lengthening	of	 the	bone.	Trabecular	 bone	 is	 formed	by	 osteoblasts	 in	 the	 primary	 spongiosa	 (ps).	 H)	 The	 bone	marrow	niche	 is	 formed	(bm).	Growth	plates	(gp)	develop	at	the	ends	of	the	long	bone.	Eventually	chondrocytes	of	the	epiphyses	become	hypertrophic,	are	invaded	by	vasculature	and	become	ossified,	forming	the	secondary	center	of	ossification	(soc).	Figure	modified	from	Kronenberg	!"#.	Upon	vascular	invasion,	the	cartilaginous	matrix	is	replaced	by	bone	in	the	so-called	primary	ossification	center.	Perichondrial	cells	diﬀerentiate	 into	osteoblasts,	 leading	to	the	formation	of	a	bone	collar.	Through	continued	proliferation	and	hypertrophy	of	
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chondrocytes	 and	 bone	 formation,	 the	 bone	 enlarges	 and	 hematopoietic	 stem	 cells	accumulate	and	establish	the	bone	marrow	niche	in	its	center.	At	opposing	ends	of	the	bone,	chondrocytes	and	their	extracellular	matrix	form	the	so-called	growth	plates	by	arranging	 in	 three	 spatially	 and	 temporally	 divided	 layers.	 Most	 distant	 from	 the	primary	 ossification	 center,	 the	 reserve	 zone	 contains	 a	 pool	 of	 immature	chondrocytes	serving	as	a	reservoir	of	cells	for	endochondral	bone	growth.	Adjacent	to	 this	 reserve	 zone,	 chondrocytes	 assume	 a	 flattened	 morphology	 and	 start	 to	proliferate.	Due	to	the	position	of	their	mitotic	spindle	apparatus	they	form	columns	of	 cells,	 which	 contribute	 to	 the	 lengthening	 of	 the	 bone	 !"!.	 Closer	 to	 the	 primary	ossification	center	cells	become	hypertrophic.	The	final	chondrocyte	layer	consists	of	terminally	 diﬀerentiated	 chondrocytes,	which	 characteristically	 express	MMP23	 and	osteopontin	!"#.	It	has	long	been	assumed	that	terminally	diﬀerentiated	chondrocytes	become	 apoptotic,	 however	 recent	 research	 suggests	 that	 the	 majority	 these	 cells	transdiﬀerentiate	and	contribute	to	the	osteoblast	population	!"#,!"".		At	 the	 interface	 between	 cartilage	 and	 bone,	 the	 chondro-osseous	 junction,	 the	avascular	cartilage	is	mineralized	and	replaced	by	bone.	This	process	is	mediated	by	protease	 activity;	 MMP01	 which	 is	 mainly	 produced	 by	 chondrocytes	 and	 newly	recruited	 osteoblasts,	 as	 well	 as	 MMP2	 stemming	 from	 monocytes	 and	(pre)osteoclasts,	 degrade	 the	 mineralized	 cartilage	 matrix	 and	 pave	 the	 way	 for	vascular	 invasion	!"#,!"%.	 Additionally	 chondroclasts,	 which	 are	 either	 a	 specialized	form	of	or	 identical	 to	osteoclasts,	 resorb	 the	mineralized	cartilage	!"#	which	 is	 then	replaced	 by	 bone.	 In	 this	 manner,	 trabecular	 bone	 is	 formed	 adjacent	 to	 the	chondro-osseous	junction	in	a	region	called	primary	spongiosa.		In	mice,	 the	 epiphyseal	 plate	 never	 fully	 disappears.	 The	 growth	 plate	 narrows	due	 to	 a	 reduced	 rate	 of	 chondrocyte	 proliferation	 and	 diﬀerentiation.	 In	 humans,	termination	of	endochondral	ossification	coincides	with	the	closure	of	the	epiphyseal	growth	 plate.	 The	 epiphysis	 fuses	 with	 the	 metaphysis	 and	 the	 epiphyseal	 growth	plate	is	replaced	by	bone.	This	event	does	not	occur	because	of	the	disappearance	of	the	 epiphyseal	 plate,	 but	 is	 an	 active	 process	 which	 underlies	 distinct	 regulatory	mechanisms	!"#.		
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1.2.1 Regulation	of	Endochondral	Ossification		Endochondral	 ossification	 is	 tightly	 regulated	 by	 paracrine	 and	 endocrine	mechanisms	 (see	 Figure	 ().	 Growth	 hormone	 (GH)	 produced	 in	 the	 brain’s	hypophysis	 is	 a	major	 endocrine	 determinant	 of	 size	 in	 the	mammalian	 body,	 as	 it	promotes	chondrocyte	proliferation.	GH	induces	the	secretion	of	insulin-like	growth	
factor-!	 (IGF-!)	 by	 the	 liver	 and	 by	 proliferating	 chondrocytes	!"!–!"#.	 Insulin-like	
growth	 factor-!	 (IGF-!),	 expressed	 in	 the	 growth	 plate	 independently	 of	 GH,	 is	required	for	normal	embryonic	growth	!"#.	IGF-!	and	IGF-!	both	bind	to	the	type	I	IGF	receptor	 (IGF,R),	 leading	 to	 the	 induction	 of	 anabolic	 processes	 and	 regulation	 of	glucose	metabolism	!"#,!"%.	Chondrocyte-derived	IGF-!	is	involved	in	controlling	the	size	of	 long	 bones	 through	 the	 volume	 of	 hypertrophic	 chondrocytes	!"".	 Circulating	liver-derived	IGF-!	also	plays	a	role	in	bone	development,	although	to	a	lesser	extent.	Studies	on	inbred	mouse	strains,	which	diﬀer	in	their	IGF-!	expression	levels,	reflect	the	 role	 of	 circulating	 IGF-!	 in	 bone	development	 and	 remodeling.	 Strains	with	 low	IGF-!	concentrations,	like	C01BL/5,	have	reduced	total	BMD	and	cortical	thickness	in	contrast	 to	mice	 to	 mice	 with	 high	 IGF-!	 levels,	 like	 C+H/HeJ	!"#.	 The	 liver-specific	deletion	of	IGF-!	shows	similar	results	!"#.		
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Figure	!:	Regulation	of	endochondral	ossification.	Chondrocyte	proliferation	and	diﬀerentiation	in	the	growth	plate	 are	 regulated	 by	 diﬀerent	 endocrine	 and	 paracrine	 factors.	 Also	 regulation	 of	 cartilage	 re-modeling	 and	vascular	 invasion	 are	 crucial	 for	 proper	 bone	 growth.	 Arrows	 indicate	 stimulatory	 pathways,	 and	 crossed	 lines	indicate	inhibitory	pathways.	Figure	modified	from	Mackie	and	colleagues	!"#.		The	 PTHrP/IHH	 positive	 feedback	 loop	 is	 the	 main	 paracrine	 pathway,	 which	regulates	 the	 rate	 of	 chondrocyte	 proliferation	 and	 diﬀerentiation	!"#	 (Figure	 ().	
Parathyroid	hormone	related	peptide	(PTHrP)	is	expressed	by	perichondrial	cells	at	the	opposing	ends	of	the	cartilage	model	in	the	fetus	and	in	early	proliferating	cells	in	the	postnatal	organism.	PTHrP	binds	to	the	G	protein	coupled	PTH/PTHrP	receptor	(PTHR&).	PTHR&	is	expressed	at	low	levels	by	proliferating	chondrocytes	and	at	high	levels	 by	 prehypertrophic	 and	 early	 hypertrophic	 chondrocytes.	 PTHrP	 stimulates	chondrocyte	 proliferation,	 but	 delays	 hypertrophy.	 In	 mice	 deficient	 in	 PTHR*	 or	PTHrP,	chondrocytes	become	prematurely	hypertrophic	!"!,!"$.	PTHrP	deficiency	leads	to	 perinatally	 lethal	 skeletal	 abnormalities.	 Contrarily,	 overexpression	 of	 PTHrP	 or	expression	 of	 a	 constitutively	 active	 PTHR6	 results	 in	 the	 delay	 of	 chondrocyte	hypertrophy	and	mineralization	!"#,!"%.	When	PTHrP	produced	at	the	epiphyseal	ends	of	the	bone	stimulates	its	receptor	in	the	proliferative	zone,	it	keeps	the	cells	in	a	state	
INTRODUCTION	28	
of	 proliferation.	 Over	 time,	 the	 distance	 between	 PTHrP	 secreting	 cells	 and	proliferating	 chondrocytes	 increases	and	 thus	 the	 influence	of	PTHrP	on	 these	 cells	decreases.	This	enables	 the	chondrocytes	 to	exit	 the	proliferative	cycle	and	undergo	hypertrophic	diﬀerentiation.		 	 	
Figure	 !:	 The	 parathyroid	
hormone-related	 protein	
(PTHrP)/Indian	 hedgehog	 (IHH)	
negative	 feedback	 loop.	Perichondrial	cells	and	chondrocytes	at	 the	 ends	 of	 long	 bones	 secrete	PTHrP.	 PTHrP	 stimulates	proliferative	 chondrocytes,	 keeping	them	 in	 a	 proliferative	 state.	 Over	time	 the	 distance	 between	proliferative	 chondrocytes	 and	PTHrP	 expressing	 cells	 increases.	When	 a	 proliferative	 chondrocyte	 is	no	 longer	 stimulated	 by	 PTHrP,	 it	starts	 to	 become	 hypertrophic	 and	produces	 Ihh.	 Ihh	 again	 stimulates	PTHrP	 production	 at	 the	 ends	 of	long	 bones,	 and	 stimulates	proliferation	 of	 adjacent	chondrocytes.	 IHH	 also	 acts	 on	perichondrial	 cells	 to	 convert	 these	cells	 into	 osteoblasts	 of	 the	 bone	collar.	 Figure	 modified	 from	Kronenberg	!"#.			When	a	cell	 is	no	longer	stimulated	by	PTHrP,	 it	starts	to	express	Indian	hedgehog	(IHH).	IHH	in	turn	stimulates	the	production	of	PTHrP	at	the	ends	of	long	bones.	This	positive	 feedback	 loop	 regulates	 the	 lengths	 of	 the	 proliferative	 columns	 and	 also	ensures	 that	 the	 diﬀerentiation	 patterns	 of	 individual	 columns	 in	 a	 growth	 plate	correlate	 to	 each	 other	!"#.	 Interestingly,	 mice	 deficient	 in	 IHH	 lack	 osteoblasts	 in	either	the	primary	spongiosa	or	bone	collar,	which	indicates	a	direct	eﬀect	of	IHH	on	the	diﬀerentiation	of	osteoblasts	from	perichondrial	cells	!"#.	
Fibroblast	 growth	 factor	 (FGF)	 signaling	 is	 another	 vital	 regulator	 of	chondrocyte	 proliferation	 and	 diﬀerentiation.	 There	 are	 33	 forms	 of	 FGF	 and	 four	forms	 of	 FGF	 receptors	 (FGFR);	 many	 of	 those	 are	 expressed	 throughout	 diﬀerent	stages	 of	 endochondral	 ossification	!"#.	 Achondroplasia,	 the	 most	 common	 form	 of	skeletal	dwarfism	in	humans	is	caused	by	a	mutation	in	the	gene	for	FGFR!,	resulting	
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in	 the	 expression	 of	 a	 constitutively	 active	 receptor	!"",!"$.	 Both,	 a	 milder	 form	 of	dwarfism	(hypochondroplasia),	and	a	more	severe	 form	of	dwarfism	(thanatophoric	dysplasia),	 also	 result	 from	 FGFR$	 mutations.	 In	 early	 development,	 FGFR!	 is	expressed	 in	 chondrocytes	 located	 in	 the	 central	 core	 of	 the	 mesenchymal	condensation,	 while	 at	 later	 stages,	 it	 is	 expressed	 by	 proliferative	 chondrocytes.	FGFR$	 knockout	 mice	 have	 increased	 chondrocyte	 proliferation	 and	 thus	 longer	proliferative	 columns,	 whereas	mice	 expressing	 constitutively	 active	 FGFR$	 display	decreased	 proliferation	 rates	!"#,!"!.	 Bone	 growth	 regulation	 through	 FGFR$	 occurs	partially	 through	 the	 PTHrP/IHH	 pathway,	 as	 FGFR$	 activation	 decreases	 IHH	expression,	 and	 FGFR$	 deficient	mice	 show	 elevated	 IHH	 expression	 levels	!"#,!%&,!'#.	Additionally,	FGFR$	 inhibits	 proliferation	 at	 least	 partially	 through	 activation	 of	 the	JAK-STAT	signaling	pathway	!"#.	
Epidermal	 growth	 factor	 (EGF)	 signaling	 plays	 a	 role	 in	 endochondral	ossification	 as	 EGF	 receptors	 (EGFR)	 are	 expressed	 in	 the	 axial	 and	 appendicular	skeleton.	 EGF	 receptors	 bind	 several	 ligands	 including	 EGF,	 transforming	 growth	factor-α	 (TGF-α),	 betacellulin,	 epiregulin,	 and	 amphiregulin	!"#.	 EGFR-deficient	mice	or	 mice	 treated	 with	 the	 EGFR	 antagonist	 Gefitinib	 show	 a	 delay	 in	 endochondral	ossification.	This	is	due	to	defective	osteoclast	recruitment	and	decreased	rank	ligand	(RANKL)	 expression,	 which	 leads	 to	 an	 elongation	 of	 the	 hypertrophic	 zone	!"#,!"%.	Likewise,	 terminally	 diﬀerentiated	 hypertrophic	 chondrocytes	 accumulate	 in	 mice	deficient	 for	 ADAM!"	 (a	 disintegrin	 and	 metalloproteinase	 ./),	 leading	 to	 delayed	bone	 growth	 and	 increased	 hypertrophic	 zone	 length	!"#.	 ADAM!"	 cleaves	 cytokines	bound	 to	 the	 cartilage	 matrix	 and	 is	 the	 major	 sheddase	 for	 several	 EGF	 ligands,	resulting	in	similar	bone	phenotypes	in	ADAM!"	and	EGFR-deficient	mice.	
Transforming	 growth	 factor-β	 (TGF-β)	 belongs	 to	 the	 TGF-β	 protein	super-family.	 In	 the	 epiphyseal	 growth	 plate,	 three	 diﬀerent	 TGF-β	 isoforms	 are	expressed	!"#.	 TGF-β!	 and	 TGF-β!	 can	 both	 be	 found	 in	 the	 proliferative	 and	 the	hypertrophic	zone.	TGF-β",	 the	most	abundant	TGF-β	 isoform	 is	present	throughout	all	zones,	with	the	highest	concentration	in	the	hypertrophic	zone	!"".	TGF-β	is	bound	to	 latent	 TGF-β	 binding	 protein	 (LTBP)	 anchored	 to	 the	 extracellular	 cartilage	matrix	!"".	 In	 order	 to	 exert	 its	 biological	 activity,	TGF-β	needs	 to	 be	 proteolytically	released	from	its	latent	complex.	Active	TGF-β	binds	to	its	receptor	(TGFBR),	leading	
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to	the	phosphorylation	of	SMAD	proteins.	A	phosphorylated	SMAD	molecule	forms	a	heterodimer	with	another	SMAD	molecule,	translocates	into	the	nucleus	and	induces	gene	 expression	!"#.	 The	 exact	 biological	 function	 of	 TGF-β	 highly	 depends	 on	 the	cellular	 context	!"!.	 All	 three	TGF-β	 isoforms	 induce	 chondrogenic	 diﬀerentiation	 of	human	 mesenchymal	 stem	 cells	 (MSC)	 in	 vitro	!"".	 In	 growth	 plate	 chondrocytes,	TGF-β	 stimulates	 proliferation	 and	 extracellular	 matrix	 (ECM)	 production,	 and	inhibits	terminal	diﬀerentiation,	keeping	the	cells	in	a	prehypertrophic	state	!"#.	Here,	TGF-β	partially	acts	through	the	PTHrP/IHH	feedback	loop.	
Bone	 morphogenetic	 proteins	 (BMPs)	 are	 also	member	 of	 the	TGF-β	protein	superfamily.	 BMPs	 bind	 to	 BMP	 receptors	 and,	 like	 for	 TGF-β,	 signaling	 occurs	through	 SMAD	proteins.	 BMP	 signaling	 plays	 an	 important	 role	 in	 the	 formation	 of	mesenchymal	 condensations	 and	 in	 skeletal	 development	!"#.	 Upon	 subcutaneous	injection,	 BMP	 induces	 endochondral	 bone	 formation	 in	 mice	!"#.	 BMP	 signaling	increases	 proliferation	 and	 the	 length	 of	 proliferating	 columns	 by	 increasing	 IHH	expression	!"#.	 BMP	 signaling	 also	 delays	 terminal	 diﬀerentiation	 of	 hypertrophic	chondrocytes.	 The	 eﬀect	 of	 BMP	 is	 opposite	 to	 that	 of	 FGF	 signaling	 and	 these	pathways	are	considered	to	be	antagonistic	!"#.	The	most	essential	 transcription	 factor	 in	cartilage	 is	SRY-box$	(SOX!).	SOX!	 is	responsible	 for	 the	 diﬀerentiation	 of	 condensed	mesenchyme	 into	 cartilage	 and	 for	the	 maintenance	 of	 the	 cartilage	 phenotype	!"#,!"%.	 It	 is	 expressed	 in	 chondrocytes	throughout	all	developmental	stages	except	hypertrophy	and	terminal	diﬀerentiation.	SOX!	 stimulates	 the	 expression	 of	 chondrocyte	 marker	 genes	 such	 as	 COL4A6,	COL!!A"	 and	 aggrecan.	 SOX!	 deficient	 early	 limb	 mesenchyme	 failed	 to	 produce	cartilage	 condensations	!"#	 while	 SOX$	 conditional	 knockout	 in	 COL"A!	 producing	cells	 led	 to	 decreased	 proliferation,	 decreased	 expression	 of	 matrix	 genes	 and	decreased	expression	of	members	of	the	PTHrP/IHH	feedback	loop.	TGF-β	and	BMP	both	 stimulate	 SOX!	 expression.	 Mice	 heterogeneous	 for	 SOX!	 show	 a	 perinatally	lethal	 osteochondrodysplasia	 resembling	 campomelic	 dysplasia,	 a	 human	pathology	caused	 by	 haploinsuﬃciency	 of	 SOX!	!"#.	 Campomelic	 dysplasia	 is	 a	 rare	 disorder	distinguished	 by	 the	 bowing	 of	 long	 bones	 and	 other	 skeletal	 deformations	 and	 is	frequently	lethal	in	neonates	due	to	respiratory	failure.	
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The	Wnt	signaling	pathway	plays	a	crucial	role	 in	skeletal	development	even	before	mesenchymal	 condensation	 takes	 place	!"#.	 In	 the	 canonical	Wnt	 signaling	 pathway,	Wnt	binds	to	a	receptor	complex	comprising	Frizzled	and	LRP	(LDL	receptor	related	protein),	 leading	 to	 the	 release	 of	 β-catenin	 from	 proteasomal	 degradation	 !"".	β-catenin	 translocates	 into	 the	 nucleus	 and	 associates	with	 transcription	 factors	 to	control	the	transcription	of	target	genes.	Wnt	signaling	is	 important	for	proper	limb	patterning.	As	a	drastic	example,	loss	of	WNT!	in	humans	leads	to	tetra-amelia,	a	lack	of	 the	 formation	 of	 all	 four	 limbs	!"!.	 Inactivation	 of	 β-catenin	 in	 mesenchymal	progenitor	cells	in	vitro	favors	chondrogenic	over	osteogenic	diﬀerentiation	!"#.	Mouse	embryos	 with	 a	 chondrocyte-specific	 deletion	 of	 β-catenin	 suﬀer	 from	 dwarfism,	decreased	chondrocyte	proliferation	and	delayed	hypertrophy	!"#.	Thus,	Wnt	signaling	promotes	chondrogenic	diﬀerentiation,	but	impairs	chondrocyte	development	at	later	stages.	 Interestingly,	 inactivation	 of	 SOX!	 in	 chondrocytes	 also	 led	 to	 a	 similar	phenotype	 as	 β-catenin	 deletion,	 because	 SOX!	 inhibits	 the	 activation	 of	β-catenin-dependent	promoters	and	stimulates	β-catenin	degradation	!"#.	
Notch	signaling	is	triggered	by	binding	of	a	ligand	of	the	Delta/Jagged	families	to	a	 Notch	 receptor	 resulting	 in	 the	 release	 of	 the	 intracellular	 portion	 of	 the	 Notch	intracellular	domain	 (NICD).	The	NICD	 translocates	 into	 the	nucleus	 and	binds	 to	 a	transcriptional	 repressor,	 converting	 it	 into	 a	 transcriptional	 activator,	 and	 in	 this	manner	 inducing	 the	 expression	 of	 target	 genes.	 In	 early	 limb	 development,	 Notch	signaling	 is	 required	 to	 prevent	 premature	 osteoblastic	 diﬀerentiation	 of	mesenchymal	 progenitor	 cells	!"#.	 Notch	 signaling	 is	 necessary	 for	 chondrocyte	proliferation	and	hypertrophy,	but	it	delays	terminal	chondrocyte	diﬀerentiation	!"#,!"%.	In	 endochondral	 ossification,	 Notch	 signaling	 promotes	 proliferation	 of	 endothelial	cells	 and	 vessel	 growth	 in	postnatal	 long	bone,	which	 is	mediated	by	 expression	of	Noggin,	 a	 BMP	 antagonist	!"#.	 Notch	 signaling	 also	 promotes	 hypertrophy	 via	regulation	of	BMP	signaling	!"#	and	via	indirect	regulation	of	SOX!	expression	!"#,!"%.	
Retinoic	 acid	 signaling	 is	 crucial	 for	 many	 developmental	 and	 immunological	processes	!!",	 but	 its	 role	 in	 endochondral	 ossification	 is	 yet	 poorly	 understood.	Retinoic	 acid	 is	 the	 biologically	 active	 form	 of	 a	 vitamin	 A	 (retinol)	 in	 the	 bone.	Retinoic	acid	binds	 to	 the	nuclear	retinoic	acid	receptor	(RAR),	which	 is	bound	to	a	retinoic	acid	response	element	(RARE)	on	the	DNA	and	either	activates	or	represses	
INTRODUCTION	32	
gene	 transcription	 upon	 ligand	 binding.	 In	 early	 limb	 development,	 retinoic	 acid	regulates	 homeobox	 (Hox)	 patterning	 genes	 for	 proximal	 limb	 development	 and	opposes	 the	 activity	 of	 FGF	 in	 limb	patterning	!!".	 BMP	 signaling	directly	 attenuates	retinoic	 acid	 synthesis	 in	 early	 limb	 development	!!!.	 Retinoic	 acid	 is	 an	 important	regulator	of	mesenchymal	progenitor	cells	and	determines	cell	fate.	For	example,	mice	deficient	 in	Cyp'(b*	 (cytochrome	P,-.	 family	 34	 subfamily	B	member	 9),	 a	 retinoic	acid	metabolizing	 enzyme,	 have	 severe	 patterning	 defects	 due	 to	 excessive	 retinoic	acid	 signaling	!!".	 In	 endochondral	 ossification,	 retinoic	 acid	 signaling	 is	 crucial	 for	chondrocytes	to	become	hypertrophic.	Treatment	of	fetal	chick	humeri	with	retinoid	antagonists	 lead	 to	 impaired	 endochondral	 ossification	 and	 chondrocytes	 failed	 to	become	 hypertrophic	!!".	 In	 the	 growth	 plates	 of	 rabbits,	 increased	 amounts	 of	endogenous	retinoic	acid	were	found	to	be	associated	with	the	hypertrophic	zone	!!",	indicating	a	role	for	retinoic	acid	in	growth	plate	maturation.	Accordingly,	in	chicken	growth	 plates,	 chondrocyte	 hypertrophy	 markedly	 increased	 the	 expression	 of	retinoic	 acid	 receptor	 ɣ	 (RARɣ)	!!".	 The	 growth	 plate	 contains	 several	 diﬀerent	receptors	for	retinoic	acid	and	mice	deficient	in	growth	plate	RARɣ,	which	is	the	most	widely	expressed	RAR	 in	 the	 growth	plate,	 suﬀer	 from	growth	 retardation	at	 about	three	weeks	of	age	!!".	High	 concentrations	 of	 retinoic	acid	 can	 impair	 endochondral	 ossification	!!".	 In	humans,	vitamin	A	intoxication	 leads	to	premature	growth	plate	closure	and	growth	arrest	!!".	 In	 cattle,	 administration	 of	 excess	 retinoic	 acid	 leads	 to	 so-called	 hyena	disease.	Due	 to	premature	growth	plate	closure	and	growth	arrest	 in	 the	 femur,	 the	shorter	 femur	 leads	 to	 a	 hyena-like	 appearance	!!".	 A	 similar	 phenomenon	 was	reported	 in	 guinea	 pigs	!!"	 and	 administration	 of	 retinoic	 acid	 to	 rats	!"#	decreased	chondrocyte	proliferation,	diﬀerentiation	and	matrix	synthesis.	In	a	study	by	de	Luca	and	 colleagues,	 already	 a	 single	 oral	 dose	 of	 retinoic	 acid	 in	 rats	 could	 reduce	 the	length	tibial	growth	plates	!"#.	The	authors	also	showed	that,	in	a	rat	metatarsal	bone	culture	 system,	 retinoic	 acid	 inhibited	 bone	 growth	 by	 reducing	 chondrocyte	proliferation	 in	 the	 proliferative	 zone,	 matrix	 synthesis	 and	 cell	 hypertrophy	!"#.	Furthermore,	retinoic	acid	stimulated	terminal	diﬀerentiation	and	annexin-mediated	mineralization	of	growth	plate	chondrocytes	!"#,!"!.			
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1.3 Bone		The	 development	 of	 the	 skeletal	 system	 occurs	 through	 both,	 endochondral	 and	intramembranous	ossification	!"!.	Bone	tissue	mainly	consists	of	a	mineralized	matrix	rich	in	collagen	type	I.	The	major	cell	types	of	bone	are	the	bone	forming	osteoblast,	the	quiescent	bone	 lining	 cell,	 the	bone	 resorbing	osteoclast,	and	 the	osteocyte,	 the	master	regulator.		Bone	 tissue	 deposition	 is	 accomplished	 by	 osteoblasts.	 Osteoblasts	 secrete	 and	mineralize	a	matrix	mainly	consisting	of	collagen	type	I.	The	exact	mechanism	of	bone	collagen	mineralization	is	a	highly	debated	topic	in	the	field	of	biomineralization	and	many	hypotheses	exist.	The	most	widely	accepted	theory	is	that	osteoblasts	actively	mineralize	collagen	by	secreting	mineralizing	matrix	vesicles	!!",!!$.	A	recent	study	by	Boonrungsiman	 et	 al.	 suggests	 that	 in	 osteoblasts,	 vesicles	 destined	 for	 matrix	mineralization	 collect	much	of	 their	mineral	 from	mitochondria	!!".	 In	 addition,	 also	vesicle-independent	 mineralization	 mechanisms	 have	 been	 described.	 Studies	 on	developing	 zebrafish	 fin	 bones	 reported	 the	 presence	 of	 globular	 amorphous	particles,	 which	 infused	 bone	 collagen	 fibers	 and	 contributed	 to	 their	mineralization	!"!,!"$.	 From	 in	 vitro	 studies	 we	 know	 that	 mineralization	 inhibitors,	such	as	fetuin-A,	are	crucial	for	proper	collagen	mineralization	!"#.	It	is	only	when	the	mineral	 is	kept	 in	a	metastable	amorphous	state	 long	enough	to	permit	penetration	into	 the	 collagen	 fibril,	 that	 collagen	 fibrils	 will	 be	 properly	 mineralized.	 Active	osteoblasts	 are	 cuboidal	 shaped	 cells,	 which	 actively	 deposit	matrix	 onto	 the	 bone	surface	 on	which	 they	 reside;	 there	 is	 always	 a	 layer	 of	 unmineralized	 bone,	 called	osteoid,	under	active	osteoblasts	!"!.	When	osteoblasts	become	inactive,	they	become	flattened	and	cover	all	available	surface	of	the	bone.	At	this	stage,	the	cells	are	called	bone	lining	cells.	They	induce	the	immediate	release	of	calcium	from	the	bone	when	blood	 calcium	 levels	 are	 too	 low.	 Bone	 lining	 cells	 are	 also	 responsible	 for	 the	protection	of	the	bone	from	harmful	bone	resorbing	chemicals.		When	an	active	osteoblast	gets	trapped	in	its	own	extracellular	matrix,	it	becomes	an	 osteocyte.	 Osteocytes	 are	 deeply	 enclosed	 in	 the	 bone	 and	 reside	 in	 so-called	lacunae.	 They	 are	 connected	 to	 other	 osteocytes	 with	 their	 filopodia	 through	microscopic	canals	in	the	bone,	the	canaliculi.	Osteocytes	are	the	master	regulators	of	
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osteoblasts	and	osteoclasts.	They	sense	mechanical	cues	and	secrete	hormones,	which	regulate	bone	production	and	resorption.	The	molecular	mechanisms	concerning	the	adaption	of	bone	to	mechanical	loading	are	yet	poorly	understood	!"".	Osteoclasts	 are	 specialized	 multinucleated	 cells,	 which	 arise	 from	 the	diﬀerentiation	 and	 fusion	 of	 macrophages	 and	 their	 main	 function	 is	 to	 resorb	mineralized	 bone.	 Osteoclasts	 have	 two	 sides	 of	 the	 plasma	membrane:	 the	 ruﬄed	border	where	bone	resorption	takes	place	and	the	clear	zone,	which	serves	as	point	of	attachment	 to	 the	 matrix.	 Osteoclasts	 secrete	 H+	 ions	 to	 dissolve	 mineral	 and	cathepsin	 K,	 an	 osteoclast	 specific	 collagen	 degrading	 protease.	 One	 might	 regard	bone	 resorption,	 a	 potentially	 debilitating	 process,	 as	 a	 highly	 specialized	 form	 of	autoimmunity,	which	is	regulated	through	many	diﬀerent	pathways.			
1.3.1 Regulation	of	Bone	Metabolism		Bone	remodeling	and	homeostasis	are	regulated	by	diﬀerent	endocrine	and	paracrine	factors.	 As	 bone	 is	 the	 body’s	major	 calcium	 storage,	 calcium	 can	 be	 released	 from	bone	to	maintain	stable	blood	calcium	levels.	During	acute	 low	blood	calcium	 levels	(hypocalcemia),	 bone	 can	 rapidly	 release	 calcium	 from	 a	 readily	 available	 pool	beneath	 bone	 lining	 cells,	 independent	 of	 hormonal	 regulation	!"!,$%&.	 Calcium	homeostasis	 is	 hormonally	 regulated	 in	 gut,	 kidney	 and	 bone	 by	 the	 parathyroid	gland	!"#	(see	Figure	().	In	the	parathyroid	gland,	the	calcium	sensing	receptor	(CaR)	detects	 low	 blood	 levels	 of	 ionized	 calcium	 and	 in	 turn	 increases	 blood	 levels	 of	parathyroid	 hormone	 (PTH).	 PTH	 binds	 to	 its	 receptor	 (PTHR)	 in	 the	 kidney	 and	increases	 renal	 calcium	 reabsorption	 in	 the	 tubuli	 and	 simultaneously	 stimulates	renal	phosphate	clearance.	Furthermore,	due	 to	PTH	mediated	stimulation	of	active	vitamin	D!	 (!,#$-dihydroxyvitamin	D/	 or	 calcitriol)	 synthesis	 in	 the	 kidney,	 calcium	absorption	in	the	 intestine	 is	 increased.	Calcitriol	 in	turn	decreases	PTH	expression.	The	 direct	 influence	 of	 vitamin	 D3	 metabolites	 on	 bone	 is	 not	 exactly	 known,	 as	contradicting	 results	 exist	 in	 the	 literature	!"#.	 PTH	 stimulates	 bone	 resorption	 and	thus	 the	 release	 of	 calcium	 and	 phosphate	 into	 the	 blood.	 PTH	 binds	 to	 PTHR	 on	osteoblasts,	 inducing	 the	 expression	 of	 receptor	 activator	 of	 NF-κB	 ligand	 (RANK	Ligand	 or	 RANKL)	!"#.	 RANKL	 binds	 to	 RANK	 expressed	 on	 osteoclasts	 and	 their	
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precursor	cells,	 inducing	activation	and	osteoclastic	diﬀerentiation,	respectively	and	thus	inducing	bone	resorption	and	calcium	release.			
		Figure	!:	Regulation	of	calcium	homeostasis.	Calcium	levels	are	sensed	by	the	parathyroid	gland,	which	adjusts	its	expression	of	PTH	and	calcitonin.	PTH	and	calcitonin	control	RANKL	and	OPG	expression	 in	bone,	regulating	bone	turnover	and	calcium	release.	In	the	kidney,	PTH	and	calcitriol	control	calcium	and	phosphate	clearance	and	reabsorption,	 and	 calcitriol	 synthesis.	 Calcitriol	 regulates	 calcium	 and	 phosphate	 adsorption	 in	 the	 gut	 and	increases	PTH	expression	in	the	parathyroid	gland.		High	blood	calcium	levels	(hypercalcemia)	stimulate	the	secretion	of	calcitonin	by	the	parathyroid	 gland.	 Calcitonin	 lowers	 blood	 calcium	 levels	 by	 inhibition	 of	osteoclast-mediated	 bone	 resorption	 and	 increase	 of	 calcium	 and	 phosphate	 renal	excretion	!"#.	 Increased	 blood	 calcium	 levels	 stimulate	 osteoblasts	 to	 produce	osteoprotegerin	 (OPG),	 a	 RANKL	 decoy	 receptor,	 which	 blocks	 osteoclast	diﬀerentiation.	 Thus,	 bone	 resorption	 is	 determined	 by	 the	 ratio	 between	OPG	and	RANKL.	Phosphate	metabolism	is	regulated	by	fibroblast	growth	factor	/0	(FGF!"),	and	the	 FGF	 receptor-klotho	 complex	 (see	 Figure	 ().	 FGF!"	 is	 expressed	 only	 by	osteoblasts	 and	 osteocytes	 and	 stimulates	 the	 kidney	 through	 an	 endocrine	mechanism	!"#.	 FGF!"	 binds	 to	 a	 complex	 composed	 of	 an	 FGF	 receptor	 (FGFR$c,	FGFR$c	or	FGFR')	 and	 its	 co-receptor	 klotho,	which	 is	 exclusively	 expressed	 in	 the	kidneys.	 The	 main	 functions	 of	 FGF!"	 are	 to	 increase	 phosphate	 clearance	 and	decrease	calcitriol	synthesis.	Calcitriol	not	only	increases	calcium,	but	also	intestinal	
INTRODUCTION	36	
phosphate	absorption	and	 is	 thus	a	direct	antagonist	of	FGF!"	regarding	phosphate	metabolism.	 FGF!"	 and	 calcitriol	 are	 regulated	 in	 a	 negative	 feedback-loop,	 as	 high	calcitriol	 levels	 increase	 FGF!"	 expression	 and	 FGF!"	 in	 turn	 decreases	 calcitriol	synthesis.	 FGF!"	 decreases	 the	 production	 of	 PTH	by	 the	 parathyroid	 gland,	hence	indirectly	decreasing	blood	calcium	levels.		
	
Figure	 !:	 Regulation	 of	 phosphate	 homeostasis.	High	 blood	 phosphate	 stimulates	 the	 expression	 of	 FGF78.	FGF#$	 stimulates	 phosphate	 clearance	 and	 decreases	 phosphate	 reabsorption	 in	 the	 kidney.	 Also,	 calcitriol	synthesis	is	decreased.	High	calcitriol	levels	also	stimulate	FGF78	expression.	FGF78	also	decreases	PTH	expression	in	the	parathyroid	gland,	indirectly	decreasing	blood	calcium	levels.			Both,	blood	calcium	and	phosphate	levels,	have	a	direct	influence	on	bone	remodeling.	It	is	thus	not	surprising	that	in	pathological	situations,	when	calcium	and	phosphate	metabolisms	 are	 deregulated,	 for	 instance	 during	 nephrological	 disorders	 such	 as	renal	 insuﬃciency,	 bone	 metabolism	 and	 mineralization	 are	 strongly	 aﬀected.	Complications	 like	 osteoporosis	!"#	 or	 adynamic	 bone	!"#	 are	 frequently	 seen	 in	hemodialysis	 patients.	 In	 the	 long	 term,	 deregulated	mineral	 homeostasis	 can	 also	lead	to	ectopic	vascular	calcification	!"#.		 	
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1.4 Experimental	Aims		The	 aim	 of	 this	 study	 was	 to	 investigate	 the	 bone	 phenotype	 anomaly	 in	fetuin-A-deficient	 mice	 and	 in	 this	 manner	 to	 clarify	 the	 mechanisms	 with	 which	fetuin-A	exerts	its	function	in	the	growth	plate.	Here,	two	diﬀerent	approaches	were	taken:		The	 first	 approach	 was	 based	 on	 a	 postnatal	 bone	 culture	 system,	 which	 was	established	 during	 previous	 work	 during	my	MSc	 thesis.	 In	 the	 present	 study,	 this	bone	culture	system	was	used	to	investigate	the	influence	of	fetuin-A	and	retinoic	acid	on	bone	growth.	The	 second	 approach	was	based	on	 a	histological	 investigation	of	bone	 growth.	Bones,	 starting	 from	 newborn	 mice	 until	 eight	 weeks	 of	 age,	 were	 examined	histologically	 to	 clarify	 the	 morphological	 changes	 taking	 place	 during	 dysplasia	development	 in	 fetuin-A-deficient	 mice.	 To	 elaborate	 a	 mechanism,	 we	 compared	gene	 expression	 in	 growth	plates	 from	young	mice	 using	 transcriptome	microarray	analysis.	Fetuin-A	 immunostaining,	microarray	 analysis	 and	 validation	were	 carried	out	as	part	of	the	Master	thesis	work	performed	by	Sina	Köppert	!"!.			 	
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! MATERIALS	AND	METHODS		
2.1 Animals		All	animal	experiments	were	conducted	in	agreement	with	German	animal	protection	law	and	were	approved	by	the	state	animal	welfare	committee.	C78BL/<	wildtype	and	C"#BL/'	 fetuin-A	 deficient	 mice	 (Ahsg-/-,	 Ahsg+/-)	 were	 maintained	 in	 a	temperature-controlled	 room	 on	 a	 ,--hours	 day/night	 cycle.	 Food	 (standard	 chow,	Ssniff)	and	water	were	 given	 ad	 libitum.	Animal	husbandry	 (cage	 cleaning,	 feeding,	watering)	 was	 performed	 by	 the	 facility’s	 animal	 care	 technicians.	 All	 experiments	were	 conducted	 according	 to	 recommendations	 by	 the	 Federation	 for	 Laboratory	Animal	 Science	 Association	 (FELASA)	 and	 approved	 by	 the	 Landesamt	 für	 Natur-,	Umwelt-	und	Verbraucherschutz	NRW	(LANUV).			
2.2 Genotyping		Tail	or	ear	biopsies	were	collected	for	genotyping.	Tissue	was	digested	in	.//	µl	of	a	!	mg/ml	 (',)*	 U/µl)	 proteinase	 K	 (Thermo	 Fisher	 Scientific)	 solution	 in	 buﬀer	("##	mM	Tris/HCl	pH	!.#,	&'	mM	EDTA,	).+	%	SDS,	!""	mM	NaCl)	over	night	at	00	°C	in	a	rotating	sample	holder.	For	DNA	 isolation,	samples	were	centrifuged	 for	 34	min	at	!"###	rpm	 and	 the	 supernatant	 was	 transferred	 to	 a	 tube	 containing	 )**	µl	isopropanol	(Applichem).	Samples	were	 inverted	carefully	and	centrifuged	again	 for	!	min	at	maximum	speed.	Supernatant	was	discarded	and	the	pellet	was	washed	with	!"#	µl	 of	 a	 &'	%	ethanol	 (for	molecular	biology,	Applichem)	 solution.	 Samples	were	centrifuged	 again	 for	 .	min,	 ethanol	 was	 discarded	 and	 DNA	 was	 dried.	 DNA	 was	reconstituted	 in	,-	µl	TE	buﬀer	 (%&	mM	Tris	pH	!.#,	 &	mM	EDTA)	 for	*+	min	at	$$	°C.	DNA	was	stored	at	-	°C	until	further	processing.	Fetuin-A	 multiplex	 PCR	 was	 carried	 out	 in	 a	 thermocycler	 (Biometra	 TRIO,	Analytik	 Jena	AG)	using	 the	 following	primers:	wildtype	sense	:’	GCT	CTT	GCC	AAT	CTT	CAA	TC	 %’,	 knockout	 sense	 +’	 TTG	AAT	GGA	AGG	ATT	GGA	GC	 &’	 and	 antisense	!’	TAT	GCC	TTG	TCA	CAG	CAC	CG	&’.	Primers	were	all	purchased	at	Eurofins	Genomics	(Ebersberg,	Germany)	and	were	diluted	to	working	solutions	of	12	µM.	The	mastermix	
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was	prepared	using	the	DreamTaqTM	Green	DNA	Polymerase	system	(Thermo	Fisher	Scientific)	as	 shown	 in	Table	 1.	 The	 PCR	protocol	used	 for	 genotyping	 is	 shown	 in			 Table	2.	PCR	Products	and	a	 !	kb	marker	 (Gene	Ruler,	Thermo	Fisher	Scientific)	were	applied	on	a	 *	%	agaorse	gel	 (Lonza)	containing	!.!#	µl/ml	ethidium	bromide	(01	%	solution,	 Sigma-Aldrich).	 After	 agarose	 gel	 electrophoresis	 (BioRad),	 the	 gel	 was	visualized	under	UV	light	(GelDoc	XR+,	BioRad).	The	expected	amplicon	lengths	were	!""	bp	for	Ahsg-/-	and	%&''	bp	for	wildtype	products.			
Table	!:	Fetuin-A	genotyping	PCR	mastermix.		 Table	 !:	 PCR	 program	 used	 for	 fetuin-A	
genotyping.		
	 							
2.3 Bone	Culture		Newborn	 mice	 (P..0)	 were	 finalized	 by	 decapitation	 and	 tails	 were	 collected	 for	genotyping.	 To	 isolate	 tibiae	 and	 femora,	 mice	 were	 skinned	 and	 hind	 legs	 were	removed	and	kept	 in	sterile	PBS	on	ice.	Bones	were	isolated	and	surrounding	tissue	was	 carefully	 removed	 using	 ultra-fine	 tweezers	 (FST)	 under	 a	 stereo	 microscope	(MZ$,	Leica	Microsystems	GmbH).	Bones	were	washed	 once	with	α-MEM	 culture	medium	 (#"#$$$$%&,	Thermo	Fisher	Scientific).	Medium	was	prepared	 from	powder	 following	 the	manufacturer’s	instructions.	Bones	were	cultured	in	α-MEM	with	additional	-.	µg/ml	l-ascorbic	acid	(cell-culture	 tested,	 Sigma-Aldrich),	 +	%	 BSA	 fraction	 V	 (Sigma-Aldrich),	 +,+	µg/ml	l-glutamine,	 ,--	U/ml	 penicillin,	 ,--	ng/ml	 antibiotics	
Reagent	 Volume	 [µl]	 per	 -.	
µl	reaction	
!"x	Buffer		 !.#	
dNTPs	'(	µM	 !.#	
Betain	(	M	 !	
Wildtype	Sense	 !.#$	
Antisense	 !.#$	
Knockout	Sense	 !.#$%	
Taq	polymerase	 !.#$%	
Nuclease-free	water	 !".$%	
gDNA		 !	
Temperature	[°C]	 Time	[min]	 Cycles	!"	 !:##	 	!"	 !:#!	 !"	x	!"	 !:##	!"	 !:##	!"	 !:##	 	!"	 ∞	 	
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(Penicillin-Streptomycin-Glutamine,	 Thermo	 Fisher	 Scientific)	 and	 ,	mM	β-glycerophosphate	(Sigma-Aldrich).	One	day	after	isolation,	bones	were	treated	with	fetuin-A,	 all-trans-retinoic	 acid	 (ATRA)	 or	 both.	 Delipidized	 fetuin-A	monomer	 (see	section	 !.#.$)	 was	 added	 at	 concentrations	 of	 -./	mg/ml	 or	 (	mg/ml.	 ATRA	 (R&'(&,	Sigma-Aldrich)	was	prepared	as	a	/00	µM	stock	solution	in	ethanol	(molecular	biology	grade,	Applichem)	and	diluted	in	culture	medium	to	concentrations	of	#$%	or	(%%	nM.	ATRA	 solutions	 were	 stored	 under	 nitrogen	 gas	 at	 -!"	°	 for	 better	 preservation.	Vehicle	 (ethanol)	was	 added	 to	 samples	which	were	not	 treated	with	 ATRA.	 Bones	were	 incubated	 at	 -.	°C	with	 &	%	CO!.	 Calibrated	micrographs	were	 taken	under	 a	light	 microscope	 (DM-IRB,	 Leica	 Microsystems	 GmbH,	 camera	 !CCD,	 JVC)	 using	Diskus	microspcopy	software	(Technisches	Büro	Hilgers).	Bone	length	was	measured	with	the	image	analysis	software	ImageJ	!"#.		
2.3.1 Delipidation	and	Purification	of	Fetuin-A	
 Crude	 fetuin-A	 (F"#$%,	 Sigma-Aldrich)	 was	 delipidized	 in	 order	 to	 remove	 lipidic	contaminations	following	a	protocol	by	Chen	!"".	Briefly,	+,-	mg	of	activated	charcoal	powder	 (Sigma-Aldrich)	 was	 added	 to	 0.20	ml	 of	 a	 '((	mg/ml	 solution	 of	 crude	fetuin-A	in	ultrapure	water.	The	pH	of	the	protein-charcoal	mixture	was	adjusted	to	2	using	concentrated	hydrochloric	acid.	The	solution	was	stirred	for	!	h	on	ice	followed	by	centrifugation	at	$%,%%%	g	 for	&'	min	at	$	°C.	The	pH	was	readjusted	 to	2	using	a	sodium	hydroxide	solution	and	the	remaining	activated	charcoal	was	removed	using	a	!.#!	µm	 syringe	 filter.	 The	 resulting	 delipidized	 solution	 contained	 a	 mixture	 of	monomer,	dimers	and	aggregates.	The	monomer	was	purified	from	the	solution	by	gel	filtration	 on	 a	 superdex	 0!!	!"/"$	column	 (GE	Healthcare).	 The	 protein	was	 eluted	with	 PBS	 at	 a	 flow	 rate	 of	 (	mg/ml.	 Fractions	 of	 1	ml	 were	 collected,	 whereby	 the	desired	 fetuin-A	 monomer	 was	 found	 in	 fractions	 11-!".	 The	 pooled	 monomer	fractions	 were	 concentrated	 by	 centrifuging	 twice	 with	 centrifuge	 filter	 units	(Centriprep	 *+k,	 Merck	 Millipore)	 following	 the	 manufacturer’s	 instructions.	 The	concentration	 of	 the	 final	 fetuin-A	 monomer	 solution	 was	 determined	 with	 a	bicinchoninic	 acid	 (BCA)	 assay	 kit	 (Thermo	 Fisher	 Scientific)	 according	 to	 the	manufacturer’s	instructions.	Per	sample,	three	technical	replicates	were	measured	in	
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a	 #$-well	 microtiter	 plate	 using	 the	 FLUOstar	 Optima	 microplate	 reader	 (BMG	Labtech)	at	*+,	nm	wavelength.	
 
2.4 Bone	Length	Measurement	
 Bones	 from	 newborn	 mice	 and	 cultured	 bones	 were	 measured	 using	 calibrated	micrographs.	For	mice	two	weeks	of	age	and	older,	calipers	were	used	for	measuring.	In	femora,	the	length	from	the	distal	condyles	to	the	greater	trochanter	was	assessed;	tibiae	were	measured	from	the	most	distal	to	the	most	proximal	protrusion.		
2.5 Determination	of	GAG	Concentration		A	protocol	was	established	following	publications	from	Zhang	et	al.	!"#	and	Frazier	et	
al.	!"#.	 From	 a	 dye	 stock	 solution	 (4	%	 alcian	 blue	 (Sigma-Aldrich),	 18	mM	 H2SO4	(Applichem)),	an	alcian	blue	working	solution	(1:100	dilution	of	dye	stock	in	18	mM	H2SO4)	 was	 prepared.	 The	 absorbance	 of	 the	 working	 solution	 should	 be	 1.4	 at	600	nm.	Dye	was	added	to	adjust	the	absorbance,	if	necessary.	The	working	solution	was	 then	 centrifuged	 at	 10,000	g	 for	 30	min.	 Triton	 X-100	 was	 added	 to	 a	concentration	of	0.25	%.	Finally,	the	solution	was	filtered	through	a	2	µm	filter.		For	 each	 sample,	 100	µl	 undiluted	 cell	 culture	 supernatant	 was	 mixed	 with	100	µl	of	additional	solution	(27	mM	H2SO4,	0.375	Triton	X-100,	4	M	guanidine	HCl),	then	1000	µl	 alcian	blue	working	 solution	was	 added.	 Solutions	were	 vortexed	 and	centrifuged	for	10	min	at	1,600	g.	The	supernatant	was	removed	and	the	pellet	was	dissolved	in	250	µl	of	dissolving	solution	(8	M	guanidine	HCl)	by	vigorous	vortexing	the	 solution.	 Samples	were	 again	 centrifuged	 for	 3	min	 at	 1,600	g	 and	 per	 sample,	200	µl	of	 the	supernatant	was	 transferred	 into	 the	well	of	a	96-well	plate.	For	each	sample,	 three	 technical	 replicates	 were	 measured.	 Absorbance	 was	 determined	 at	600	nm	wavelength	using	a	spectrophotometer	(FLUOStar	Optima,	BMG	Labtech).	To	quantify	glycosaminoglycan	concentrations,	a	standard	curve	was	prepared	using	 chondroitin	 sulfate	 (C9819,	 Sigma-Aldrich)	 dissolved	 in	 cell	 culture	medium,	with	concentrations	ranging	from	10	to	125	µg/ml.		
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2.6 Histology		
2.6.1 Preparation	of	Paraffin	Sections		Mice	were	 finalized	with	an	overdose	of	 Isofluran	(Forene,	AbbVie)	and	subsequent	cervical	 dislocation.	 Bones	 were	 harvested	 and	 immediately	 fixed	 in	 ice-cold	 &	%	paraformaldehyde	(PFA,	Sigma-Aldrich)	or	zinc	fixative	(BD	Biosciences)	at	1	°C	on	a	shaker	 for	 *+	h.	 PFA	 was	 prepared	 from	 PFA	 powder	 in	 phosphate	 buﬀered	 saline	(Merck	Millipore)	and	frozen	as	a	12	%	concentrated	solution	at	pH	!.#.	After	fixation,	bones	were	decalcified	in	/!"	mM	EDTA	in	PBS,	pH	!.#	at	#	°C	on	a	shaker	for	one	to	ten	days,	depending	on	the	age	of	the	animal.		Bones	 were	 dehydrated	 in	 ascending	 ethanol	 concentrations	 and	 xylol	 in	 a	vacuum	 infiltration	 processor	 (Tissue	 Tek	 VIP,	 Sakura	 Finetek)	 and	 embedded	 in	paraﬃn	on	a	tissue	embedding	center	(EG**+,,	Leica).	Samples	were	sectioned	on	a	sledge	microtome	 (pmf	medical)	 into	 1	µm	 thin	 sections	 and	 stretched	 on	 a	 water	bath	 (Fa.	 Jung)	 at	 !"	°C.	 Samples	 were	 mounted	 on	 microscope	 slides	 (Superfrost,	Thermo	 Fisher	 Scientific)	 and	 dried	 overnight	 at	 56	°C.	 Prior	 to	 further	 processing,	glass	slides	were	placed	 in	an	oven	at	01	°C	for	&'	min	 to	ensure	better	adhesion	of	the	specimen	to	the	glass	slide.	Slides	were	deparaﬃnized	by	two	changes	of	xylol	for	!	min	each,	followed	by	washing	in	descending	ethanol	concentrations.		
2.6.2 Preparation	of	Frozen	Sections		Mice	were	 finalized	with	an	overdose	of	 Isofluran	(Forene,	AbbVie)	and	subsequent	cervical	 dislocation.	 Bones	 were	 harvested	 and	 immediately	 transferred	 into	cryo-molds	 (Sakura	 Finetek)	 containing	O.C.T.	 compound	 (Sakura	 Finetek).	 Samples	were	 frozen	 on	 isopentane	 (Sigma-Aldrich)	 cooled	 on	 dry	 ice	 and	 stored	 at	 -!"	°C	until	further	processing.	Bones	were	 sectioned	on	a	cryotome	 (CM,---,	 Jung)	 into	5	µm	 thin	sections	and	mounted	 on	microscope	 slides	 (Superfrost,	 Thermo	 Fisher	 Scientific).	 Sections	were	stored	at	 -!"	°C	until	 further	processing.	Prior	 to	staining,	 slides	were	washed	for	%	min	in	ultrapure	water.	
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2.6.3 Preparation	of	Acrylate	Sections		Mice	were	 finalized	with	an	overdose	of	 Isofluran	(Forene,	AbbVie)	and	subsequent	cervical	 dislocation.	 Bones	 were	 harvested	 and	 immediately	 fixed	 in	 ice-cold	 &	%	paraformaldehyde	 (PFA)	 at	 3	 °C	 on	 a	 shaker	 for	 $%	h.	 They	 were	 stored	 in	 /0	%	ethanol	 until	 further	 processing.	 Acrylate	 embedding,	 sectioning	 and	 staining	were	carried	out	by	the	Institute	for	Osteology	and	Biomechanics	of	the	University	Medical	Center	 Hamburg-Eppendorf.	 Briefly,	 samples	 were	 slowly	 dehydrated	 in	 ascending	ethanol	concentrations	and	infiltrated	in	methyl	methacrylate	(MMA,	&''()',	Merck	Millipore)	destabilized	with	1.1	g/l	benzoyl	peroxide	(BPO,	)*+,-+,	Merck)	and	+**	ml	nonylphenol	(Sigma	Aldrich)	then	embedded	in	MMA,	destabilized	with	1,1	g/l	BPO,	!""	 ml/l	 nonylphenol	 and	 the	 starter	 N,N	 Dimethyl-p-toluidine	 ("##$%$,	 Merck	Millipore)	at	,	°C.	After	hardening,	the	specimen-containing	MMA	blocks	were	sanded	down	 to	 a	 diamond	 shape	 and	 .	µm	 thin	 sections	 were	 cut	 with	 a	 rotational	microtome.	Sections	were	then	transferred	to	gelatin-coated	slides	and	stretched	on	the	 slides	 with	 stretching	 solution	 (()	%	 #-butoxyethanol,	 ./	%	 ethanol).	 After	sectioning,	 all	 glass	 slides	 were	 stacked	 with	 Parafilm	 (Bemis	 Company)	 and	 filter	paper	(Whatman)	between	each	slide	and	pressed	together	with	a	screw	clamp	and	dried	overnight	at	-.	°C.	For	toluidine	blue	staining,	plastic	was	removed	from	the	sections	with	three	changes	 of	 +-methoxyethyl	 acetate.	 Samples	 were	 slowly	 rehydrated	 in	 descending	ethanol	concentrations.	They	were	stained	 for	,-	min	with	 !	%	 [w/v]	 toluidine	blue	solution	(pH	!.#),	dehydrated	in	ascending	ethanol	concentrations	and	two	changes	of	xylol,	then	mounted	with	DPX	(Sigma-Aldrich)	and	coverslipped.		
2.6.4 Determination	of	Cellular	Parameters	from	Acrylate	Sections		Toluidine	blue	stained	acrylate	sections	of	undecalcified	bone	were	observed	under	a	microscope.	For	 each	 sample,	 four	different	 fields	 of	 view	 of	 trabecular	 bone	were	selected.	From	each	field	of	view,	three	micrographs	were	taken,	each	with	a	different	focus	setting	to	better	see	the	different	cells.	For	each	region,	bone	perimeter	and	area	were	 measured	 using	 ImageJ	 image	 analysis	 software	!"#.	 The	 numbers	 of	
MATERIALS	AND	METHODS	 45	
bone-residing	 osteocytes	 inside	 the	 trabecular	 bone,	 the	 numbers	 of	 bone-forming	osteoblasts	and	bone-resorbing	osteoclasts	were	determined	from	the	sections.	Also,	the	area	under	osteoblasts	and	osteoclasts	was	measured	using	ImageJ	!"#.		
2.6.5 Fetuin-A	Immunohistology		Deparaﬃnized	 sections	 were	 blocked	 with	 0	%	[w/v]	 milk	 powder	 (Applichem)	 in	PBS	 (Biochrom)	 for	 !	h	at	 room	 temperature.	 Primary	 rabbit	 anti-mouse	 antiserum	(K#$%,	 (:(**	 dilution	 in	 PBS)	 was	 incubated	 either	 at	 room	 temperature	 for	 &	h	 or	overnight	at	,	°C.	After	washing	the	slides	in	PBS	three	times	for	0	min	each,	sections	were	 incubated	 with	 the	 secondary	 Alexa	 456-labeled	 goat	 anti-rabbit	 antibody	(Thermo	 Fisher	 Scientific)	 for	 .	h	 at	 room	 temperature.	 Blocking	 and	 antibody	incubation	 were	 performed	 in	 humidity	 chamber	 to	 prevent	 drying.	 Samples	 were	repeatedly	 washed	 with	 PBS	 and	 counterstained	 with	 DAPI	("’,%-diamidino-!-phenylindole)	nuclear	stain.	After	staining,	sections	were	mounted	in	aqueous	mountant	(Shandon	Immu-Mount,	Thermo	Fisher	Scientific),	coverslipped	and	examined	with	a	fluorescence	microscope	(Leica	Microsystems	GmbH).		
2.6.6 Safranin	O	Staining		Deparaﬃnized	 sections	 were	 stained	 with	 Weigert’s	 iron	 hematoxylin	 working	solution	 (Carl	 Roth	 GmbH	 &	 Co.	 KG)	 for	 ./	min	 and	 then	 samples	 were	 blued	 for	!"	min	under	running	tap	water.	Sections	were	 incubated	 in	+.+-	%	[w/v]	 fast	green	FCF	(Sigma-Aldrich)	in	water	for	1	min	and	quickly	washed	twice	with	1	%	acetic	acid	before	staining	with	!.#	%	[w/v]	safranin	O	(Sigma-Aldrich)	for	,	min.	Samples	were	dehydrated	 in	 ascending	 ethanol	 concentrations	 and	 xylol,	 mounted	 in	 resinous	mountant	(Histokitt,	Carl	Roth	GmbH	&	Co.	KG)	and	coverslipped.		
2.6.7 Toluidine	Blue	Staining		Toluidine	 blue	 stock	 solution	 (/	%	[w/v]	 toluidine	 blue	 (Sigma-Aldrich)	 in	 +,	%	ethanol)	 was	 freshly	 diluted	 in	 /:/1	 in	 /	%	 ultrapure	water	 containing	 )	%	 sodium	
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chloride	and	the	pH	was	adjusted	to	*	using	glacial	acetic	acid.	Deparaﬃnized	sections	were	stained	for	-	min	in	the	toluidine	blue	working	solution	and	dehydrated	quickly	in	!"	%	and	 &''	%	ethanol	 and	xylol.	 Sections	were	mounted	 in	 resinous	mountant	(Histokitt,	Carl	Roth	GmbH	&	Co.	KG)	and	coverslipped.	Toludine	 blue	 staining	 of	 paraffin	 sections	 was	 quantified	 using	 ImageJ	software	!"#.	For	 each	 sample,	 one	 section	was	 evaluated.	Briefly,	 regions	of	 interest	were	 defined	 on	 micrographs	 of	 toluidine	 blue	 stained	 sections	 in	 imageJ,	corresponding	to	the	proliferative	and	the	hypertrophic	zone.	The	color	threshold	was	adjusted	to	include	all	stained	areas,	and	the	image	was	binarized	(black/white)	and	the	black	areas	were	quantified.		
2.6.8 Von	Kossa	Staining		Undecalcified	frozen	sections	were	fixed	in	ice-cold	acetone	for	,	min,	then	washed	in	ultrapure	water	for	another	.	min.	Slides	were	incubated	for	(	min	in	%	%	[w/v]	silver	nitrate	(Carl	Roth)	and	washed	for	23	min	with	deionized	water.	The	silver	nitrate	was	developed	 in	 sodaformol	 (Applichem)	 for	 3	min	 followed	 by	 -.	min	 washing	 in	deionized	water	 and	 )	min	 incubation	 in	 +	%	 sodium	 thiosulfate	 (Merck	Millipore).	After	 another	 ()	min	 washing	 step,	 counterstaining	 was	 performed	 using	 4.6	%	nuclear	 fast	 red	 (with	 !	%	 aluminum	 sulfate	 in	 distilled	 water,	 Sigma-Aldrich)	 for	!	min.	 Samples	 were	 dehydrated	 in	 descending	 ethanol	 concentrations	 and	 xylol,	mounted	 with	 resinous	 mountant	 (Histokitt,	 Carl	 Roth	 GmbH	 &	 Co.	 KG)	 and	coverslipped.			
2.6.9 TUNEL	Staining	for	Apoptosis		Apoptotic	cells	were	visualized	using	the	terminal	deoxynucleotidyl	transferase	dUTP	nick	 end	 labeling	 (TUNEL)	 method.	 Deparaﬃnized	 sections	 were	 stained	 with	 the	DeadEnd™	Fluorometric	 TUNEL	 System	 (Promega)	 according	 to	 the	manufacturer’s	protocol.		
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2.7 Proliferation	Measurement		For	 proliferation	 measurement	 both	 in	 vitro	 and	 in	 vivo,	 the	 Click-iT®	 EdU	 Alexa	Fluor®	 ())	 Imaging	 Kit	 (Thermo	 Fisher	 Scientific)	 was	 used	 according	 to	 the	manufacturer’s	protocols.		
2.7.1 Proliferation	In	Vitro			A	solution	of	+,	mM	EdU	in	sterile	PBS	was	diluted	in	medium	to	a	concentration	of	25	µM.	Cultured	bones	were	incubated	in	EdU-containing	medium	for	!"	h,	fixed	with	zinc	 fixative	 (BD	 Biosciences)	 and	 prepared	 for	 routine	 paraﬃn	 embedding	 as	described	 in	 !.#.$).	 !	µm	 thin	 paraffin	 sections	 were	 stained	 according	 to	 the	manufacturer’s	protocol	and	counterstained	with	DAPI	(Sigma-Aldrich).	Proliferation	was	 assessed	 in	 the	 proliferative	 zone	 and	 in	 periosteum/perichondrium	 using	 a	semiquantitative	scoring	system	as	shown	in	Table	3.		
Table	!:	Scoring	system	for	proliferation	measurement	of	in	vitro	cultured	bones.	
	
								
2.7.2 Proliferation	In	Vivo		A	solution	of	+,	mM	EdU	in	sterile	PBS	was	injected	intraperitoneally	into	./	days	old	male	 mice.	 Per	 gram	 bodyweight,	 34	µl	 of	 the	 solution	 was	 injected.	 Mice	 were	sacrificed	with	 isoflurane	 1	h	 after	 injection.	 Bones	were	 isolated	 and	 prepared	 for	paraﬃn	 sectioning	 as	 described	 in	 section	 !.#.$.	 Paraffin	 embedded	 samples	 were	sectioned	 at	 +	µm	 thickness,	 stained	 according	 to	 the	 manufacturer’s	 protocol	 and	conterstained	with	DAPI	(Sigma-Aldrich).	Number	of	EdU	positive	and	total	number	
Score	 EdU+	cells		in	area	of	interest	[%]	!	 !	!	 !	-	!"	!	 !"	-	!"	!	 !"	-	!"	!	 !"	-	!"	!	 !"	-	!"	
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of	cells	in	the	proliferative	zones	were	determined	with	automated	counting	using	the	image	analysis	software	ImageJ	!"#.			
2.8 Micro-Computed	Tomography	Measurements		Femora	were	fixed	in	ice-cold	$	%	PFA	in	PBS	on	a	shaker	for	/0	h	and	stored	in	+,	%	ethanol	 until	 measurement.	 Measurements	 were	 carried	 out	 at	 the	 Institute	 for	Osteology	 and	 Biomechanics	 of	 the	 University	Medical	 Center	Hamburg-Eppendorf.	The	 samples	 were	 placed	 in	 a	 radio-translucent	 sample	 holder	 filled	 with	 PBS	 to	prevent	 desiccation.	 Micro-computed	 tomography	 (µCT)	 scanning	 was	 performed	using	 a	 µCT	 +,	 desktop	 cone-beam	microCT	 (Scanco	Medical)	 with	 a	 voxel	 size	 of	!"	µm	($%%%	projections	per	slice	with	*+,-	samples	and	*++	s	sample	time	at	a	tube	energy	of	!!	kVp	with	 an	 intensity	 of	 12!	mA).	Reconstructed	 slices	were	 inspected	using	the	Scanco	MicroCT	software	suite.	Specifically,	trabecular	bone	was	analyzed	in	the	 distal	 metaphysis	 in	 a	 volume	 situated	 -.//	mm	 to	 %&&	mm	 proximal	 of	 the	growth	 plate	 using	 the	 script	 ‘UCT_EVALUATIONV=_MULTIAUTO’	 (parameters:	 Seg:	!.#|%|&'!|%!!!|(|!.#|%|&'!|%!!!|(|!.#|&|)!!|%!!!|(;	 Misc:	 &'|)!|%!|&|)|%).	 Cortical	bone	was	analyzed	in	an	.///	mm	long	volume	situated	in	the	middle	of	the	diaphysis	using	 the	 same	 script	 as	 above	 with	 the	 following	 parameters:	 Seg:	!.#|%|&!!|%!!!|'|!.#|%|&!!|%!!!|'|!.#|(|&)!|%!!!|'|!.#|(|&)!|%!!!|';	 Misc:	!"|$"|!|!|"|!).	Reconstructed	samples	were	visualized	using	Philips	Imalytics	!"#.	Angle	measurements	were	performed	using	ImageJ	image	analysis	software	!"#.		
2.9 Laser	Capture	Micodissection			Bones	were	 isolated	 and	 embedded	 under	 nuclease-free	 conditions	 as	described	 in	section	!.#.!.	Embedded	samples	were	stored	at	 -!"	°C	until	 further	processing.	For	microarray	analysis,	-.	µm	thick	frozen	sections	from	right	femora	of	()	days	old	male	pups	were	prepared	under	nuclease-free	conditions.	Sections	were	 transferred	onto	PEN-membrane	 slides	 (Zeiss)	 and	 fixed	 in	 &'	%	 ethanol	 for	 !	min,	 dehydrated	 in	!""	%	ethanol	for	,	min,	air	dried	at	room	temperature	for	+	min	and	stored	at	-!"	°C	
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for	 up	 to	 ()	h	 until	 further	 processing.	 LCM	 was	 performed	 using	 a	 Zeiss	 P.A.L.M.	micro	 laser	 system.	 For	 each	 sample,	 approx.	 34	 sections	 were	 prepared	 and	processed.	For	each	section,	the	entire	growth	plate	(resting	zone,	proliferative	zone	and	hypertrophic	 zone)	was	 isolated	and	 captured	 in	 specialized	adhesive	 cap	 tube	(Zeiss).	The	 isolated	 tissue	was	suspended	 in	%&	µl	extraction	buﬀer	 (PicoPure	RNA	Isolation	 Kit,	 Thermo	 Fisher	 Scientific),	 incubated	 at	 *+	°C	 for	 '(	min	 and	 stored	at	-!"	°C	until	RNA	isolation,	which	was	carried	out	according	to	the	manufacturer’s	protocol	(PicoPure	RNA	Isolation	Kit,	Thermo	Fisher	Scientific).		
2.10 Microarray	Analysis		Microarray	 measurements	 were	 carried	 out	 by	 the	 Chip	 facility	 of	 the	 Aachen	University	Clinics.	RNA	quality	and	quantity	were	assessed	using	NanoDrop	(Thermo	Fisher	 Scientific)	 and	 Agilent	 Bioanalyzer	 (Agilent	 Technologies).	 For	 microarray	analysis,	RNA	was	transcribed	and	labeled	using	the	GeneChip	WT	PLUS	Reagent	Kit	(Aﬀymetrix)	 according	 to	 the	 manufacturer’s	 instructions.	 Labeled	 cDNA	 was	hybridized	 to	 GeneChip	 Mouse	 Transcriptome	 Array	 8.:	 (Aﬀymetrix)	 and	 the	hybridization	was	visualized	using	the	proprietary	Aﬀymetrix	staining	kit.	Gene	data	analysis	was	performed	using	Aﬀymetrix	Expression	Console	Software.	The	SST-RMA	algorithm	 was	 used	 for	 data	 normalization.	 Robust	 mean	 signal	 values	 were	calculated	using	the	Tukey’s	biweight	estimator.	For	calculating	significance	(p-value),	the	 non-parametric	Wilcoxon’s	 rank	 test	was	 used.	Probe	 sets	with	 a	 p-value	 <	 (.*	were	considered	as	diﬀerentially	expressed.	To	 validate	 the	 microarray	 data,	 a	 portion	 of	 the	 RNA	 used	 for	 gene	 chip	analysis	 was	 reverse	 transcribed	 and	with	 the	 resulting	 cDNA,	 real	 time	 PCR	 was	performed	(see	section	!.##)	on	seven	target	genes	(Cxcl%,	Ifit,,	Usp,0,	Gbp3,	Igtp,	Il,b,	
Stat$),	which	were	highly	diﬀerentially	expressed	according	to	microarray	analysis.		 	
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2.11 Real-Time	PCR		Validation	of	microarray	data	was	carried	out	using	real-time	PCR.	Isolated	RNA	was	reverse	 transcribed	 into	 cDNA	 using	 the	 Maxima	 First	 Strand	 cDNA	 Synthesis	 Kit	(Thermo	 Fisher	 Scientific)	 according	 to	 the	manufacturer’s	 protocol.	 As	 total	 RNA	concentrations	 were	 low,	 all	 remaining	 RNA	 was	 used	 for	 the	 reaction.	 The	concentration	 of	 the	 resulting	 cDNA	 was	 determined	 with	 a	 Nanodrop	 (Thermo	Fisher	Scientific)	and	cDNA	was	diluted	to	34	ng/ml	and	stored	at	-!"	°C.	For	the	real-time	PCR	reaction	Primers	were	pre-diluted	in	nuclease-free	water	to	concentrations	of	,	µM	or	&'	µM.	Primer	sequences	are	shown	in	Table	4.	We	used	the	 Maxima	 SYBR	 Green/ROX	 qPCR	 Master	 Mix	 (K:;;<,	 Thermo	 Fisher	 Scientific).	Table	 5	 shows	 the	 composition	 of	 the	 PCR	 reaction	mixture.	Mastermix	 and	 cDNA	template	were	combined	inside	an	optical	12-wells	plate,	and	PCR	was	performed	in	a	Lightcycler	(Applied	Biosystems).	The	program	used	is	shown	in	Table	'.	Fold-changes	 were	 determined	 with	 the	 ΔΔCT	 method	 using	 the	 gene	 for	glyceraldehyde	 !-phosphate	 dehydrogenase	 (GAPDH)	 as	 internal	 control.	 Primers	were	previously	tested	for	efficiency.		
Table	!:	Primer	sequences	for	microarray	data	validation.	
Primer	 Primer	Sequence	(-´	–	!´)	Gapdh	fwd	 AGATGGTGATGGGCTTCCC	Gapdh	rev	 GGCAAATTCAACGGCACAGT	Cxcl%	fwd	 GGAGTTCGAGGAACCCTAGTG	Cxcl%	rev	 GGGATTTGTAGTGGATCGTGC	Ifit%	fwd	 GCCTATCGCCAAGATTTAGATGA	Ifit%	rev	 TTCTGGATTTAACCGGACAGC	Usp$%	fwd	 TTGGGCTCCTGAGGAAACC	Usp$%	rev	 CGATGTTGTGTAAACCAACCAGA	Gbp$	fwd	 CTGCACTATGTGACGGAGCTA	Gbp$	rev	 GAGTCCACACAAAGGTTGGAAA	Igtp	fwd	 CTCATCAGCCCGTGGTCTAAA	Igtp	rev	 CACCGCCTTACCAATATCTTCAA	Il#b	fwd	 GCAACTGTTCCTGAACTCAACT	Il#b	rev	 ATCTTTTGGGGTCCGTCAACT	Stat$	fwd	 GCTGCCTATGATGTCTCGTTT	Stat$	rev	 TGCTTTTCCGTATGTTGTGCT		 			
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Table	!:	Composition	of	PCR	reaction	mixture.	 	 	Table	!:	Real-time	PCR	program.	
		 						
2.12 Statistics		Statistical	 analysis	 of	 data	 was	 performed	 with	 Prism	 5	 for	 Mac	 OS	 software	(Graphpad).	 For	 the	 determination	 of	 statistical	 significance,	 one-way	 ANOVA	with	Tukey’s	multiple	comparison	test	was	applied.	For	the	determination	of	correlation	in	contingency	tables,	Fisher’s	exact	test	was	used.			 	
Reagent	 Volume	 [µl]	 per	 !"	µl	
reaction	Master	Mix	(+x)	 !".$	Forward	Primer	 !.#	Reverse	Primer	 !.#	MgCl!	 !.#	-	!	mM	cDNA		 !	Nuclease-free	water	 To	$%	µl	total	volume	
Temperature	
[°C]	
Time	[min]	 Cycles	
!"	 !:##	 	!"	 !":""	 	!"	 !:#$	 !"	x	!"	-	!"	 !:##	
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! RESULTS		
3.1 Influence	of	Fetuin-A	and	Retinoic	Acid	one	Bone	
Growth	In	Vitro		Fetuin-A-deficient	mice	have	shortened	femoral	bones,	indicating	a	role	for	fetuin-A	in	endochondral	 ossification	!"#,!"!.	 Retinoic	 acid	 signaling	 plays	 a	 major	 role	 in	endochondral	 ossification	 as	 well	 as	 in	 many	 other	 developmental	 processes	!!".	Animals	 treated	 with	 high	 doses	 of	 retinoic	 acid	 show	 a	 shortening	 of	 their	femora	!!"-!"#.	We	thus	hypothesized	that	fetuin-A	regulates	retinoic	acid	signaling	in	the	 growth	 plate	 and	 the	 fetuin-A	 deficient	 bone	 phenotype	 is	 a	 consequence	 of	excess	retinoic	acid	signaling	in	growth	plate	cartilage.		
	
Figure	!":	Ex	vivo	bone	growth.	Micrographs	of	a	cultured	tibia	over	the	course	of	seven	days	show	the	increase	in	length	and	width.	Scale	bar	is	,--!	µm.		
3.1.1 Bone	Culture		To	elucidate	the	role	of	fetuin-A	in	retinoic	acid	signaling	during	endochondral	bone	growth,	 a	bone	culture	 system,	 first	established	during	my	Master	 thesis	work,	was	used	 !"#.	Bone	 culture	 systems	are	utilized	 to	 investigate	 the	 influence	of	hormones	and	 cytokines	 on	 endochondral	 ossification	!"#.	 Usually,	 embryonic	 metatarsal	rudiments	 are	 used	 for	 bone	 culture,	 but	 culture	 of	 postnatal	 bones	 has	 also	 been	reported	in	the	literature	!"#.	
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In	 this	study,	we	utilized	bones	 from	newborn	mice.	Briefly,	 tibiae	and	 femora	were	isolated	 from	 newborn	 (P2.4)	 mice	 and	 cultured	 for	 four	 days	 with	 and	 without	fetuin-A	 and	 all-trans-retinoic	 acid	 (ATRA).	 Figure	 ()	 shows	 how	 a	 single	 tibia	 in	culture	 increased	 in	 length	 over	 time.	 This	 demonstrates	 that	 endochondral	ossification	continued	ex	vivo	after	the	bone	was	isolated	from	the	animal.		
		
Figure	!!:	The	influence	of	genetic	background	and	fetuin-A	deficiency	on	Δ	bone	length	of	cultured	bones.	Bones	from	diﬀerent	genetic	backgrounds	(BL/7	and	DBA/:),	either	wildtype	or	fetuin-A-deficient	(Ahsg-/-),	were	cultured	with	 vehicle	 for	 four	 days.	Error	 bars	 show	mean	 ±	 SD.	 Data	was	 collected	 from	 3	 to	 45	 independent	experiments	per	genotype.	 Statistical	 evaluation	was	 carried	out	using	ANOVA	with	Bonferroni	 post	 test.	There	were	no	statistically	significant	differences.		
3.1.2 The	Influence	of	Fetuin-A	and	ATRA	on	Bone	Growth	In	Vitro			Bones	 from	diﬀerent	genotypes	were	used	 for	bone	culture.	We	utilized	bones	 from	C"#BL/'	 wildtype,	 C"#BL/'-Ahsg-/-,	 DBA/'	 wildtype	 and	 DBA/'-Ahsg-/-	 mice.	 To	determine	 the	 changes	 in	 bone	 length,	 ten	 individual	 experiments	were	 performed	with	BL/)	wildtype,	 01	with	BL/)	Ahsg-/-,	 nine	with	DBA/-	wildtype	and	eight	with	DBA/%	Ahsg-/-	bones.	On	average,	nine	 tibiae	and	eight	 femora	per	experiment	were	used.	 On	 day	 one	 after	 isolation,	 bones	 were	 incubated	 for	 four	 days	 in	 medium	containing	either	,-.	nM	or	&''	nM	retinoic	acid,	with	or	without	0.2	mg/ml	fetuin-A	and	 vehicle	 or	 with	 vehicle	 (ethanol)	 only	 as	 a	 control.	 The	 lengths	 of	 tibiae	 and	femora	were	determined	on	day	one	and	day	four	of	culture	and	the	relative	change	in	bone	length	(Δ	bone	length)	was	plotted	against	the	genotype.	Figure	((	shows	the	bone	lengths	of	bones	treated	with	vehicle	(ethanol)	alone,	which	 served	 as	 a	 control.	 Bones	 from	 BL/6	mice	 showed	 a	 similar	Δ	bone	 length	
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between	 wildtype	 and	 Ahsg-/-.	 Also,	 tibiae	 and	 femora	 from	 BL/5	 mice	 had	comparable	Δ	bone	lengths.	Bones	from	DBA/)	wildtype	mice	showed	a	slightly	lower	mean	 Δ	bone	 length	 compared	 to	 BL/3	 wildtype	 mice.	 Also	 bones	 from	 DBA/'	
Ahsg-/-	mice	showed	a	slight	increase	in	Δ	bone	length	with	respect	to	DBA/4	wildtype	bones.	However,	none	of	the	observed	differences	were	statistically	significant.	Figure	 ()	 shows	 Δ	 bone	 lengths	 of	 treated	 bones.	 Addition	 of	 ).+	 mg/ml	fetuin-A	to	bones	 from	C"#BL/$	wildtype	mice	did	not	alter	Δ	bone	 length	of	 tibiae	and	 femora	 compared	 to	 controls	 (see	 Figure	 ()A).	 Addition	 of	 either	 $%&	nM	 or	!""	nM	ATRA	led	to	a	significant	decrease	in	Δ	bone	length	in	tibiae	and	femora	from	wildtype	mice.	When	BL/3	wildtype	 bones	were	 treated	with	 either	 *+,	 or	 .,,	nM	ATRA	 and	 (.*	mg/ml	 fetuin-A	 simultaneously,	 the	 influence	 on	 Δ	 bone	 length	 was	similar	as	that	of	ATRA	alone.	Thus	in	wildtype	bones,	treatment	with	fetuin-A	did	not	influence	 bone	 growth,	 either	 alone	 or	 in	 combination	 with	 ATRA,	 while	 ATRA	decreased	bone	growth.	Results	were	similar	for	bones	from	BL/4	Ahsg-/-	mice	with	one	exception	(see	Figure	()B).	Tibiae	and	femora	from	Ahsg-/-	mice	treated	with	fetuin-A	alone	showed	a	slight,	but	not	significant	increase	in	Δ	bone	length	compared	to	controls.	Treatment	 of	 tibiae	 and	 femora	 from	 DBA/(	 wildtype	 mice	 with	 3.5	mg/ml	fetuin-A	did	not	alter	Δ	bone	length,	compared	to	controls	(see	Figure	()C).	Addition	of	either	'()	or	+))	nM	ATRA	led	to	a	decrease	in	Δ	bone	length	in	wildtype	tibiae	and	femora,	 albeit	 the	 diﬀerence	 to	 control	 samples	 was	 not	 statistically	 significant.	 In	DBA/%	 wildtype	 bones	 treated	 with	 either	 *+,	 or	 .,,	nM	 ATRA	 and	 ).+	mg/ml	fetuin-A	simultaneously,	Δ	bone	 length	was	comparable	to	bones	treated	with	ATRA	alone.	This	increase	was	seen	in	all	bones,	except	femora	treated	with	011	nM	ATRA	and	 fetuin-A.	Thus,	 fetuin-A	slightly	 lowered	 the	ATRA-induced	growth	reduction	 in	DBA/%	wildtype	bones,	albeit	not	significantly.	Addition	of	).+	mg/ml	fetuin-A	alone	to	bones	from	DBA/1	Ahsg-/-	mice	slightly,	but	 not	 significantly,	 increased	 Δ	 bone	 length	 in	 femora,	 but	 not	 in	 tibiae	 (see	Figure	!"D).	Treatment	with	 /01	or	 311	nM	ATRA	 led	 to	 a	 slight	decrease	 in	Δ	bone	length	of	tibiae	and	femora.	When	DBA/6-Ahsg-/-	bones	were	treated	with	either	#$%	or	 $%%	nM	 ATRA	 and	 ).+	mg/ml	 fetuin-A	 simultaneously,	 the	 influence	 on	 Δ	 bone	
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length	was	similar	 to	 that	of	ATRA	alone.	Only	 in	 femora	 treated	with	 123	nM	ATRA	and	fetuin-A,	there	was	a	slight	increase	in	Δ	bone	length.	
		Figure	 !":	 The	 influence	 of	 the	 treatment	 of	 bones	 cultured	 with	 &.(	mg/ml	 fetuin-A,	 ATRA,	 or	 a	
combination	 thereof	 on	 Δ	 bone	 length.	The	 change	 in	Δ	 bone	 length	 was	 determined	 for	 bones	 from	 BL/5	wildtype	 (A),	BL/1	Ahsg-/-	 (B),	DBA/)	wildtype	 (C)	and	DBA/)	Ahsg-/-	 (D)	mice.	Treatment	with	ATRA	with	and	without	fetuin-A	decreased	Δ	bone	length	independent	of	genetic	background	or	genotype.	Error	bars	show	mean	±	SD.	Data	was	collected	from	!	to	%&	independent	experiments	per	genotype.	Statistical	evaluation	was	carried	out	using	ANOVA	with	Bonferroni	post	test:	*p<$.$&,	**p<$.$),	***p<$.$$).	The	number	below	the	significance	symbols	refers	to	the	column	to	which	the	data	showed	a	significant	difference.	
	
Figure	 !":	 The	 influence	 of	 the	 treatment	 of	 bones	with	 &	mg/ml	 fetuin-A	 on	Δ	bone	 length.	Results	 for	control	bones	and	bones	 treated	with	ATRA	alone	were	 taken	 from	Figure	 ().	Treatment	of	bones	with	 1	mg/ml	fetuin-A,	 with	 and	 without	 ATRA,	 led	 to	 similar	 results	 compared	 to	 treatment	 with	 &.(	mg/ml	 fetuin-A	 (see	Figure	!").	 Error	 bars	 show	 mean	 ±	 SD.	 Data	 was	 collected	 from	 one	 independent	 experiment	 per	 genotype.	Statistical	evaluation	was	carried	out	using	ANOVA	with	Bonferroni	post	 test:	*p<$.$&,	**p<$.$),	***p<$.$$).	The	number	below	the	significance	symbols	refers	to	the	column	to	which	the	data	showed	a	significant	difference.		
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3.1.3 Addition	of	ATRA	to	Cultured	Bones	Induced	Cartilage	
Degradation	Which	Was	Exacerbated	by	Fetuin-A				To	clarify	the	role	of	fetuin-A	in	bone	culture,	two	experiments	were	carried	out	with	bones	 from	 C+,BL/0	 mice	 using	 )	mg/ml	 instead	 of	 /.1	mg/ml	 fetuin-A,	 one	experiment	 for	 each	 genotype.	 Figure	 ()	 shows	 the	 respective	Δ	bone	 lengths.	 The	results	 for	 control	 and	ATRA-treated	 bones	were	 taken	 from	Figure	 ().	The	Δ	bone	lengths	 of	 bones	 treated	with	 1	mg/ml	 fetuin-A	alone	or	 in	 combination	with	ATRA	were	 similar	 to	 those	 from	 bones	 treated	 with	 $.&	mg/ml	 fetuin-A	 alone	 or	 in	combination	 with	 ATRA	 respectively	 (compare	 Figure	 ()).	 Interestingly,	 bones	cultured	with	1	mg/ml	 fetuin-A	alone	displayed	an	 increase	 in	 the	circumference	of	the	epiphysis	as	shown	in	Figure	14D.		
Figure	!":		Swelling	and	degradation	of	cartilage	in	
bone	 culture.	 A	 tibia	 treated	 with	 ,	mg/ml	 fetuin-A	alone	on	day	one	(A)	and	on	day	four	(B)	of	culture.	A	swelling	 of	 the	 growth	 plate	 can	 be	 seen	 (black	arrows).	 Another	 tibia	 treated	 with	 #	mg/ml	 fetuin-A	and	%&&	nM	ATRA	on	day	one	(C)	and	day	 four	(D)	of	culture.	 While	 the	 proximal	 epiphysis	 shows	 a	reduction	 of	 tissue	 in	 the	 region	 of	 the	 growth	 plate	(left	 arrow),	 the	 distal	 epiphysis	 is	 missing	 (right	arrow).	Scale	bar	is	/000	µm.		To	 quantify	 the	 observed	 cartilage	degradation,	 glycosaminoglycan	 (GAG)	concentrations	 were	 determined	 in	culture	media	and	toluidine	blue	stained	bone	 paraﬃn	 sections	 were	 evaluated.	GAGs	 are	 long	 unbranched	polysaccharides,	 which	 are	 bound	 to	glycoproteins,	 such	 as	 aggrecan,	 and	make	up	a	 large	portion	of	 the	 cartilage	extracellular	matrix.		The	presence	of	GAGs	in	the	medium	indicated	that	they	were	released	from	cartilage	through	degradation.	We	measured	GAG	content	in	culture	media	from	BL//	wildtype	and	Ahsg-/-	bones	on	day	 two	and	day	 four	of	culture,	using	 the	alcian	blue	method.	
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Briefly,	alcian	blue	dye	was	added	to	the	medium	and	formed	complexes	with	GAGs.	The	 complexes	 were	 isolated,	 washed	 and	 redissolved.	 Alcian	 blue	 dye	 from	complexes	was	quantified	using	a	spectrophotometer.	Concentrations	were	calculated	using	a	chondroitin	sulfate	standard	curve.	Figure	 ()	 shows	 GAG	 concentrations	 organized	 by	 treatment	 on	 day	 two	(Figure	()A	and	C)	and	day	four	(Figure	()B	and	D)	of	culture.	In	samples	from	BL/6	wildtype	bones	(Figure	()A	and	B),	GAG	concentrations	were	similar	on	day	two	and	on	day	four.	Control	samples	of	BL/5	wildtype	bones	contained	around	01	µg/ml	GAG	in	 the	 medium	 on	 both	 days.	 Addition	 of	 0.1	mg/ml	 fetuin-A	 alone	 led	 to	 a	 slight	increase	in	GAG	concentration	in	tibia	and	femur	samples	on	day	two,	but	not	on	day	four.	Addition	of	,-.	and	0..	nM	ATRA	increased	GAG	concentrations	on	both	days	for	both,	tibiae	and	femora.	Treatment	of	wildtype	bones	with	a	combination	of	fetuin-A	and	 either	 '()	 or	 +))	nM	 ATRA	 led	 to	 varying	 results.	 In	 tibia	 samples,	 fetuin-A	increased	 GAG	 concentrations	 in	 combination	 with	 ATRA,	 but	 only	 on	 day	 two.	 In	femur	 samples,	 only	 a	 combination	 of	 123	nM	 ATRA	 and	 fetuin-A	 increased	 GAG	release	on	day	two.	In	all	other	instances,	GAG	concentrations	were	similar	to	that	in	samples	treated	with	ATRA	alone.	Thus,	 in	wildtype	bones,	GAG	release	was	slightly	increased	on	day	,	by	addition	of	fetuin-A,	and	even	more	increased	by	ATRA	on	both	days,	but	a	combination	of	fetuin-A	and	ATRA	led	to	varying	results.	In	samples	from	Ahsg-/-	bones,	GAG	concentrations	in	the	media	were	generally	higher	 on	 day	 four	 than	 to	 day	 two,	 in	 contrast	 to	 wildtype	 samples.	 GAG	concentrations	 in	 Ahsg-/-	 control	 samples	 were	 around	 0	µg/ml	 on	 day	 two	 and	around	 ()	µg/ml	on	day	 four.	Addition	of	 0.1	mg/ml	 fetuin-A	 slightly	 increased	GAG	concentrations	 compared	 to	 control	 samples	 on	 both	 days	 and	 in	 both	 bone	 types.	Addition	 of	 ATRA	 led	 to	 an	 increase	 in	 GAG	 concentrations.	 Similar	 GAG	concentrations	 were	 found	 in	 samples	 treated	 with	 a	 combination	 of	 fetuin-A	 and	ATRA.	 In	 tibia	 samples	 however,	 treatment	 with	 fetuin-A	 and	 &'(	nM	 ATRA	simultaneously,	 increased	 GAG	 concentrations	 compared	 to	 treatment	 with	 ATRA	alone,	on	both	days.	Thus,	in	Ahsg-/-	bones,	GAG	release	was	slightly	increased	on	both	by	addition	of	fetuin-A	as	well	as	ATRA	and	a	combination	of	fetuin-A	and	ATRA	led	to	varying	results.	Notably,	GAG	release	was	higher	on	day	four	compared	to	day	two.		
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Figure	!":	The	influence	of	fetuin-A	and	ATRA	on	bone	cartilage	degradation.	GAG	concentrations	in	culture	media	were	measured	 on	 day	 two	 and	 day	 four	 of	 culture	 using	 alcian	 blue.	 GAG	 concentrations	were	 plotted	against	treatment	for	wildtype	(A,	B)	and	Ahsg-/-	bones	(C,	D).	The	GAG	concentration	in	the	medium	was	increased	when	bones	were	treated	with	ATRA,	with	and	without	fetuin-A.	Error	bars	show	mean	±	SD.	Data	was	collected	from	 two	 independent	 experiments	 for	 wildtype	 and	 five	 independent	 experiments	 for	Ahsg-/-	mice.	 Statistical	evaluation	was	 carried	 out	 using	ANOVA	with	Bonferroni	 post	 test:	 *p<$.$&,	 **p<$.$),	 ***p<$.$$).	 The	 number	below	the	significance	symbols	refers	to	the	column	to	which	the	data	showed	a	significant	difference.		Paraﬃn	 sections	 of	 cultured	 bones	 were	 stained	 with	 toluidine	 blue,	 and	 the	percentage	of	stained	area	in	the	proliferative	and	the	hypertrophic	zone	in	proximal	tibia	and	distal	femur	was	determined.	Toluidine	blue	stains	GAGs	on	paraﬃn	sections	in	 a	 dark	 blue	 color.	 Hence,	 loss	 of	 toluidine	 blue	 staining	 indicates	 a	 loss	 of	 GAGs	from	the	cartilage.	Figure	!"	shows	exemplary	micrographs	of	toluidine	blue	stained	paraﬃn	sections	from	proximal	tibiae	below	micrographs	of	the	corresponding	bones.	In	 control	 bones,	 the	 cartilaginous	 epiphyses	were	 always	 homogeneously	 stained	
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with	 toluidine	blue	 (Figure	 !"G).	Paraﬃn	sections	 from	bones	 treated	with	 fetuin-A	alone	(Figure	16H)	were	comparable	to	controls.	Bones	treated	with	either	ATRA	or	a	combination	of	fetuin-A	and	ATRA,	showed	loss	of	toluidine	blue	staining	in	the	area	of	 proliferative	 and	 hypertrophic	 cartilage	 (Figure	 16I-L).	 In	 some	 samples,	 an	unstained	 line	 appeared	 between	 the	 proliferative	 and	 the	 hypertrophic	 zone,	 as	shown	 in	 Figure	 16L.	 The	 percentage	 of	 toluidine	 blue	 stained	 area	 in	 both,	 the	proliferative	and	the	hypertrophic	zone	of	bones	from	BL/8	wildtype	and	Ahsg-/-	mice	was	 evaluated	 and	 the	 results	 are	 shown	 in	 Figure	 17.	 In	 wildtype	 control	 bones,	toluidine	 blue	 staining	 was	 around	 011	%	 in	 the	 proliferative	 zone,	 indicating	 that	without	treatment	no	measurable	degradation	took	place	in	the	proliferative	zone.	In	the	hypertrophic	 zone,	 staining	was	 around	12	%	 in	 control	 bones,	about	 '(	%	 less	compared	 to	 the	 proliferative	 zone.	 Regarding	 the	 enlarged	 size	 of	 cells	 in	 the	hypertrophic	 zone,	 the	 missing	 percentage	 in	 staining	 could	 be	 ascribed	 to	hypertrophic	 chondrocytes,	 as	 toluidine	 blue	 only	 stained	 the	 extracellular	 matrix.	Treatment	of	wildtype	bones	with	fetuin-A	alone	led	to	a	slight	decrease	of	toluidine	blue	 staining	 in	 the	 hypertrophic	 zone	 in	 one	 tibia	 sample.	Wildtype	 bones	 treated	with	&'(	nM	ATRA	showed	a	slight	decrease	in	the	percentage	of	stained	area	in	both	the	proliferative	and	the	hypertrophic	zone.	Addition	of	011	nM	ATRA	led	to	a	slight	decrease	in	stained	area	in	the	proliferative	zone,	and	even	more	in	the	hypertrophic	zone.	Here,	the	staining	of	the	hypertrophic	zone	had	a	high	standard	variation,	with	some	 of	 the	 samples	 displaying	 a	 very	 high	 decrease	 in	 stained	 area.	 A	 similar	decrease	in	staining	was	shown	using	a	combined	treatment	with	fetuin-A	and	ATRA.	
	
Figure	 !":	 Toluidine	 blue	 staining	 histology.	Figures	 A-H	 show	micrographs	 from	 proximal	 tibial	 epiphyses,	figures	G-L	show	the	respective	histological	sections	stained	with	toluidine	blue.	Bones	were	treated	with	fetuin-A,	ATRA	or	both	 for	 four	days	 in	 culture.	 Fetuin-A	alone	 induced	 a	 slight	 swelling	 in	 the	 growth	plate	but	did	not	visibly	 aﬀect	 toluidine	 blue	 staining.	 Bones	 treated	with	 ATRA	 or	 fetuin-A	 and	 ATRA	 in	 combination	 showed	 a	reduced	staining	in	proliferative	and	hypertrophic	zones	to	varying	degrees.	Scale	bars	are	both	!""	µm.	
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The	results	 for	Ahsg-/-	bones	were	similar	to	those	from	wildtype	bones.	Addition	of	!.#	mg/ml	fetuin-A	to	cultured	Ahsg-/-	bones	led	to	a	slight	decrease	of	stained	area	in	the	hypertrophic	zone.	Treatment	of	Ahsg-/-	bones	with	+,-	or	!""	nM	ATRA	led	to	a	decrease	 of	 the	 stained	 area	 in	 the	 proliferative	 zone	 with	 a	 very	 high	 standard	deviation.	 A	 combination	 of	 -..	mg/ml	 fetuin-A	 and	 &'(	nM	 ATRA	 led	 to	 similar	results	 in	 tibiae.	 Staining	 was	 more	 decreased	 in	 the	 proliferative	 and	 the	hypertrophic	zone	in	femora	treated	simultaneously	with	fetuin-A	and	&'(	nM	ATRA.	Treatment	of	tibia	and	femora	with	fetuin-A	and	&''	nM	ATRA	led	to	a	similar	loss	of	staining	 in	 the	 proliferative	 zone,	 compared	 to	 ATRA	 treatment	 alone,	 but	 a	 higher	loss	of	staining	in	the	hypertrophic	zone.		To	summarize,	neither	the	determination	of	GAG	release	from	cultured	bones,	nor	 toluidine	 blue	 stained	 bone	 paraffin	 sections	 could	 show	 that	 a	 combined	treatment	with	fetuin-A	and	ATRA	led	to	a	clear	increase	in	GAG	degradation,	albeit	an	increased	degradation	was	visible	on	bone	micrographs.		
Figure	 !":	 Evaluation	of	
toluidine	 blue	 staining.	The	 percentage	 of	toluidine	 blue	 stained	area	 in	 bone	 paraﬃn	sections	in	proximal	tibia	and	 distal	 femur	 was	determined	 using	 the	software	 ImageJ.	Percentage	 of	 stained	area	 was	 plotted	 against	the	 treatment	 for	wildtype	 (A,	 B)	 and	
Ahsg-/-	 (C,	 D)	 bones.	Treatment	 with	 fetuin-A,	ATRA	 or	 both	 led	 to	 a	decrease	 in	 staining	 to	varying	 degrees.	 Error	bars	 show	 mean	 ±	 SD.	Data	 was	 collected	 from	three	to	four	independent	experiments	 per	genotype.	 Statistical	evaluation	 was	 carried	out	 using	 ANOVA	 with	Bonferroni	 post	 test.	There	 were	 no	statistically	 significant	differences.		
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3.1.4 Localization	of	Fetuin-A			Treatment	 of	 cultured	 bones	 with	 fetuin-A	 alone	 led	 to	 cartilage	 swelling.	 A	combination	 of	 ATRA	 and	 fetuin-A	 caused	 visible	 cartilage	 degradation	 and	detachment.	To	evaluate	the	localization	of	added	fetuin-A	in	the	growth	plate,	bones	were	 cultured	 in	 the	 presence	 of	 fluorescent	 Alexa546-tagged	 fetuin-A.	 Figure	 18	shows	 representative	 paraﬃn	 sections	 stained	 with	 DAPI	(4’,6-Diamidin-2-phenylindol)	 from	 a	 tibia	 cultured	 with	 Alexa546-fetuin-A	 alone	(Figure	18A)	and	a	diﬀerent	tibia	cultured	with	Alexa546-fetuin-A	and	&''	nM	ATRA	(Figure	 18B).	 When	 fetuin-A	 alone	 was	 added	 to	 the	 medium,	 the	 mineralized	hypertrophic	 zone	 showed	 a	 bright	 red	 fluorescence,	 indicating	 the	 presence	 of	labeled	 fetuin-A.	 Also	 very	 few	 cells	 in	 the	 proliferative	 zone	were	 red	 fluorescent.	Upon	addition	of	ATRA,	almost	all	cells	of	the	proliferative	zone	were	red	fluorescent.	Red	fluorescence	was	located	intracellularly	and	overlapped	with	DAPI	staining	(see	inserts	Figure	18B).	Also	 some	DAPI	negative	 cells	 showed	a	 red	 fluorescent	 signal.	Thus,	in	the	presence	of	ATRA,	fetuin-A	localizes	in	proliferative	zone	chondrocytes.	
	
Figure	 !":	 Localization	 of	 added	 fetuin-A	 in	 the	 growth	 plates	 of	 cultured	 bones.	 Bones	 were	 cultured	without	 (A)	 and	with	 (B)	 /00	nM	ATRA	 in	 the	presence	of	Alexa	Fluor®	>?@-labeled	 (red)	 fetuin-A.	A)	Labeled	fetuin-A	accumulated	in	matrix	and	cells	of	the	hypertrophic	zone.	Few	cells	in	the	proliferative	zone	were	fetuin-A	positive.	B)	Bones	cultured	with	ATRA	showed	an	increased	accumulation	of	labeled	fetuin-A	inside	proliferative	zone	chondrocytes	(E).	Fetuin-A	was	located	intracellularly	(C,	D).	Scale	bar	is	9::	µm.	
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3.1.5 Proliferation	In	Vitro		Fetuin-A	was	localized	in	the	proliferative	zone	of	growth	plate	cartilage,	and	cartilage	degradation	 took	 place	 in	 both,	 the	 proliferative	 and	 the	 hypertrophic	 zone	 upon	treatment	with	ATRA	or	ATRA	combined	with	fetuin-A.	Thus,	we	investigated	whether	fetuin-A	and	ATRA	had	an	influence	on	chondrocyte	proliferation	in	the	growth	plate.	For	 proliferation	 measurements,	 bones	 from	 C34BL/8	 wildtype	 and	
Ahsg-/-	 mice	 were	 used.	 The	 thymidine	 analog	 .-ethynyl-!-deoxyuridine	 (EdU)	 was	added	 into	 the	culture	medium	 for	 the	 last	 /0	hours	of	 culture.	 Samples	were	 fixed,	decalcified	 and	 routinely	 paraﬃn	 embedded	 and	 sections	 were	 stained	 for	EdU-incorporation.	 After	 a	 first	 assessment	 of	 the	 stained	 sections,	 it	 was	 obvious,	that	proliferation	not	only	took	place	in	the	proliferative	zone	of	the	growth	plate,	but	also	in	cortical	bone,	the	periosteum	and	perichondrium,	the	bone	marrow	niche	and	the	reserve	zone.	A	first	evaluation	showed,	that	the	major	diﬀerences	in	proliferation	between	 samples	 occurred	 in	 the	 proliferative	 zone	 and	 in	 the	 periosteum	 and	perichondrium.	 Figure	 19	 shows	 three	 representative	 tibiae	 from	 wildtype	 bones	after	 staining	 for	 EdU.	 The	 control	 sample	 shows	 a	 high	 number	 of	 EdU	 positive	(EdU+)	 cells	 in	 the	proliferative	 zone.	The	 tibia	 treated	with	 fetuin-A	alone	 shows	a	lower	number	of	EdU+	cells	in	the	proliferative	zone,	but	high	numbers	of	EdU+	cells	in	 the	 periosteum	 and	 perichondrium.	 The	 bone	 treated	 with	 a	 combination	 of	fetuin-A	and	ATRA	 shows	almost	no	EdU+	cells	 in	 the	proliferative	 zone,	 but	 a	high	number	of	EdU+	cells	in	the	periosteum	and	perichondrium.	Proliferation	 in	 the	 proliferative	 zone	 of	 the	 growth	 plate	 and	 in	 the	periosteum	and	perichondrium	was	evaluated.	EdU	staining	of	 the	paraﬃn	sections	was	determined	in	a	semiquantitative	manner	because,	especially	 in	the	periosteum	and	 perichondrium,	 cells	 were	 diﬃcult	 to	 count	 separately	 using	 an	 automated	method.	Staining	was	evaluated	using	a	scoring	system	from	6	to	7.	For	evaluation	of	proliferative	 zones,	 both,	 the	 proximal	 and	 the	 distal	 epiphyses	were	 assessed.	 The	results	are	shown	in	Figure	20.	In	 samples	 from	wildtype	mice,	 treatment	with	 fetuin-A	alone	decreased	 the	number	 of	 proliferative	 cells	 in	 the	 proliferative	 zone,	 in	 tibia	 and	 femur.	 In	 the	periosteum	and	perichondrium	however,	 the	number	of	EdU+	proliferative	cells	was	
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increased.	Addition	of	/01	or	!""	nM	ATRA	to	wildtype	bones	decreased	the	number	of	 EdU+	 cells	 in	 the	 proliferative	 zone	 but	 did	 not	 aﬀect	 the	 periosteum	 and	perichondrium.	 A	 combination	 of	 1.2	mg/ml	 fetuin-A	 and	 &'(	 nM	 ATRA	 showed	similar	results	to	treatment	with	fetuin-A	alone.	In	bones	 from	Ahsg-/-	mice,	 treatment	with	 fetuin-A	decreased	 the	number	of	EdU+	cells	 in	the	proliferative	zone	in	tibiae,	but	not	 in	femora.	The	number	of	EdU+	cells	in	periosteum	and	perichondrium	in		Ahsg-/-		tibiae	was	higher	than	in	wildtype	tibiae	and	addition	of	fetuin-A	did	thus	not	 increase	the	number	of	EdU+	cells	in	the	periosteum	 and	 perichondrium	 in	 tibiae,	 but	 led	 to	 a	 slight	 increase	 in	 femora.	Addition	of	ATRA	alone	decreased	the	number	of	EdU+	cells	in	the	proliferative	zone	but	 did	 not	 aﬀect	 proliferation	 in	 the	 periosteum	 and	 perichondrium.	 In	 the	proliferative	 zone,	 a	 combination	 of	 fetuin-A	 and	 ATRA	 showed	 similar	 results	compared	to	treatment	with	ATRA	alone.	 In	the	periosteum	and	perichondrium,	the	simultaneous	treatment	with	fetuin-A	and	ATRA	did	not	aﬀect	proliferation	in	tibiae,	but	in	femora	the	number	of	EdU+	cells	was	increased.		 	
Figure	 !":	 EdU	 incorporation	marks	
proliferative	cells	 in	ex	vivo	cultured	
bones.	 EdU	 was	 added	 to	 cultured	bones	 for	 the	 last	 -.	 h	 of	 culture	 and	incorporated	 EdU	 was	 fluorescently	labeled	 on	 paraﬃn	 sections.	 Upper	panel	 shows	 three	 exemplary	representative	tibiae.	A	high	number	of	EdU	 positive	 cells	 were	 found	 in	 the	proliferative	 zones	 of	 untreated	 bones	(arrows).	 In	 bones	 treated	 with	fetuin-A,	 proliferation	 in	 the	proliferative	 zones	 was	 decreased.	However,	a	high	number	of	EdU	positive	cells	were	found	in	the	periosteum	and	perichondrium	(short	arrows).	In	bones	treated	 with	 both,	 !""	nM	 ATRA	 and	fetuin-A	EdU	positive	cells	were	almost	absent	 in	 the	 proliferative	 zone.	 PZ	 =	proliferative	 zone,	 HZ	 =	 hypertrophic	zone.	 Lower	 panel	 shows	 five-fold	magnifications	 of	 the	 proximal	proliferative	 zone.	 Upper	 scale	 bar	 is	!"#	µm,	lower	scale	bar	is	()	µm.		 	
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Taken	 together,	 the	 addition	 of	 +.-	mg/ml	 fetuin-A	 to	 cultured	 bones	 decreased	proliferation	 in	 the	proliferative	 zone,	but	 increased	proliferation	 in	 the	periosteum	and	 perichondrium.	 Tibiae	 from	 Ahsg-/-	 mice	 already	 showed	 higher	 numbers	 of	proliferative	 cells	 in	 the	 periosteum	 and	 perichondrium.	 Addition	 of	 ATRA	 alone	decreased	proliferation	in	the	proliferative	zone,	but	had	no	influence	on	proliferation	in	periosteum	and	perichondrium.	The	influence	of	ATRA	seemed	less	pronounced	on	
Ahsg-/-	femora.		
	
Figure	!":	Analysis	of	proliferation	in	proliferative	zone	and	periosteum/perichondrium.	EdU	staining	was	evaluated	 semiquantitatively	 from	stained	 paraﬃn	 sections	 using	 a	 scoring	 system	 from	3	 to	 4	 (see	Figure	 ()).	Treatment	with	ATRA	and	fetuin-A	both	resulted	in	a	decrease	in	EDU+	cells	in	the	proliferative	zone.	Fetuin-A	also	increased	the	number	of	EDU+	cells	in	the	periosteum	and	the	perichondrium.	Error	bars	show	mean	±	SD.	Data	was	 collected	 from	 three	 to	 four	 independent	 experiments	per	 genotype.	 Statistical	 evaluation	was	 carried	 out	using	ANOVA	with	Bonferroni	post	test:	*p<$.$&,	**p<$.$),	***p<$.$$).	The	number	below	the	significance	symbols	refers	to	the	column	to	which	the	data	showed	a	significant	difference.	
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3.1.6 Apoptosis			Treatment	 of	 bones	 with	 either	 fetuin-A	 or	 ATRA	 led	 to	 decreased	 chondrocyte	proliferation	 in	 the	 growth	 plate	 and	 treatment	 of	 bones	 with	 ATRA	 alone	 or	 in	combination	with	fetuin-A	resulted	in	decreased	bone	growth.	Decreased	growth	and	proliferation	could	both	have	been	caused	by	apoptosis	of	growth	plate	chondrocytes.	During	 apoptosis,	 nuclear	 DNA	 is	 cleaved	 which	 can	 be	 visualized	 on	 decalcified	paraﬃn	sections	using	the	TUNEL	(Terminal	deoxynucleotidyl	transferase	dUTP	Nick	End	Labeling)	method.		To	 measure	 apoptosis,	 cultured	 bones	 from	 BL/-	 wildtype	 and	 Ahsg-/-	 and	DBA/%	wildtype	mice	were	stained	with	a	TUNEL	staining	kit.	Per	 treatment	group,	two	to	three	tibiae	and	femora	were	stained.	Generally,	 large	 numbers	 of	 TUNEL	 positive	 (TUNEL+)	 cells	 were	 found	 to	varying	 degrees	 in	 the	 bone	 marrow	 and	 the	 hypertrophic	 zone,	 independent	 of	treatment.	TUNEL+	cells	were	also	found	to	varying	degrees	in	the	peripheral	regions	of	cartilage,	in	the	perichondrium	and	in	the	periosteum.	Notably,	around	half	of	the	samples	showed	a	TUNEL+	region	in	their	proliferative	zone,	which	varied	in	size	and	sometimes	extend	into	the	reserve	zone.	This	TUNEL+	region	was	always	connected	to	the	 TUNEL+	 hypertrophic	 zone.	 Figure	 21	 shows	 exemplary	 micrographs	 of	 bone	paraﬃn	sections	stained	with	the	TUNEL	method.	Figure	21A	shows	a	vehicle-treated	distal	 femur.	 Here,	 cells	 in	 the	 hypertrophic	 zone	 and	 bone	 marrow	 were	 TUNEL	positive.	Figure	21B	shows	a	bone	treated	with	./!	nM	ATRA	and	).+	mg/ml	fetuin-A.	Here	a	region	 in	the	center	of	 the	proliferative	zone	and	cells	 in	the	periphery	were	TUNEL	 positive.	 In	 order	 to	 correlate	 growth	 plate	 apoptosis	 with	 treatment,	 all	available	 samples	 were	 analyzed	 and	 the	 data	 from	 bones	 of	 diﬀerent	 genetic	backgrounds	and	genotypes	was	pooled.	The	resulting	contingency	graph	is	shown	in	Figure	21C.	All	samples	were	categorized	by	the	presence	or	absence	of	TUNEL+	cells	in	one	or	both	proliferative	zones.	Out	of	six	control	bones,	only	one	showed	apoptotic	cells	 in	 its	 proliferative	 zones.	 In	 all	 treated	bones,	 about	 half	 of	 the	 bones	 showed	TUNEL+	 cells	 the	 proliferative	 zone.	 Thus,	 we	 could	 not	 correlate	 the	 presence	 of	apoptotic	 cells	 in	 the	 proliferative	 zone	 to	 a	 certain	 treatment.	 However,	 treatment	
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alone	seemed	to	increase	apoptosis.	However,	we	did	not	find	a	significant	correlation	between	apoptosis	and	treatment	in	general.		
Figure	 !":	 TUNEL	 staining	 for	 apoptotic	 cells.	 Two	exemplary	 distal	 femora	 from	 BL/3	wildtype	mice	 are	shown	 to	 illustrate	 the	 appearance	 of	 TUNEL	 staining	for	apoptosis	in	cultured	bones.	A)	Untreated	exemplary	femur	 shows	a	high	number	of	TUNEL	positive	 cells	 in	the	bone	marrow	and	in	the	hypertrophic	zone,	only	few	in	 other	 regions.	 B)	 Exemplary	 femur	 treated	 with	fetuin-A	 and	 &''	nM	 ATRA	 contains	 a	 region	 in	 the	center	 of	 the	 proliferative	 zone	with	 high	 numbers	 of	TUNEL	positive	cells	(long	arrow)	and	a	TUNEL	positive	region	 in	 the	 peripheral	 cartilage	 (short	 arrows).	 PZ	 =	proliferative	zone,	HZ	=	hypertrophic	zone.	Scale	bar	 is	!"#	µm.	 C)	 Contingency	 analysis	 of	 TUNEL	 staining	 in	the	 proliferative	 zone.	 All	 TUNEL	 stained	 paraﬃn	sections	were	evaluated	for	the	presence	or	absence	of	a	region	of	TUNEL	positive	cells	in	the	proliferative	zone.	The	 contingency	 graph	 shows	 the	 classification	 in	TUNEL	 positive	 TUNEL+	 PZ)	 or	 TUNEL	 negative	proliferative	 zone	 (TUNEL-	PZ)	 arranged	 by	 treatment.	Data	was	collected	from	four	independent	experiments.				
3.2 Skeletal	Development	in	the	Absence	of	Fetuin-A		As	 the	results	of	bone	culture	experiments	 (section	!.#)	could	not	clarify	 the	role	of	fetuin-A	 in	 in	 endochondral	 ossification,	 a	 diﬀerent	 approach	 was	 taken.	 Skeletal	development	was	investigated,	starting	from	newborn	mice	(P6.8)	until	mice	of	eight	weeks	 of	 age.	 We	 used	 mice	 from	 heterozygous	 breeding	 resulting	 in	 wildtype,	
Ahsg+/-	and	Ahsg-/-	littermates.	
3.2.1 Growth	Inhibition	and	Morphological	Changes	in	Femora	of	
Ahsg-/-	Mice	Start	after	Weaning		The	 length	of	 femora	and	 tibiae	 from	at	 least	 three	male	and	 three	 female	mice	 for	each	genotype	(WT,	Ahsg+/-,	Ahsg-/-)	and	age	(P*.,,	P./.,,	/	weeks,	3	weeks,	4	weeks,	5	weeks,	and	*	weeks)	was	measured.	Figure	33	 illustrates	 the	development	of	 length	over	time	for	femur	(Figure	--A)	and	tibia	(Figure	--B).	Growth	curves	for	wildtype	and	Ahsg+/-	bones	were	similar	for	both,	femur	and	tibia.	Starting	from	four	weeks	of	age,	 femora	 and	 tibiae	 from	Ahsg-/-	mice	were	 significantly	 shorter	 and	 this	 length	
RESULTS	68	
discrepancy	 increased	over	time	in	 femora.	Femora	from	Ahsg-/-	mice	exhibited,	 to	a	varying	 degree,	 malformations	 in	 the	 distal	 femoral	 epiphysis,	 while	 femora	 from	
Ahsg+/-	 mice	 did	 not	 show	 any	 obvious	 morphological	 abnormalities.	 Ahsg-/-	 bones	appeared	widened	 in	 their	distal	condyles;	 therefore	 the	width	of	 the	distal	 femoral	epiphysis	was	measured.	As	shown	in	Figure	44C,	distal	 femur	width	 in	Ahsg-/-	mice	increased	at	four	weeks	of	age,	coinciding	with	the	shortening	of	the	femora.	
	
Figure	!!:	Growth	of	wildtype	and	fetuin-A-deficient	femora	and	tibiae.	The	change	in	bone	length	over	time	from	newborn	mice	until	eight	weeks	of	age	was	measured	 for	 femora	(A)	and	tibiae	(B).	C)	Width	of	 the	distal	femoral	epiphysis	from	mice	two	weeks	to	eight	weeks	of	age.	Starting	from	four	weeks,	femur	and	tibia	length	was	decreased	in	bones	from	Ahsg-/-	mice,	and	the	width	of	the	distal	femoral	epiphysis	was	increased.	The	number	of	mouse	per	bone	type	(tibia	or	femur)	per	genotype	ranged	between	'(	and	+,	for	newborn	mice	and	ten	to	$%	for	mice	two	weeks	of	age	and	older.	Statistical	evaluation	was	carried	out	using	Student’s	t-test,	comparing	data	from	
Ahsg-/-	to	wildtype	mice:	n.s.	p≥'.'(,	*p<#.#%,	**p<#.#),	***p<#.##).			 	
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3.2.2 Bones	from	Ahsg-/-	Mice	Were	Shortened	and	Malformed		To	 investigate	 the	morphological	 anomalies	 of	Ahsg-/-	 femora	 in	more	 detail,	 bones	from	 eight	 weeks	 old	 mice	 were	 viewed	 by	 computed	 tomography	 (µCT).	 We	examined	 femora	 from	C'(BL/,	wildtype,	Ahsg-/-,	 as	well	 as	Ahsg-/-/	ApoE-/-	double	deficient	mice.	The	latter	were	studied,	as	they	also	exhibit	an	abnormal	shortening	of	their	 femora.	Additionally,	bones	 from	mice	on	 the	genetic	background	DBA/;,	both	wildtype	 and	 Ahsg-/-,	 were	 examined.	 Exemplary	 images	 from	 three-dimensional	reconstructions	 from	 µCT	 measurements	 are	 shown	 in	 Figure	 23	 for	 BL/(	 mice,	Figure	 24	 for	 BL/(	 double	 deficient	 mice	 and	 Figure	 25	 for	 D&	 mice.	 Supporting	Figures	!-!	show	the	complete	set	of	reconstructed	images.	The	µCT	analysis	of	bones	from	 Ahsg-/-	 and	 Ahsg-/-/	 ApoE-/-	 mice	 revealed	 a	 striking	 feature	 that	 had	 gone	unnoticed	 in	all	previous	bone	 studies	on	Ahsg-/-	mice.	The	distal	 femoral	 epiphysis	was	 dislodged	 posterior,	 the	 lateral	 and	 medial	 condyles	 and	 epicondyles	 were	flattened	and	widened,	causing	narrowing	of	the	intercondylar	fossa.	In	sagittal	views	of	the	bones,	the	growth	plate	showed	a	striking	angular	deformation.	We	measured	this	angular	deformation	in	all	mice	as	demonstrated	in	Figure	26A	and	B.	The	angle	of	 the	 epiphysis	 with	 respect	 to	 the	 shaft	 was	 decreased	 in	 knockout	 animals,	especially	 in	male	 BL//	mice	 (Figure	 26C).	 The	 angulation	 appeared	 less	 severe	 in	female	 BL/*	 animals	 but	 was	 nevertheless	 present.	 Female	 Ahsg-/-/	 ApoE-/-	 double	deficient	mice	showed	similar	values	to	their	male	counterparts.	
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Figure	 !":	Two-	 and	 three-dimensional	 reconstructions	 of	 µCT	measurements	 of	 femora	 from	 C34BL/8	
wild	 type	 and	Ahsg-/-	mice.	Note	 the	morphological	 changes	of	 the	distal	 femur	 in	Ahsg-/-	mice.	Measurements	were	carried	out	at	the	IOBM	in	Hamburg	with	the	help	of	Timur	Yorgan.		 	
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Figure	 !":	Two-	 and	 three-dimensional	 reconstructions	 of	 µCT	measurements	 of	 femora	 from	 C34BL/8	
wildtype	and	Ahsg-/-/	ApoE-/-	double	deficient	mice.	Measurements	were	carried	out	at	the	IOBM	in	Hamburg	with	the	help	of	Timur	Yorgan.	
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Figure	 !":	 Two-	 and	 three-dimensional	 reconstructions	 of	 µCT	 measurements	 of	 femora	 from	 DBA/7	
wildtype	 and	 Ahsg-/-	 mice.	 Measurements	were	 carried	 out	 at	 the	 IOBM	 in	 Hamburg	with	 the	 help	 of	 Timur	Yorgan.	
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Figure	 !":	 Angular	 displacement	 of	 the	 growth	 plate.	 Exemplary	 two-dimensional	 reconstructions	 of	 a	wildtype	(A)	and	an	Ahsg-/-	femur.	The	red	lines	illustrate	the	measurement	of	growth	plate	angles.	C)	shows	the	resulting	measurements	of	growth	plate	angles.	Error	bars	show	mean	±	SD.		Statistical	evaluation	was	carried	out	using	ANOVA	with	Bonferroni	post	test:	*p<$.$&,	**p<$.$),	***p<$.$$).			Additionally,	 we	 determined	 trabecular	 and	 cortical	 µCT	 parameters	 in	 BL/;	 and	DBA/%	mice	 as	 shown	 in	 Figure	 27	 and	 Figure	 28,	 respectively.	 Bone	 volume	 over	tissue	volume	(BV/TV)	indicates	the	percentage	of	mineralized	trabecular	bone	tissue	in	a	given	volume.	Trabecular	and	cortical	bone	mineral	density	(BMD)	is	the	amount	of	mineral	in	trabecular	bone	and	cortical	bone	respectively.		The	BV/TV	was	generally	higher	in	BL/!	males	than	in	females,	but	there	were	no	diﬀerences	between	genotypes.	In	BL/!	female	mice,	BV/TV	was	lower	in	wildtype	mice	 compared	 to	 fetuin-A	 deficient	 mice,	 albeit	 not	 significantly.	 Trabecular	 BMD	was	 significantly	 higher	 in	 BL/1	male	wildtype	mice	 compared	 to	 all	 other	 groups.	There	 were	 no	 diﬀerences	 in	 trabecular	 number.	 Trabecular	 spacing	 was	 slightly	increased	in	BL/-	male	Ahsg-/-	mice	and	even	more	in	BL//	male	Ahsg	-/-/	ApoE-/-	mice	compared	 to	 bones	 from	 wildtype	 males.	 In	 female	 mice,	 trabecular	 spacing	 was	slightly	decreased	in	Ahsg-/-	bones,	but	increased	in	bones	from	Ahsg-/-/	ApoE-/-	mice,	compared	to	wildtype	female	bones.	Trabecular	thickness	was	significantly	increased	in	Ahsg-/-	and	Ahsg	-/-/	ApoE-/-	both	male	and	female	mice.	No	diﬀerences	were	found	in	 cortical	 porosity	 or	 cortical	 BMD.	 Cortical	 thickness	 was	 increased	 in	 male	 and	female	Ahsg-/-	and	Ahsg-/-/	ApoE-/-	mice.	Thus,	trabecular	parameters	varied	between	
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genotypes,	 however	 inconsistently.	 Cortical	 BMD	 and	 porosity	 were	 similar,	 but	cortical	thickness	was	increased	in	fetuin-A	deficient	mice.		
		
Figure	!":	Bone	parameters	of	 femora	 from	C/0BL/3	mice	as	determined	by	µCT	measurement.	BV/TV	=	bone	volume	over	tissue	volume,	BMD	=	bone	mineral	density.	Error	bars	show	mean	±	SD.		Statistical	evaluation	was	carried	out	using	ANOVA	with	Bonferroni	post	test:	*p<$.$&,	**p<$.$),	***p<$.$$).	Measurements	were	carried	out	at	the	IOBM	in	Hamburg	with	the	help	of	Timur	Yorgan.		
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Figure	!":	Bone	parameters	of	femora	from	DBA/1	mice	as	determined	by	µCT	measurement.	BV/TV	=	bone	volume	over	 tissue	volume,	BMD	=	bone	mineral	density.	Error	bars	show	mean	±	SD.	Statistical	evaluation	was	carried	out	using	ANOVA	with	Bonferroni	post	test:	*p<$.$&,	**p<$.$),	***p<$.$$).	Measurements	were	carried	out	at	the	IOBM	in	Hamburg	with	the	help	of	Timur	Yorgan.	After	µCT	measurements,	femora	were	embedded	in	acrylate	and	sectioned.	Cellular	parameters	were	determined	from	toluidine	blue	stained	acrylate	sections	of	ten	male	BL/$	 wildtype	 and	 nine	 male	 BL/$	 Ahsg-/-	 mice.	 Figure	 29	 shows	 exemplary	micrographs	 of	 a	 toluidine	 blue	 stained	 undecalcified	 acrylate	 section	 of	 trabecular	bone,	 illustrating	 the	 morphology	 of	 the	 diﬀerent	 cell	 types.	 We	 determined	 bone	perimeter,	 the	 osteocyte,	 osteoblast	 and	 osteoclast	 number,	 as	 well	 as	 the	 surface	perimeter	 covered	 by	 osteoblasts	 and	 osteoclasts.	 Osteoblast	 number	 and	 surface,	
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osteoclast	number	and	surface	as	well	 as	osteocyte	number	were	all	 comparable	 in	wildtype	and	Ahsg-/-	bones	(see	Figure	30).	This	indicates	that	fetuin-A	deficiency	did	not	have	an	influence	on	neither	cellular	activity	nor	diﬀerentiation.		
Figure	 !":	 Toluidine	 blue	 staining	 of	
undecalcified	 acrylate	 sections	 of	 bone	 for	 the	
determination	of	cellular	parameters.	A)	A	lower	magnification	 micrograph	 of	 trabecular	 bone	 from	the	 primary	 spongiosa.	 Bone	 (B)	 is	 surrounded	 by	bone	marrow	 (BM).	 Unresorbed	 cartilage	 (CG)	 can	be	 found	 inside	 of	 bone	 trabecular.	 Scale	 bar	 is	!"#µm.	B)	A	higher	magnification	picture	shows	the	cells	in	an	on	a	bone	trabecula.	Osteocytes	(OT)	can	be	found	inside	the	bone.	Active	osteoblasts	(OB)	on	the	 bone	 surface	 lay	 down	 unmineralized	 osteoid	(light	 blue	 area	 underneath	 the	 cells).	 Next	 to	 the	osteoblasts,	 two	 osteoclasts	 (OC)	 actively	 resorb	bone.	 Scale	 bar	 is	 !"#µm.	 Stained	 sections	 were	provided	by	the	IOBM	in	Hamburg.							
Figure	 !":	 Cellular	 parameters	 as	
determined	 from	 toluidine	 blue	 stained	
acrylate	sections.	Error	bars	show	mean	±	SD.	Statistical	 evaluation	 was	 carried	 out	 using	Student’s	 t-test.	 No	 statistically	 significant	differences	 in	 cellular	parameters	were	 found	between	wildtype	and	Ahsg-/-	mice.				 	
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3.2.3 Prevalence	of	the	Dysplasia		We	determined	the	prevalence	of	 the	phenotype	 in	Ahsg-/-	male	and	 female	mice	on	both	C'(BL/,	and	DBA/2	background,	starting	from	four	weeks	of	age.	The	results	are	shown	in	Figure	31.	The	prevalence	was	comparable	in	male	and	female	mice	for	both	genotypes	and	on	both	genetic	backgrounds.	For	BL/8	Ahsg-/-	mice,	''	out	of	&'	mice	had	distal	femur	dysplasia	in	one	or	both	legs	and	45	mice	had	no	obvious	phenotype	anomaly.	For	D,	Ahsg-/-	mice,	'(	out	of	-.	mice	had	distal	 femur	dysplasia	 in	one	or	both	 legs	and	-.	had	no	obvious	phenotype	anomaly.	Taken	 together,	about	+,	%	of	
Ahsg-/-	mice	on	the	background	C23BL/7	had	a	phenotype	anomaly,	while	on	DBA/*	background,	only	/0	%	of	all	mice	showed	the	dysplasia.	 		
Figure	 !":	 Prevalence	 of	 the	
dysplasia	 in	Ahsg-/-	mice	 on	 either	
C"#BL/'	 (A)	 or	 DBA//	 (B)	 genetic	
background.	 For	 C&'BL/+	 mice,	 ##	male	 and	 ()	 female	 mice	 were	examined.	For	DBA/1	mice,	 #$	 female	and	%&	male	mice	were	examined.		
3.2.4 Fetuin-A	Deficient	Pups	Have	Elongated	Hypertrophic	Zones		To	 investigate	 the	 development	 of	 the	 distal	 femoral	 dysplasia,	 bone	 sections	were	examined	 histologically,	 from	 newborn	 mice	 until	 eight	 weeks	 of	 age.	 Here	 we	restricted	 ourselves	 to	 examining	 bones	 from	 mice	 on	 the	 genetic	 background	C"#BL/'	only.	Bone	sections	and	measurements	of	P,-."	mice	revealed,	that	in	femora	(Figure	 31A)	 and	 in	 all	 other	 long	 bones	 examined	 (Supporting	 Figure	 -),	 the	hypertrophic	zones	of	Ahsg-/-	mice	were	significantly	increased	in	length	(Figure	32B).	Proliferative	zones	of	Ahsg-/-	mice	were	also	slightly,	but	not	significantly	elongated.	In	heterozygous	Ahsg+/-	mice,	zone	lengths	were	not	altered.	The	elongation	disappeared	at	about	three	to	four	weeks	of	age	in	all	long	bones.		To	 investigate,	 whether	 the	 hypertrophic	 zone	 elongation	 was	 caused	 by	 an	increase	 in	 proliferation,	 /-ethynyl-!’-deoxyuridine	 (EdU)	 was	 administered	intraperitoneally	to	,-	days	(P,-.3)	old	male	pups,	which	were	sacrificed	/01	minutes	after	 injection.	 Tibiae	 and	 femora	were	 isolated,	 fixed,	decalcified	 and	 prepared	 for	
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routine	paraﬃn	embedding.	Figure	33	shows	representative	exemplary	micrographs	after	 staining	 of	 femoral	 sections	 for	 EdU,	 demonstrating	 that	 the	 number	 of	 EdU	positive	cells	in	the	proliferative	zone	appeared	to	be	similar	in	wildtype,	Ahsg+/-	and	
Ahsg-/-	mice.	The	numbers	of	EdU	positive	chondrocytes	in	the	proliferative	zones	of	proximal	 tibiae	 and	distal	 femora	were	determined	 from	histological	 sections	using	automated	counting.	Figure	33	shows	that	no	diﬀerences	were	found	in	the	numbers	of	EdU	positive	cells	between	the	diﬀerent	genotypes.	 	
Figure	 !":	 Fetuin-A	
deficient	 mice	 have	
elongates	
hypertrophic	 zones.	A)	Histological	staining	with	 safranin	 O/	 fast	green	 reveals	 an	elongated	hypertrophic	 zone	 in	
Ahsg-/-	 P"#.%	 pups.	Scale	bars	are	'((	µm.	B)	 Length	measurements	 of	reserve	 (RZ),	proliferative	 (PZ)	 and	hypertrophic	 zones	(HZ)	 from	 *+	 days	 old	male	 wildtype,	
Ahsg+/-	and	Ahsg-/-	mice	as	 determined	 from	paraﬃn	sections.	Error	bars	 show	 SD.	Statistical	 evaluation	 was	 carried	 out	 using	 ANOVA	 with	 Bonferroni	 post	 test:	 *p<$.$&,	 **p<$.$).	 The	 number	below	the	significance	symbols	refers	to	the	column	to	which	the	data	showed	a	significant	difference.				 	
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Figure	 !!:	 Proliferation	 in	
the	 growth	 plates	 of	 P"#.%	
mice.	 A-C)	 Representative	images	 of	 distal	 femoral	growth	 plates	 from	 EdU	injected	 P*+.-	 pups.	 An	 EdU	positive	 signal	 indicates	proliferation.	Proliferation	 in	the	 proliferative	 zone	 (PZ)	appeared	 similar	 in	 all	genotypes.	 Scale	 bars	 are	!""	µm.	 D)	 The	 numbers	 of	EdU	 positive	 cells	 in	 the	proliferative	 zone	 were	similar	 in	 distal	 femoral	 and	proximal	tibial	growth	plates	of	 wildtype,	 Ahsg+/-	 and	
Ahsg-/-	 mice.	 	 Error	 bars	show	 mean	 ±	 SD.	 Data	 was	collected	 from	 three	independent	 experiments.	Statistical	 evaluation	 was	carried	 out	 using	 ANOVA	with	 Bonferroni	 post	 test.	There	 were	 no	 statistically	significant	differences.				In	 order	 to	 evaluate	 whether	 fetuin-A	 deficiency	 leads	 to	 aberrant	 chondrocyte	apoptosis,	we	stained	femoral	and	tibial	decalcified	paraﬃn	sections	from	P56.8	pups	using	a	TUNEL	staining	kit.	Figure	34	shows	representative	micrographs	of	paraﬃn	sections	from	wildtype,	Ahsg+/-	and	Ahsg-/-	mice.	TUNEL	positive	cells	were	frequently	detected	in	the	bone	marrow.	In	the	hypertrophic	zone	only	very	few,	if	any	cells	were	apoptotic	and	there	was	no	obvious	diﬀerence	between	the	genotypes.	 		
Figure	 !":	 Apoptosis	 in	
the	 growth	 plates	 of	
P"#.%	 mice.	 Exemplary	paraﬃn	 sections	 of	 distal	femoral	 growth	 plates	from	 P"#.%	 pups	 stained	with	 the	 TUNEL	 method.	Scale	bars	are	*++	µm.		 	
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Undecalcified	 frozen	 sections	 from	 P'(.*	 pups	 were	 stained	 with	 von	 Kossa	 to	visualize	the	mineralization	of	the	growth	plate.	As	fetuin-A	is	an	established	inhibitor	of	unwanted	calcification,	fetuin-A	deficiency	might	lead	to	aberrant	mineralization	of	the	growth	plate.	Figure	35A	shows	exemplary	pictures	of	von	Kossa	stained	 frozen	sections.	 No	 diﬀerences	 were	 found	 between	 wildtype	 and	 Ahsg+/-	 samples.	 The	elongated	 growth	 plates	 of	Ahsg-/-	mice	 did	 not	 show	 dystrophic	 calcification.	 Even	though	 the	 mineralized	 portion	 of	 the	 growth	 plate	 was	 longer	 in	 Ahsg-/-	 mice,	mineralization	 was	 restricted	 to	 the	 last	 few	 rows	 of	 hypertrophic	 cartilage,	comparable	to	wildtype	mice.	
	
Figure	!":	Growth	plate	mineralization	in	P23.5	mice.	Von	Kossa	staining	of	undecalcified	femora	from	wildtype	(WT),	 Ahsg+/-	and	 Ahsg-/-	 P"#.%	 pups.	 Von	 Kossa	 stains	 mineralized	 tissue	 in	 black.	 Scale	 bars	 upper	 panel	 are	!""	µm,	lower	panel	'((	µm.			
3.2.5 Fetuin-A	Deficient	Mice	Develop	Growth	Plate	Lesions		We	analyzed	decalcified	femur	paraﬃn	sections	to	study	growth	plate	development	in	
Ahsg-/-	mice.	Figure	36A	shows	 safranin	O	 stained	 sections	of	distal	 femora	 from	23	days	old	mice.	In	the	growth	plates	of	Ahsg+/-	as	well	as	Ahsg-/-	mice	cellular	infiltrates	appear	 between	 the	 proliferative	 and	 hypertrophic	 zone.	 The	 safranin	 O	 staining	around	 these	 cellular	 infiltrates	 appeared	 lighter,	 indicating	 degradation	 of	 the	
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cartilaginous	 extracellular	 matrix.	 The	 appearance	 of	 cellular	 infiltrates	 was	 highly	variable;	 while	 in	 some	 femora	 cellular	 infiltrates	 were	 present,	 in	 others	 the	elongated	hypertrophic	zone	was	still	there.	Figure	 36B	 shows	 micrographs	 of	 four	 weeks	 old	 mice.	 While	 cellular	infiltrates	could	be	seen	in	Ahsg+/-	samples,	Ahsg-/-	mice	showed	a	disorganization	of	growth	 plate	 chondrocytes	 and	 the	 beginning	 formation	 of	 bone	 bridges.	 The	presence	of	erythrocytes	in	the	middle	of	the	growth	plate	suggests	that	growth	plate	vascularization	 took	 place.	 Four	 weeks	 was	 also	 the	 earliest	 time	 point	 at	 which	femoral	dysplasia	was	observed.	
	
Figure	!":		Cellular	infiltrates	and	altered	growth	plate	architecture	in	fetuin-A	deficient	mice.	A)	Safranin	O	staining	 of	 paraﬃn	 sections	 of	 distal	 femora	 from	 23	days	 old	 wildtype	 (WT),	Ahsg+/-	 and	Ahsg-/-	mice.	 Arrows	indicate	 the	 location	of	 cellular	 infiltrates	between	 the	proliferative	and	 the	hypertrophic	 zone.	Note	 the	 loss	of	safranin	O	staining	around	 the	 foreign	cells.	B)	Safranin	O	staining	of	paraﬃn	sections	of	distal	 femora	 from	67	days	 old	 wildtype	 (WT),	 Ahsg+/-	 and	 Ahsg-/-	 mice.	 Arrow	 indicates	 the	 presence	 of	 cellular	 infiltrate	 in	 the	
Ahsg+/-	sample.	The	growth	plate	from	an	Ahsg-/-	mouse	shows	disordering	and	thinning.	The	beginning	formation	of	 a	 bone	 bridge	 (low	 magnification	 picture,	 big	 arrow)	 can	 be	 seen.	 The	 presence	 of	 erythrocytes	 (high	magnification,	arrow)	indicates	vascularization.	Scale	bars	upper	panels	are	-..	µm,	lower	panels	()	µm.	
RESULTS	82	
The	 phenotypes	 of	 eight	 weeks	 old	 Ahsg-/-	 mice	 were	 highly	 variable,	 as	 shown	 in	Figure	37.	In	general,	growth	plate	cartilage	appeared	disorganized	but	invasive	cells	were	absent.	Figure	37	shows	diﬀerent	examples	of	distal	 femora	 from	eight	weeks	old	 BL/(	 mice;	 while	 in	 Figure	 37C,	 the	 growth	 plate	 is	 disorganized,	 Figure	 37B	reveals	bony	lesions	interrupting	the	growth	plate.	The	femur	in	Figure	37D	appears	bigger	and	deformed	and	 the	growth	plate	 is	partially	absent	and	replaced	by	bone	tissue.	Collectively,	 the	 findings	suggest	a	decisive	event	around	 three	 to	 four	weeks	postnatal,	 resulting	 in	 posterior	 displacement	 of	 the	 distal	 femur	 and	 in	 the	 bone	dysplasia	described	 in	 earlier	 studies.	Varying	degrees	of	 severity	 and	 the	 resulting	remodeling	of	bone	explain	the	highly	variable	final	phenotype.		
	
Figure	!":	Healing	of	distal	femoral	growth	plates	in	eight	weeks	old	Ahsg-/-	mice.	Safranin	O	stained	paraﬃn	sections	 from	 (A)	wildtype	 and	 (B-D)	Ahsg-/-	mice.	Phenotypes	of	 distal	 femoral	 growth	plates	displayed	a	high	variability.	B)	Bone	bridges	disturb	the	growth	plate	architecture.	C)	Growth	plate	cartilage	is	disordered.	D)	Distal	femur	is	grossly	malformed	and	growth	plate	is	partially	interrupted	by	bone.	Scale	bars	upper	panels	are	-..	µm,	lower	panels	+,,	µm.		
3.2.6 Heterozygous	Ahsg+/-	Mice	Have	Growth	Plate	Lesions	
Containing	Cellular	Infiltrates	But	Do	Not	Develop	Dysplasia			Similar	to	homozygous	Ahsg-/-	mice,	heterozygous	Ahsg+/-	mice	had	cellular	infiltrates	in	 their	 distal	 femoral	 growth	 plates	 at	 the	 age	 of	 three	weeks	 (Figure	 ()A),	while	growth	 plates	 of	 four	 weeks	 old	Ahsg+/-	 mice	 also	 contained	 invading	 cells	 (Figure	!"B).	 Several	 eight	weeks	 old	Ahsg+/-	mice	 showed	 extended	 lesions	 in	 their	 distal	femoral	 growth	 plates,	 located	 between	 proliferative	 and	 hypertrophic	 zone,	
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containing	 large	 numbers	 of	 invading	 cells	 as	 shown	 in	 Figure	 ().	 Out	 of	 #$	heterozygous	mice	analyzed,	nine	mice	had	at	least	one	lesion	in	their	distal	femoral	growth	plates.	These	lesions	were	much	larger	compared	to	those	found	in	three	and	four	weeks	 old	 animals.	Figure	38	 shows	 an	 example	 of	 a	 large	 lesion	 found	 in	 the	distal	femur	of	an	Ahsg+/-	male	mouse.	This	growth	plate	lesion	was	lined	with	cellular	infiltrates.	 To	 rule	 out	 that	 the	 cellular	 infiltrates	 were	 actually	 apoptotic	chondrocytes,	 we	 performed	 terminal	 deoxynucleotidyl	 transferase	 dUTP	 nick	 end	labeling	(TUNEL)	on	samples	containing	lesions.	Figure	38E	shows	a	typical	result	of	the	TUNEL	staining	with	no	evidence	of	TUNEL	positive	cells	in	the	lesion.	The	lesion	stained	strongly	for	DAPI,	confirming	that	presence	of	cellular	infiltrates.		
	
Figure	!":	 Lesions	 in	 the	 distal	 femoral	 growth	 plate	 of	 heterozygous	Ahsg+/-	mice.	A)	Safranin	O	stained	paraﬃn	section	of	a	distal	femur	from	an	eight	weeks	old	BL/(	Ahsg+/-	mouse.	A	huge	lesion	with	two	cavities	is	present	 in	 the	 middle	 of	 the	 growth	 plate,	 located	 between	 proliferative	 and	 hypertrophic	 zone.	 Scale	 bar	 is	!""	µm.	B)	Magnification	of	(A).	Arrows	indicate	the	presence	of	aggregates	of	cellular	infiltrates,	which	also	line	the	cavities.	C)	Magnification	of	(A).	Arrow	points	to	another	aggregation	of	cellular	infiltrates,	which	is	connected	to	 a	 vertical	 line	 in	 the	 growth	 plate.	 D)	 Magnification	 of	 (A).	 Short	 arrows	 mark	 the	 location	 of	 vertical	 and	horizontal	 lines	 inside	 the	growth	plate.	E)	TUNEL	staining	of	 a	growth	plate	 lesion	 from	a	BL/<	Ahsg+/-	mouse	distal	 femur	 shows	 no	 TUNEL	 positive	 cells	 in	 the	 lesion.	 The	 lesion	 strongly	 stains	with	DAPI,	 confirming	 the	presence	of	cellular	infiltrates.	Scale	bar	is	+,,	µm.		
3.2.7 Fetuin-A	Is	Localized	in	Hypertrophic	Chondrocytes		Fetuin-A	is	produced	in	the	liver	and	is	distributed	in	all	vascularized	tissues.	Due	to	its	high	aﬃnity	to	mineral,	it	is	one	of	the	most	abundant	non-collagenous	proteins	in	
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mineralized	bone.	The	localization	of	fetuin-A	in	the	avascular	cartilage	was	hitherto	unknown.	 We	 analyzed	 the	 distribution	 of	 fetuin-A	 protein	 in	 growth	 plates	 of	newborn	 and	 adolescent	 mice	 by	 immunofluorescence	!"!.	 As	 fetuin-A-deficient	animals	displayed	the	dysplasia	only	 in	the	 femur,	we	also	compared	 its	 localization	between	 distal	 femur	 and	 proximal	 tibia.	 In	wildtype	 animals,	 staining	 for	 fetuin-A	protein	was	 found	 intracellularly	 in	 chondrocytes	 of	 the	hypertrophic	 zone,	 both	 in	femora	(Figure	39),	and	 in	tibiae	(Figure	40)	of	both	sexes	at	all	ages	analyzed.	The	staining	pattern	was	similar	in	Ahsg+/-	mice.	Intriguingly,	wherever	cellular	infiltrates	were	present	in	Ahsg+/-	mice,	hypertrophic	chondrocytes	stained	negative	for	fetuin-A	(Figure	41B).			
	
Figure	 !":	 Localization	 of	 fetuin-A	 in	 distal	 femoral	 growth	 plates	 of	 wildtype	 mice.	Paraﬃn	 sections	 of	decalcified	femora	were	stained	with	anti-mouse	fetuin-A	antibody	and	Alexa./0-tagged	secondary	antibody	(red	fluorescence).	Femora	from	Ahsg-/-	mice	served	as	negative	control.	Fetuin-A	was	detected	in	bone	tissue,	but	also	inside	 hypertrophic	 growth	 plate	 chondrocytes	 of	 wildtype	 femora	 and	 was	 fully	 absent	 in	 femora	 from	
Ahsg-/-	mice.	Scale	bars	are	*+	µm.	Prepared	with	the	help	of	Sina	Köppert.			 	
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Figure	!":	 Localization	 of	 fetuin-A	 in	 proximal	 tibial	 growth	 plates	of	wildtype	mice.	Paraﬃn	sections	of	decalcified	tibiae	were	stained	with	anti-mouse	fetuin	-A	antibody	and	Alexa./0-	tagged	secondary	antibody	(red	fluorescence).	Tibiae	from	Ahsg-/-	mice	served	as	negative	control.	As	in	femoral	samples,	fetuin-A	was	detected	in	bone	 tissue,	 but	 also	 inside	 hypertrophic	 growth	 plate	 chondrocytes	 of	wildtype	 tibiae	 and	was	 fully	 absent	 in	tibiae	from	Ahsg-/-	mice.	Scale	bars	are	*+	µm.	Prepared	with	the	help	of	Sina	Köppert.		 		
Figure	 !":	 Localization	 of	
fetuin-A	 in	 distal	 femoral	
growth	 plates	 of	 heterozygous	
Ahsg+/-	 mice	 with	 and	 without	
lesion.	 Paraﬃn	 sections	 of	decalcified	 femora	 were	 stained	with	 anti-mouse	 fetuin-A	antibody.	 A)	 In	 samples	 without	cellular	 infiltrates	 or	 lesions,	fetuin-A	 was	 localized	 inside	hypertrophic	 growth	 plate	chondrocytes.	 B)	 When	 cellular	infiltrates	 and	 lesions	 were	present	 (green	 arrows)	 fetuin-A	was	fully	absent	from	the	growth	plate.	 Scale	 bars	 are	 *+	 µm.		Prepared	 with	 the	 help	 of	 Sina	Köppert.		 	
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3.2.8 Genome-Wide	Analysis	of	Gene	Expression	Using	
RNA-Chip-Technology		To	 investigate	 the	 molecular	 mechanisms	 preceding	 growth	 plate	 dysplasia	 in	 the	absence	 of	 fetuin-A,	 gene	 expression	 in	 wildtype,	 Ahsg+/-	 and	 Ahsg-/-	 growth	 plate	chondrocytes	 was	 analyzed	 using	 the	 Mouse	 Transcriptome	 Assay	 (MTA)	 from	Aﬀymetrix	!"!.	We	utilized	bones	 from	12	days	old	mice,	as	 these	did	not	yet	display	lesions	 or	 cellular	 infiltrates.	 For	 each	 genotype,	 the	 right	 femora	 from	 three	male	mice	were	 collected.	Whole	 growth	plates	were	 isolated	 from	 frozen	 sections	using	laser	 capture	microdissection,	 and	 high	 quality	 RNA	was	 extracted	 from	 the	 tissue.	Samples	with	an	RNA	integrity	number	(RIN)	of	at	 least	;	were	used	for	microarray	analysis.	As	 shown	 above	 (Figure	 39),	 fetuin-A	 protein	 was	 localized	 in	 cells	 of	 the	hypertrophic	 zone,	 which	 could	 be	 either	 due	 to	 protein	 uptake	 or	 fetuin-A	mRNA	expression	by	hypertrophic	chondrocytes.	As	seen	in	Table	7,	microarray	data	clearly	showed	 that	 fetuin-A	was	 not	 expressed	 by	 growth	 plate	 chondrocytes,	 suggesting	fetuin-A	uptake	from	the	extracellular	fluid.	Figure	42	displays	a	heatmap	representation	of	 the	microarray	analysis	data.	All	 three	samples	 from	wildtype	mice	showed	a	high	similarity	to	each	other,	as	did	the	three	samples	from	Ahsg-/-	mice.	A	huge	diﬀerence	was	observed	when	comparing	wildtype	 to	 Ahsg-/-	 samples.	 Samples	 from	 heterozygous	 Ahsg+/-	 mice	 were	heterogeneous;	while	one	sample	appeared	more	similar	to	Ahsg-/-	samples,	the	other	two	Ahsg+/-	samples	appeared	more	similar	to	samples	from	wildtype	mice.	Due	to	the	high	 heterogeneity	 of	 samples	 from	 Ahsg+/-	 mice,	 we	 focused	 further	 analysis	 on	comparing	samples	from	wildtype	mice	to	those	from	Ahsg-/-	mice.		
Table	!:	 Raw	data	 of	microarray	 analysis	 of	 the	Ahsg	gene.	Signal	 intensities	were	similar	 for	samples	 from	wildtype	(WT),	and	fetuin-A-deficient	mice	(Ahsg+/-,	Ahsg-/-).	Prepared	with	the	help	of	the	Genomics	Facility.	Wildtype	bi-weighted	average	 Ahsg+/-	bi-weighted	average	 Ahsg-/-	bi-weighted	average	 Fold-change	Ahsg-/-	vs.	WT	 P-value	!.!#	+/-!.!#	 !.!#	+/-!.##	 !.!#	+/-!.!#	 -!	 !.!!"##$		
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Figure	 !":	 Heatmap	
representation	of	microarray	
data.	 This	 heatmap	 shows	 the	gene	 expression	 in	 wildtype	mice	 compared	 to	 Ahsg-/-mice,	gene	 expression	 in	 Ahsg-/-	 and	
Ahsg+/-	mice	 both	 compared	 to	wildtype	 mice.	 A	 huge	diﬀerence	 in	 gene	 expression	can	 be	 seen	 between	 samples	from	wildtype	and	Ahsg-/-	mice.	Data	 was	 generated	 with	 the	help	 of	 Sina	 Köppert.	 Graph	shown	 was	 modified	 from	 a	graph	 provided	 by	 Genomics	Facility.				Supporting	 Table	 0	 presents	 an	 overview	 of	 the	 !""	 most	 highly	 diﬀerentially	regulated	genes.	Strikingly,	the	chemokine	CXCL9	was	upregulated	about	==>-fold	and	also	 other	 immunity-related	 genes	 were	 amongst	 the	 most	 highly	 diﬀerentially	regulated	genes.	Of	all	significantly	diﬀerentially	regulated	genes,	345	genes	were	upregulated	and	only	()	were	downregulated.	This	is	best	illustrated	by	the	volcano	plot	depicted	in	Figure	43.	The	most	strongly	downregulated	gene	was	only	*-fold	downregulated,	and	most	of	these	genes	were	pseudogenes.	From	the	most	strongly	diﬀerentially	regulated	genes,	we	picked	seven	genes	to	 validate	 the	 microarray	 data.	 We	 performed	 quantitative	 real	 time	 PCR	 on	 the	original	 RNA	 that	 had	 been	 used	 for	 microarray	 analysis	 and	 confirmed	 the	microarray	analysis	results	in	all	candidate	genes	as	shown	in	Figure	43A.		Pathway	 enrichment	 analysis	 was	 performed	 using	 four	 databases	 (Gene	ontology,	Wikipathways,	KEGG,	EMBL-EBI).	All	genes	with	an	up-	or	down	regulation	of	at	 least	!.#$-fold	were	included	in	the	analysis.	Results	of	the	enrichment	analysis	are	presented	in	Supporting	Table	0.	The	results	of	the	enrichment	analysis	point	to	a	strong	immune	system	response	in	the	growth	plates	of	Ahsg-/-	mice.	After	 analyzing	 the	most	 highly	 diﬀerentially	 regulated	 genes	 in	more	detail,	we	 discovered	 that	most	 of	 those	 genes	 were	 inducible	 by	 either	 type	 I	 or	 type	 II	interferon.	 Interestingly,	 STAT#,	 which	 is	 a	master	 regulator	 of	 interferon	 signaling,	was	upregulated	!!.#$-fold	according	to	microarray	analysis.	The	regulation	of	STAT!	
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expression	 occurs	 through	 positive	 autoregulation	 and	 thus	 STAT!	 upregulation	strongly	 suggests	 the	 activation	 of	 the	 JAK-STAT	 signaling	 pathway	 by	 interferon	signaling	!"#.		
Figure	!":	 Volcano	plot	 representation	
of	 microarray	 data.	 Each	 point	represents	 a	 gene.	 The	 p-value	 signifies	the	 statistical	probability	 that	 the	gene	 is	diﬀerentially	regulated.	The	left	half	of	the	graph	 shows	 all	 genes,	 which	 are	downregulated;	 the	 right	 half	 shows	genes,	 which	 are	 upregulated	 in	 samples	from	 Ahsg-/-	 mice.	 All	 colored	 spots	represent	 the	 significantly	 diﬀerentially	regulated	 genes,	 which	 are	 at	 least	 !.#$	fold	 down-	 (blue)	 or	 upregulated	 (red).	Genes	marked	with	a	circle	were	used	for	validation	with	qPCR.	Data	was	generated	with	 the	 help	 of	 Sina	 Köppert.	 Graph	shown	 was	 modified	 from	 a	 graph	provided	by	Genomics	Facility.				 We	 compared	 all	 genes	 which	 were	 upregulated	 at	 least	 three-fold	 to	 the	Interferome	database	!"!.	 The	parameters	 for	 the	 query	were	 set	 to	 in	vivo,	 species:	
mus	musculus,	sample	type:	normal.	A	search	including	789	genes	returned	777	genes	as	belonging	to	the	queried	responses.	Figure	44B	shows	that	)*	of	 these	genes	are	regulated	by	both,	IFN	type	I	and	IFN	type	II	response,	and	56	genes	are	regulated	by	IFN	type	I	response	alone.	It	is	however	important	to	note	that	the	database	is	biased	towards	IFN	type	I	response	genes.		
	
Figure	!!:	A)	Comparison	of	microarray	with	real-time	PCR	data.	Seven	candidate	genes	were	validated	using	quantitative	 real	 time	PCR.	Both	methods	yielded	 similar	 results.	Error	bars	 show	SD	Statistical	 evaluation	was	carried	out	using	Student’s	t-test	test:	**p<).)+,	***p<).))+.	Data	was	generated	with	the	help	of	Sina	Köppert.	B)	
Venn-diagram	of	 Interferome	database	 search	 results.	All	genes,	which	were	upregulated	at	 least	 three-fold,	were	 searched	 for	 in	 the	 Interferome	 database.	 A	 search	 of	 123	 genes	 returned	 111	 hits.	 The	 resulting	 diagram	shows	by	which	interferon	signaling	pathway	the	queried	genes	were	regulated.		
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! DISCUSSION		
4.1 Influence	of	Fetuin-A	and	Retinoic	Acid	on	Bone	Growth	
In	Vitro		Fetuin-A	is	a	liver-derived	protein,	which	is	highly	abundant	in	mineralized	bone	and	fetuin-A-deficient	mice	 develop	 a	 bone	 phenotype	 anomaly	 in	 their	 femora	!"#,!"!.	 In	this	 thesis,	 the	 role	 of	 fetuin-A	 in	 long	 bone	 development	 was	 investigated.	 As	overdosing	 on	 retinoic	 acid	 leads	 to	 a	 similar	 bone	 phenotype	 anomaly	 as	 seen	 in	fetuin-A	 deficient	 mice	 !!",	 fetuin-A	 and	 all-trans-retinoic	 acid	 were	 studied	 in	 a	postnatal	bone	culture	system.	
4.1.1 Retinoic	Acid		Addition	of	all-trans-retinoic	acid	(ATRA)	to	cultured	bones	decreased	bone	growth	in	tibiae	and	femora	from	wildtype	and	Ahsg-/-	mice.	The	growth	of	bones	from	DBA/-	mice	was	 inhibited	 to	 a	 lesser	 extent	 by	 ATRA	 treatment	 compared	 to	 bones	 from	C"#BL/'	mice.		The	treatment	of	bones	with	ATRA	led	to	a	decreased	number	of	proliferative	cells	in	the	proliferative	zone.	This	was	in	accordance	with	the	findings	of	de	Luca	et	
al.	!"#.	 The	 authors	 showed	 a	 decrease	 in	proliferation	 upon	 ATRA	 treatment	 in	 rat	metatarsal	rudiment	culture.	Culturing	 bones	 in	 the	 presence	 of	 ATRA	 induced	 cartilage	 degradation,	 as	demonstrated	by	the	loss	of	toluidine	blue	staining	on	paraﬃn	sections	and		increased	GAG	release	 into	 the	culture	medium.	Cartilage	degradation	due	 to	ATRA	 treatment	has	previously	been	 reported	 in	 the	 literature.	Kistler	et	al.		demonstrated	a	 loss	 of	toluidine	 blue	 staining	 in	 sections	 from	 rat	 growth	 plate	 cartilage	 explants	 treated	with	 high	 concentrations	 of	 retinoic	 acid	!"#,	 in	 accordance	 with	 our	 findings.	 The	authors	reported	that	the	degradation	was	inhibited	by	the	addition	of	cycloheximide,	an	 inhibitor	 of	 protein	 biosynthesis.	 This	 strongly	 suggested	 that	 the	 chondrocytes	themselves	 were	 involved	 in	 cartilage	 matrix	 degradation.	 Also,	 EDTA	 inhibited	ATRA-induced	 degradation,	 indicating	 the	 involvement	 of	 matrix	 metalloproteases.	Furthermore,	 the	 authors	 showed	 that	 chondrocytes	 in	 ATRA-treated	 cartilage	
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transdiﬀerentiated	 into	 fibroblast-like	 cells	 containing	 lysosomal	 structures,	suggesting	 lytic	activity.	Similarly,	Ballock	et	al.	!"#	demonstrated	the	upregulation	of	metalloprotease	 gene	 transcription	 in	 retinoic	 acid-treated	 chondrocytes.	 Fosang	 et	
al.	!""	 claimed	 that	 MMP-.	 was	 the	 main	 protease	 responsible	 for	 ATRA	 cartilage	degradation.	In	contrast,	a	study	by	Price	et	al.	!"#	did	not	find	MMP	activity	to	be	the	culprit	for	cartilage	degradation.			
4.1.2 Fetuin-A		In	bones	from	Ahsg-/-	mice,	addition	of	fetuin-A	alone	increased	bone	growth	slightly	but	not	significantly,	independent	of	genetic	background.	Addition	of	fetuin-A	alone	to	cultured	wildtype	bones	however,	did	not	aﬀect	bone	growth,	independent	of	genetic	background.	This	might	be	because	bones	from	wildtype	mice	already	contained	large	amounts	of	fetuin-A	!".	However,	in	untreated	control	bones	there	were	no	diﬀerences	in	growth	between	bones	from	wildtype	and	Ahsg-/-	mice.		Bones	treated	with	fetuin-A	showed	a	decreased	number	of	proliferative	cells	in	the	proliferative	zone	(with	the	exception	of	Ahsg-/-	femora).	This	was	inconsistent	with	 the	 finding	 that	addition	of	 fetuin-A	 increased	 the	growth	of	Ahsg-/-	bones	and	did	not	aﬀect	growth	in	wildtype	bones.	However,	proliferation	was	only	measured	on	the	 last	day	of	culture	and	 thus	 the	eﬀect	of	 fetuin-A	on	proliferation	on	other	days	was	 not	 known.	 Fetuin-A	 might	 have	 also	 influenced	 bone	 growth	 through	 other	mechanisms.	For	instance,	Ishikawa	and	Yang	showed	that	fetuin-A	increased	alkaline	phosphate	 activity	 in	 cultured	 chondrocytes	!"#,!"%,	 indicating	 that	 fetuin-A	 might	influence	chondrocyte	differentiation.	It	was	striking	that	fetuin-A,	which	is	usually	only	present	in	mineralized	bone	tissue,	bone	marrow	and	the	hypertrophic	zone,	could	have	had	such	an	influence	on		avascular	 proliferative	 zone	 chondrocytes.	 In	 bones	 cultured	 in	 the	 presence	 of	labeled	 fetuin-A,	 few	 proliferative	 cells	 stained	 positive	 for	 fetuin-A.	 Thus,	 in	 bone	culture	fetuin-A	might	have	diﬀused	through	cartilage	and	in	this	manner	influenced	proliferative	 chondrocytes.	 Alternatively,	 fetuin-A	might	have	 influenced	 cells	 of	 the	perichondrium,	 or	 hypertrophic	 chondrocytes	 to	 secrete	 cytokines,	 which	 in	 turn	
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inhibited	proliferation.	It	is	however	questionable,	if	this	finding	is	relevant	for	the	in	
vivo	 function	 of	 fetuin-A,	 as	 fetuin-A	 deficiency	 did	 not	 have	 an	 influence	 on	chondrocyte	proliferation	in	vivo,	at	least	not	in	+,	days	old	mice.	While	 fetuin-A	 decreased	 proliferation	 in	 the	 proliferative	 zone,	 it	 also	increased	 the	proliferation	 in	periosteal	and	perichondrial	 cells.	The	perichondrium	and	periosteum	both	contain	mesenchymal	precursor	cells	which	aid	in	bone	growth	and	fracture	repair	!"!,$%&.	The	finding	that	 fetuin-A	increased	cell	proliferation	 in	the	those	regions	suggests	that	fetuin-A	might	have	a	positive	influence	on	mesenchymal	stem	cell	proliferation	in	vitro.	Addition	of	 fetuin-A	 in	bone	culture	 induced	a	visible	 swelling	of	 the	growth	plate.	Fetuin-A	thus	either	increased	matrix	production,	or	the	number	of	cells	in	the	growth	 plate.	 Alternatively,	 fetuin-A	 might	 have	 induced	 collagen	 degradation.	Degradation	of	collagen	would	have	weakened	the	tensile	strength	of	the	growth	plate	cartilage	 and	 lead	 to	 increased	 water	 uptake,	 as	 the	 GAGs	 in	 cartilage	 bind	 large	amounts	of	water.	Swelling	of	cartilage	occurs	in	osteoarthritis	as	a	result	of	collagen	degradation	!"#.	 One	 important	 collagen-degrading	 enzyme,	 which	 is	 crucial	 in	endochondral	 ossification,	 is	 matrix	 metalloprotease	 )	 (MMP))	!"#.	 Ochieng	 et	 al.	demonstrated	that	in	vitro,	fetuin-A	stabilized	MMP.	activity	by	inhibiting	its	autolytic	degradation,	 even	 at	 physiologic	 concentrations	!"#.	 Furthermore,	 serum	 from	wildtype,	but	not	 from	Ahsg-/-	mice	 inhibited	autolytic	degradation	of	MMP5	 in	vitro.	In	our	bone	culture	system,	addition	of	fetuin-A	might	have	stabilized	MMP)	activity	and	 thus	 led	 to	 collagen	 degradation	 in	 growth	 plate	 cartilage,	 which	 resulted	 in	swelling.	 Macrophages	 and	 monocytes	 present	 in	 bone	 were	 a	 potential	 source	 of	MMP#	in	our	bone	culture	system.		GAG	release	into	the	medium	was	slightly	increased	in	fetuin-A-treated	bones	compared	to	untreated	samples	but	lower	compared	to	ATRA-treated	bones.	Staining	of	paraﬃn	sections	 from	fetuin-A-treated	bones	showed	minor	degradation	 in	some	samples,	mainly	in	the	hypertrophic	zone.	Fetuin-A	might	have	activated	or	stabilized	proteolytic	enzymes	and	in	this	manner	induced	degradation	of	not	only	collagen,	but	also	GAGs,	 or	 caused	a	 slight	 release	of	GAGs	due	 to	weakening	of	 the	 extracellular	matrix	protein	network.	Taken	together,	 fetuin-A	might	play	a	role	 in	degradation	of	cartilage	extracellular	matrix.	
DISCUSSION	92	
4.1.3 Fetuin-A	and	ATRA	in	Combination		The	 initial	 hypothesis	 of	 the	 present	 study	 was	 that	 the	 femur	 dysplasia	 in	fetuin-A-deficient	mice	 is	a	phenocopy	of	retinoic	acid	 intoxication	and	 fetuin-A	 is	a	regulator	 of	 retinoic	 acid	 signaling	 in	 the	 growth	 plate.	 Thus,	 fetuin-A	deficiency	 in	
vivo	would	result	in	an	increase	in	retinoic	acid	signaling	in	the	growth	plate,	leading	to	 the	 observed	 bone	 phenotype	 anomaly.	We	 thus	 hypothesized	 that	 when	 bones	were	 treated	 simultaneously	 with	 fetuin-A	 and	 ATRA,	 fetuin-A	 would	 prevent	 the	ATRA-induced	growth	inhibition	and	cartilage	degradation.		In	bones	from	C"#BL/'	wildtype	and	Ahsg-/-	mice,	the	relative	change	in	bone	length	after	treatment	with	a	combination	of	fetuin-A	and	retinoic	acid,	was	similar	to	that	 after	 treatment	 with	 ATRA	 alone.	 Thus	 generally,	 addition	 of	 fetuin-A	 did	 not	prevent	the	ATRA-induced	growth	impairment.	The	 number	 of	 EdU	 positive	 cells	 in	 the	 proliferative	 zone	 was	 decreased	 upon	addition	 of	 ATRA	 alone	 and	 even	 more	 upon	 addition	 of	 fetuin-A	 alone,	 and	 the	combination	of	 fetuin-A	and	ATRA	 led	 to	a	similar	decrease	compared	 to	 treatment	with	fetuin-A	alone.	Thus,	fetuin-A	did	not	prevent	the	decrease	in	proliferation	in	the	proliferative	zone	caused	by	ATRA.		The	 results	 of	 this	 study	 suggested	 that	 fetuin-A	 might	 exacerbate	ATRA-induced	 cartilage	 degradation.	 When	 bones	 were	 treated	 with	 ATRA	 and	!	mg/ml	or	$.&	mg/ml	fetuin-A	simultaneously,	cartilage	degradation	was	obvious	on	micrographs	of	whole	cultured	bones.	 In	bones	cultured	with	 &	mg/ml	 fetuin-A	and	ATRA,	 the	 cartilaginous	 epiphyses	detached	 from	 the	 bones.	Measurements	 of	 GAG	concentrations	 in	 culture	 medium	 however	 showed	 that	 treatment	 of	 bones	 with	fetuin-A	and	ATRA	combined	only	led	to	a	very	slight	increase	in	GAG	release	into	the	medium	compared	to	treatment	with	ATRA	alone.	There	was	also	no	evidence	for	an	increased	 GAG	 degradation	 on	 toluidine	 blue	 stained	 paraffin	 sections.	 Thus,	 the	visible	increase	in	degradation	was	not	reflected	in	GAG	concentration	measurements	and	 toluidine	 blue	 staining,	 indicating	 that	 the	 fetuin-A	 did	 not	 exacerbate	ATRA-induced	 degradation	 of	 GAGs.	 Fetuin-A	 alone	 might	 have	 induced	 cartilage	degradation	 through	 the	degradation	of	 collagen.	As	mentioned	previously,	 fetuin-A	was	 reported	 to	 stabilize	 the	 collagenase	 MMP5	 in	 vitro	!"#.	 ATRA	 induces	 the	
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degradation	of	GAGs	in	cartilage	!"#.	Degradation	of	both,	GAGs	and	collagen	combined	could	have	led	to	increased	cartilage	degradation	and	detachment	of	the	cartilaginous	epiphyses.	It	is	unclear	at	this	point,	whether	ATRA	and	fetuin-A	act	synergistically,	or	if	the	observed	results	are	additive.	To	 localize	 added	 fetuin-A	 in	 the	 growth	 plate,	 bones	 were	 cultured	 in	 the	presence	of	Alexa!"#-tagged	 fetuin-A.	 In	 the	absence	of	ATRA,	 labeled	 fetuin-A	was	found	mainly	 in	 the	 hypertrophic	 zone	 and	 only	 few	 cells	 of	 the	 proliferative	 zone	were	 positive	 for	 fetuin-A.	 In	vivo,	 fetuin-A	 has	been	 localized	 only	 in	 hypertrophic	chondrocytes.	Bones	cultured	 in	 the	presence	of	 labeled	 fetuin-A	and	ATRA	showed	an	 accumulation	 of	 fetuin-A	 in	 chondrocytes	 of	 the	 proliferative	 zone.	 As	ATRA-induced	 cartilage	 degradation,	 it	 might	 have	 rendered	 the	 cartilage	 more	permeable	 for	 fetuin-A.	 Alternatively,	 ATRA	 treatment	 might	 have	 resulted	 in	 an	increased	 uptake	 of	 fetuin-A	 by	 proliferative	 chondrocytes.	 Thus	 in	 cultured	 bones,	fetuin-A	was	ectopically	localized	in	proliferative	chondrocytes,	very	unlike	in	vivo.		
4.1.4 Apoptosis		Paraﬃn	 sections	 from	 cultured	 bones	 were	 stained	 for	 apoptotic	 cells	 using	 the	TUNEL	 method.	 TUNEL	 positive	 cells	were	 found	 in	 diﬀerent	 regions	 of	 bone	 and	cartilage.	About	 half	 of	 all	 treated	 bones	 showed	 areas	 in	 their	 proliferative	 zones,	which	 contained	 a	 high	 number	 of	 TUNEL	 positive	 chondrocytes.	 Contingency	analysis	showed	that	there	was	no	correlation	between	the	type	of	treatment	and	the	presence	 of	 apoptotic	 cells	 in	 the	 proliferative	 zone.	 However,	 apoptosis	 in	 the	proliferative	 zone	 was	 generally	 more	 prominent	 in	 treated	 bones,	 as	 this	 was	observed	in	about	half	of	all	treated	bones	and	only	in	one	out	of	six	untreated	bones.	Apoptosis	 was	 thus	 unlikely	 the	 cause	 of	 increased	 degradation	 and	 cartilage	detachment	upon	treatment	with	fetuin-A	and	ATRA.	The	high	incidence	of	apoptotic	cells,	 especially	 in	 the	 proliferative	 zone,	 could	 be	 an	 explanation	 for	 the	 generally	high	 standard	 variations	 found	 during	measurements	 of	 bone	 growth,	 degradation	and	proliferation.		
In	 vivo,	 apoptotic	 cells	 in	 bones	 are	 present	 in	 bone	 marrow	 and	 in	 the	
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hypertrophic	 zone,	but	 to	a	 far	 lower	degree	 compared	 to	 cultured	bones.	The	high	numbers	of	apoptotic	cells,	especially	in	the	proliferative	zone,	most	probably	had	an	influence	 on	 bone	 growth.	 The	 discrepancy	 between	 apoptosis	 in	 vivo	 and	 in	 vitro	demonstrates	the	limitations	of	our	postnatal	bone	culture	system.		
4.1.5 The	Influence	of	Genetic	Background	and	Genotype		As	DBA/'	mice	also	developed	 the	dysplasia,	 albeit	 to	a	 lesser	extent	 than	C'(BL/,	mice,	 we	 performed	 some	 of	 the	bone	 culture	 experiments	 using	 bones	 from	both,	BL/$	and	DBA/%	mice.	The	increase	in	bone	length	during	the	course	of	four	days	was	less	 in	 cultured	DBA/%	wildtype	 control	 bones	 compared	 to	BL/8	 control	 bones.	 In	contrast,	bones	from	fetuin-A-deficient	DBA/-	mice	showed	a	similar	length	increase	compared	 to	 BL/.	 mice.	 Upon	 addition	 of	 fetuin-A	 into	 the	 culture	 medium,	DBA/%-Ahsg-/-		and	C!"BL/!-Ahsg-/-			bones	showed	an	increase	in	bone	growth.	Thus,	the	 influence	 of	 added	 fetuin-A	 on	 bone	 growth	 was	 independent	 of	 genetic	background,	but	influenced	by	the	fetuin-A	genotype.		The	 most	 interesting	 genotype-dependent	 diﬀerence	 was	 found	 during	 GAG	concentration	measurements	 of	 culture	media.	 GAG	 concentrations	were	measured	on	day	two	and	day	four	of	culture	after	starting	treatment	on	day	one.	BL/7	wildtype	bones	 showed	 similar	 GAG	 concentrations	 on	 both	 days.	 However,	 GAG	concentrations	of	BL/!-Ahsg-/-	samples	were	much	lower	on	day	two	then	on	day	four.	Thus,	either	chondrocytes	 from	Ahsg-/-	bones	 reacted	diﬀerently	 to	ATRA	 treatment,	or	 there	 might	 be	 a	 diﬀerence	 in	 the	 composition	 of	 their	 extracellular	 matrix	between	wildtype	and	Ahsg-/-	bones.			
4.1.6 Summary:	Influence	of	Fetuin-A	and	Retinoic	Acid	on	Bone	
Growth	In	Vitro			To	 sum	 up,	 the	 results	 of	 the	 bone	 culture	 did	 not	 clarify	 the	 role	 of	 fetuin-A	 in	endochondral	 ossification,	 or	 its	 role	 in	 retinoic	 acid	 signaling.	 Also,	 there	 was	 no	clear	role	of	genetic	background	or	genotype	of	the	bones.	Due	to	the	high	number	of	apoptotic	 cells,	 and	 the	 ectopic	 localization	of	 fetuin-A	 in	 the	proliferative	 zone,	we	
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conclude	 that	 the	 bone	 culture	 system	was	 very	 artificial	 and	 could	 thus	 not	 yield	reliable	 results.	 Nonetheless,	 we	 conclude	 that	 fetuin-A	 plays	 a	 role	 in	 cartilage	degradation	in	vitro.		
4.2 The	Role	of	Fetuin-A	in	Endochondral	Ossification	
In	Vivo		
4.2.1 The	Role	of	Fetuin-A	in	Growth	Plate	Mineralization		We	 sought	 to	 identify	 the	 role	 of	 fetuin-A	 in	 endochondral	 ossification	 by	 studying	bone	development	in	the	C/0BL/4-Ahsg-/-	mouse.	Fetuin-A	has	been	established	as	a	systematically	 acting	 inhibitor	 of	 ectopic	 calcification	!"".	 In	 patients,	 low	 serum	fetuin-A	 levels	 are	 correlated	 with	 increased	 risk	 of	 aortic	 calcification	 and	cardiovascular	mortality	!!!–!!".	Ahsg-/-	mice	on	the	genetic	background	DBA/5	develop	severe	ectopic	calcifications	in	almost	all	major	organs	!"".	As	fetuin-A-deficient	mice	have	 shortened	 femoral	 bones,	 inhibition	of	 premature	 growth	plate	mineralization	would	be	 an	 obvious	 role	 for	 fetuin-A	 in	 endochondral	 ossification.	 In	 the	 previous	study	on	 the	 bone	phenotype	 of	Ahsg-/-	mice	by	 Seto	et	al.	!"#,	an	 increased	mineral	content	 in	Ahsg-/-	growth	plates	was	reported.	From	this,	 the	conclusion	was	drawn	that	 fetuin-A-deficient	 femora	 were	 shorter	 due	 to	 premature	 growth	 plate	mineralization.	However,	the	present	study	casts	doubt	on	this	hypothesis.	Von	Kossa	staining	 of	 growth	 plates	 from	 12	 days	 old	mice	 showed	 no	 aberrant	 growth	 plate	mineralization	in	Ahsg-/-	mice.	 In	contrast,	almost	completely	calcified	growth	plates	were	observed	in	a	study	on	mice	deficient	for	matrix-GLA-protein	(MGP),	which	is	a	true	 inhibitor	 of	 growth	 plate	 mineralization	!"!.	 MGP	 is	 locally	 expressed	 by	hypertrophic	growth	plate	chondrocytes	and	excessive	growth	plate	mineralization	in	the	absence	of	MGP	leads	to	dwarfism.	We	now	presume	that	fetuin-A	might	not	be	as	crucial	 for	 the	 inhibition	 of	 excessive	 growth	 plate	 cartilage	 mineralization	 as	previously	thought.	In	order	to	substantiate	this	hypothesis,	a	more	detailed	analysis	of	 growth	 plate	mineralization	would	 be	 necessary.	 The	 increased	mineral	 content,	which	was	reported	by	Seto	et	al.	!"#	in	growth	plates	of	Ahsg-/-	mice,	can	be	explained	by	the	presence	of	bone	bridges	found	in	several	distal	femora	in	the	present	study.		
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Seto	et	al.	!"#	also	reported	an	increased	cortical	thickness	in	Ahsg-/-	femora	and	we	could	confirm	this	finding	in	our	present	study.	We	hypothesize,	that	the	increased	cortical	 thickness	 is	most	 likely	a	consequence	of	 increased	mechanical	 loading	and	ensuing	 remodeling	 of	 the	 bone	 according	 to	 Wolﬀ’s	 law	!"#	 as	 a	 result	 of	 the	dysplasia.		
4.2.2 Elongated	Hypertrophic	Zones	in	Ahsg-/-	Mice		In	the	absence	of	 fetuin-A,	mice	displayed	an	elongation	of	their	hypertrophic	zones	until	the	age	of	three	weeks.	A	possible	reason	for	this	might	have	been	an	increase	in	proliferation	 in	 the	 proliferative	 zone,	 leading	 to	 an	 increased	 number	 of	 cells	undergoing	 hypertrophic	 differentiation.	 However,	 we	 could	 rule	 out	 that	 the	elongation	was	caused	by	an	increased	chondrocyte	proliferation.		A	 number	 of	 genetically	 altered	 mouse	 strains	 likewise	 show	 elongated	hypertrophic	zones.	From	mouse	models	we	know	that	hypertrophic	zone	elongation	can	occur	due	 to	 a	delay	 in	 chondrocyte	maturation	or	hypertrophic	diﬀerentiation	and	due	to	impaired	hypertrophic	cartilage	remodeling.	Mice	 deficient	 for	 ADAM$%/TACE	 in	 their	 chondrocytes	 develop	 lengthened	hypertrophic	zones	due	to	a	delay	in	hypertrophic	maturation	and	due	to	a	decrease	in	hypertrophic	cartilage	degradation	!"#–!"".	ADAM&'	is	a	membrane-bound	protease	regulating	 TNF-α	 and	 EGFR	 ligands	 and	 is	 thus	 important	 for	 proper	 hypertrophic	maturation.	ADAM./-deficient	mice	also	had	fewer	osteoclasts	and	a	lower	expression	of	MMP&	at	the	chondro-osseous	junction,	thus	remodeling	of	hypertrophic	cartilage	was	impaired.	A	similar	phenotype	was	seen	in	EGFR-deficient	mice	!"#.	In	 mice	 with	 an	 overexpression	 of	 RUNX4/CBFA!	 in	 hypertrophic	chondrocytes,	 the	 hypertrophic	 zone	was	 elongated,	 and	matrix	mineralization	was	decreased,	due	to	a	delay	in	chondrocyte	maturation	!"#.	MAPK	 signaling	 is	 also	 important	 for	 hypertrophic	 zone	 maturation.	 Mice	deficient	in	ERK,	and	ERK.	in	chondrocytes	had	an	elongated	hypertrophic	zone	due	to	impaired	terminal	diﬀerentiation	!"#.	Mice	treated	with	the	angiotensin	II	receptor	(AGTRII)	antagonist	Losartan	showed	decreased	ERK+	and	ERK-	phosphorylation	in	their	growth	plates	!"#.	However,	these	mice	had	elongated	hypertrophic	zones	due	to	
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and	 increase	 in	 hypertrophic	 diﬀerentiation	 as	 AGTRII	 decreases	 hypertrophic	diﬀerentiation.	Also	Rbpjκ	-/-	mice,	which	are	deficient	in	Notch	signaling	in	the	growth	plate,	showed	hypertrophic	zone	elongation	due	to	impaired	chondrocyte	maturation	!"#,!%#.	Increased	 hypertrophic	 diﬀerentiation	 can	 also	 cause	 hypertrophic	 zone	elongation.	Reactive	oxygen	species	(ROS)	are	important	in	hypertrophic	chondrocyte	maturation	 and	mice	 deficient	 for	 the	 anti-oxidative	 stress	 gene	Atm	developed	 an	elongated	 hypertrophic	 zone	 due	 to	 increased	 hypertrophic	 maturation	!"#.	 Mice	deficient	in	apoptosis	signal-regulating	kinase	-	(ASK-)	similarly	developed	elongated	hypertrophic	zones	due	 to	a	deficiency	 in	chondrocyte	apoptosis	and	maturation	!"#.	Ask$	 is	 strongly	 expressed	 in	 hypertrophic	 chondrocytes	 and	 is	 induced	 by	 ROS.	Defects	 in	 the	 remodeling	 of	 the	 hypertrophic	 zone,	 i.e.	 deficiency	 in	 the	 major	proteolytic	 enzymes	matrix	metalloprotease	 1	 (MMP1)	 and	matrix	metalloprotease	(MMP$%),	or	both,	led	to	an	increased	hypertrophic	zone	length	!"#,!"%.	Proper	 vascular	 invasion	 into	 the	 terminal	 hypertrophic	 zone	 is	 crucial	 for	endochondral	ossification.	Mice	treated	with	a	soluble	VEGF	decoy	receptor	or	mice	deficient	for	cartilage	VEGF	showed	hypertrophic	zone	elongation	and	dwarfism	!"!,!"$.	Additionally,	 the	 “targeted	 induction	 of	 endoplasmatic	 reticulum	 stress”	 also	led	 to	 defective	 cartilage	 degradation	 as	 osteoclast	 recruitment	 to	 the	chondro-osseous	junction	was	decreased	!"#.	In	 summary,	 decreased	 as	 well	 as	 increased	 chondrocyte	 maturation	 or	defective	 remodeling	 of	 the	 growth	 plate	 are	 the	 most	 important	 reasons	 for	hypertrophic	zone	elongation.	The	 cause	 for	 the	 elongated	hypertrophic	 zone	 in	Ahsg-/-	mice	 remains	 to	be	elucidated.	As	mineralization	of	the	hypertrophic	zone	of	Ahsg-/-	appears	normal,	we	do	not	assume	that	chondrocyte	maturation	is	aﬀected.	As	fetuin-A	has	been	shown	to	inhibit	the	autolytic	degradation	of	MMP4	in	vitro,	and	in	this	manner	enhance	MMP#	stability	and	activity,	this	could	be	a	possible	mechanism	in	the	growth	plate	!"#.			 	
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4.2.3 Cellular	Invasion		In	this	study	we	demonstrated	that	at	an	age	of	three	weeks,	Ahsg-/-	mice	developed	lesions	in	their	growth	plates,	which	contained	foreign	cells.	TUNEL	staining	showed	that	these	foreign	cells	were	not	apoptotic	chondrocytes.	Thus	we	assumed,	that	these	cells	 invaded	 the	 growth	 plate	 from	 the	 bone	 marrow	 cavity	 or	 the	 vasculature.	Occasionally	we	observed	vascular	invasion,	as	some	lesions	contained	erythrocytes.	Interestingly,	the	cellular	infiltrates	were	always	located	between	the	proliferative	and	the	hypertrophic	zone.	A	clearing	of	the	safranin	O	staining	around	the	invading	cells	indicated	matrix	degradation.	We	hypothesize,	that	in	the	distal	femoral	growth	plates	of	Ahsg-/-	mice,	cellular	infiltrates	led	to	growth	plate	cartilage	degradation,	resulting	in	a	mechanical	weakening	and	the	formation	of	a	fault	line	at	the	boundary	between	proliferative	 and	 hypertrophic	 zone.	This	 led	 to	 a	 deformation	 of	 the	 growth	plate,	leading	to	the	observed	distal	femur	dysplasia.	The	occurrence	of	the	dysplasia	solely	in	the	femur	might	be	a	consequence	of	mechanical	loading.	Also,	skeletal	muscles	are	anchored	 at	 the	 distal	 femur	 and	 exert	 mechanical	 force	 upon	 contraction,	 which	might	 increase	the	risk	of	deformation.	However,	not	only	the	femur	was	affected	 in	
Ahsg-/-	 mice,	 as	 tibiae	 of	 Ahsg-/-	 mice	 were	 also	 reduced	 in	 size.	 Therefore,	 a	histological	study	of	tibiae	and	other	bones	from	Ahsg-/-	mice	might	offer	more	insight.		Cellular	 infiltrates	 in	 the	 growth	 plate,	 like	 in	 the	 fetuin-A-deficient	 mouse,	have	been	reported	in	studies	on	growth	plate	fractures	or	injuries	in	rats	or	mice	and	have	 been	 identified	 as	 inflammatory	 cells	 and	 mesenchymal	 stem	 cells	!"#–!"#.	Wattenbarger	et	al.	applied	a	valgus	force	to	rat	proximal	tibiae	to	induce	type	I	Salter	Harris	fractures	!"#.	They	discovered	that,	when	the	fracture	was	contained	within	the	physis,	the	fracture	was	uneventful	and	healed	without	complications.	However,	when	the	 fracture	 extended	 into	 the	 metaphysis	 or	 the	 epiphysis,	 horizontal	 lines	 and	cavities	appeared	throughout	the	growth	plate	and	chondrocytes	were	disordered.	In	those	instances,	bone	bridges	formed,	bridging	the	epiphysis	and	metaphysis.	In	some	instances	the	growth	plate	partially	disappeared	or	was	displaced.	The	formation	of	bone	bridges	is	a	major	complication	in	children	after	growth	plate	injury.	It	occurs	in	about	 '(	%	of	 all	 cases	 and	 can	 lead	 to	 growth	 arrest	 and	 angular	 deformation	!"#.	Xian	and	colleagues	applied	a	drill-hole	 injury	model	of	rat	proximal	 tibiae	!"#.	They	
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described	 that	 the	 healing	 of	 growth	 plate	 injuries	 occurs	 in	 three	 phases.	 Initially,	cells	of	the	immune	system	invade	the	growth	plate		(inflammatory	phase).	Two	days	after	injury,	vimentin	positive	mesenchymal	precursor	cells	invaded	the	injury	region	(fibrogenic	phase).	Starting	from	day	seven,	small	bone	trabeculae	were	present	and	mature	 bone	 was	 formed	 over	 time	 (osteogenic	 phase).	Mesenchymal	 cells,	 which	infiltrated	 the	 wound	 during	 the	 fibrogenic	 phase,	 diﬀerentiated	 into	 osteoblasts.	Thus,	 during	 growth	 plate	 injury,	 inflammatory	 cells	 invade	 the	 growth	 plate	 and	induce	damage,	such	as	cartilage	degradation,	disordering	of	the	cells	and	formation	of	bone	bridges	through	intramembranous	ossification.		In	 our	Ahsg-/-	we	 observed	 the	 formation	 of	 bone	 lesions	 inside	 the	 growth	plate	and	 the	partial	 replacement	of	 the	growth	plate	by	bone,	very	similar	 to	what	was	described	 in	 the	 literature	 for	 growth	plate	 injury	healing.	Thus,	 in	 the	 growth	plates	 of	 Ahsg-/-	 mice,	 similar	 mechanisms	 might	 take	 place	 to	 those	 described	 in	animal	studies	of	growth	plate	injuries.		
4.2.4 Localization	of	Fetuin-A	Protein	in	Hypertrophic	Chondrocytes		In	eight	weeks	old	Ahsg-/-	mice,	growth	plate	lesions	had	healed	and	cellular	infiltrates	could	no	 longer	be	observed.	 In	 several	 samples	 from	Ahsg+/-	mice	 at	 the	 same	age	however,	a	 high	 number	 of	 atypical	 cells	were	 found	 in	 their	distal	 femoral	growth	plates.	 On	 histological	 sections,	 large	 defects	 were	 observed,	 which	 were	 localized	between	the	proliferative	and	the	hypertrophic	zone.	Here,	both	zones	were	partially	detached	from	each	other	and	the	resulting	surface	was	lined	with	cells,	but	the	defect	appeared	empty	on	the	histological	section.	Intriguingly,	in	bones	from	heterozygous	mice,	which	appeared	normal,	in	that	they	did	not	have	cellular	infiltrates	or	defects,	fetuin-A	was	 present	 in	 the	 cells	 of	 the	 hypertrophic	 zone.	 However,	 when	 cellular	infiltrates	 or	 defects	 were	 present,	 no	 fetuin-A	 could	 be	 detected	 in	 hypertrophic	chondrocytes.	 This	 corroborates	 that	 the	 localization	 of	 fetuin-A	 in	 hypertrophic	chondrocytes	 is	 crucial	 for	 proper	 bone	 development.	 However,	 these	 results	 also	show	 that	 in	 heterozygous	 mice,	 the	 healing	 of	 lesions	 is	 delayed,	 compared	 to	homozygous	fetuin-A-deficient	mice.			
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4.2.5 Gene	Expression	Microarray	Analysis		To	understand	the	molecular	mechanisms	occurring	 in	growth	plate	cartilage	 in	 the	absence	of	fetuin-A,	we	analyzed	gene	expression	in	34	days	old	mice.	This	time	point	was	chosen,	because	from	histological	studies,	 in	P%&.(	mice	no	other	morphological	diﬀerences	 were	 apparent	 than	 the	 elongated	 hypertrophic	 zone,	 and	 no	 cellular	infiltrates	were	detectable.	Thus,	all	changes	in	gene	expression	would	be	associated	with	the	absence	of	fetuin-A,	but	not	with	secondary	eﬀects.	Gene	 expression	 analysis	 revealed	 a	 striking	 upregulation	 of	 inflammatory	genes	 in	 the	growth	plates	of	 01	days	old	Ahsg-/-	mice.	Further	analysis	showed	that	most	of	those	inflammatory	genes	were	involved	in	interferon	type	signaling,	i.e.	they	were	expressed	in	response	to	either	interferon	type	I	or	II.	Thus,	fetuin-A-deficiency	was	 associated	 with	 the	 activation	 of	 an	 interferon	 type	 inflammatory	 response	 in	growth	 plate	 cartilage.	 As	 we	 only	 isolated	 RNA	 from	 growth	 plate	 cartilage,	 we	assume	that	chondrocytes	themselves	express	the	inflammatory	genes.	Alternatively,	the	inflammatory	activation	of	chondrocytes	might	have	been	triggered	by	infiltrating	immune	 cells	 that	were	 sparse	 and	went	undetected	 in	 histology,	 but	 nevertheless	secreted	pro-inflammatory	cytokines,	or	cells	close	to	the	chondro-osseous	junction,	which	were	isolated	accidentally.	The	presence	of	immune	cell-specific	marker	genes	was	 suggested	 by	 the	 increased	 expression	 of	 CD#$	 (".$$-fold),	 H"-EB#	 (".""-fold),	
H"-Aa	 (".$-fold)	 and	 H"-Ab#	 (".$%-fold)	 encoding	 class	 II	 major	 histocompatibility	complex	(MHC)	proteins.	Class	 II	MHC	proteins	are	exclusively	expressed	by	cells	of	the	immune	system.	Several	cytokine/chemokine	or	co-stimulatory	signals	including	tumor	 necrosis	 factor	 (TNF)	 ($.&'-fold),	 CD#$	 (".$%-fold),	 CD#$	 (".$$-fold),	 CD#$	(".$$-fold),	 Ccr!	 (".$%-fold),	 CD#$	 (".$$-fold),	 and	 CD#$%	 (".$$-fold)	 were	 likewise	upregulated	and	indicated	the	presence	immune	cells.	However,	the	upregulation	was	very	moderate	suggesting	few	if	any	invading	immune	cells	at	that	stage.	Microarray	 analysis	 revealed	 up	 to	 /0-fold	 upregulation	 of	 Stat$	 in	
Ahsg-/-	 growth	 plates.	 STAT!	 plays	 a	 key	 role	 in	 interferon	 signaling	 and	 its	upregulation	 is	 thus	 a	 strong	 indicator	 for	 interferon	 signaling	 to	 be	 involved	!"#.	STAT!	 signaling	 has	 been	 shown	 to	 play	 a	 role	 in	 endochondral	 ossification	 by	crosstalking	 with	 FGF	 signaling.	 Murakami	 et	 al.	 suggested	 that	 in	 achondroplasia,	
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FGFR$	 signaling	 inhibits	 chondrocyte	 proliferation	 through	 STAT4	!"#.	 Sahni	 and	colleagues	 demonstrated,	 that	 in	 mice	 overexpressing	 human	 FGF3,	 decreased	proliferation	 and	 increased	 chondrocyte	 apoptosis	 were	 mediated	 by	 STAT!	signaling	!"#.	The	activation	of	STAT!	signaling	in	the	growth	plate	of	Ahsg-/-	mice	is	a	subject	 for	 future	work.	 Currently	we	 are	 not	 able	 to	 distinguish	 the	 cause	 for	 this	inflammatory	response.	Experiments	with	immune	cell	depletion	in	fetuin-A-deficient	mice	will	tell	if	the	cartilage	inflammation	is	dependent	on	immune	cells.	We	suggest	that	in	fetuin-A-deficient	mice,	prehypertrophic	chondrocytes	first	become	activated	by	autocrine	stimulation	and	then	attract	immune	cells	by	secreting	inflammatory	 cytokines	 including	 CXCL6	 (chemokine,	 C-X-C	motif,	 ligand	 .),	 which	was	upregulated	about	)*+-fold	in	Ahsg-/-	growth	plate	cartilage.	CXCL!,	together	with	CXCL!"	(which	was	also	upregulated	!.#$-fold)	and	CXCL!!	(not	upregulated)	bind	to	the	 G	 protein-coupled	 receptor	 CXCR..	 CXCL1	 and	 CXCL!"	 are	 regarded	 as	 driver	chemokines	in	inflammation	!"!.	CXCR&	is	expressed	on	the	surface	of	activated	T	cells	and	CXCR'	and	its	ligands	regulate	the	migration	of	especially	Th!	cells	to	the	sites	of	Th!-driven	 inflammation	!"#.	 CXCL&	 is	 also	 mainly	 induced	 by	 type	 II	 Interferon,	strongly	 suggesting	 that	 IFNɣ was	 involved	 in	 the	 growth	 plate	 inflammatory	response	in	Ahsg-/-	mice.		
4.2.6 TGF-β	Signaling		The	 first	 study	 on	 the	 fetuin-A-deficient	 phenotype	 explained	 the	 shortening	 of	femoral	bones	by	increased	transforming	growth	factor	β	(TGF-β)	signaling	!"#.	TGF-β	signaling	is	involved	in	many	diﬀerent	cellular	processes,	but	is	mainly	known	for	its	anti-inflammatory	 properties	!"#.	 For	 instance,	 TGF-β!	 deficiency	 in	 mice	 causes	 a	dramatic	 inflammatory	 disease	!"#.	 Fetuin-A	 has	 previously	 been	 shown	 to	 inhibit	TGF-β	signaling	in	vitro	and	it	was	suggested	to	act	as	a	decoy	receptor	for	TGF-β	and	bone	morphogenetic	proteins	(BMPs)	due	to	perceived	structural	similarities	with	the	TGF-β	 receptor	!	!".	 If	 fetuin-A	was	 an	 inhibitor	 of	 TGF-β	 signaling	 in	 growth	 plate	cartilage,	 the	 absence	 of	 fetuin-A	 should	 increase	 TGF-β	 signaling,	which	would	 be	rather	 anti-inflammatory	 and	 contradict	 the	 findings	 of	 this	 study.	Also,	we	did	not	find	 any	 evidence	 in	 our	 microarray	 analysis	 data	 for	 the	 involvement	 of	 TGF-β	
DISCUSSION	102	
signaling	in	our	fetuin-A-deficient	mice.		
4.2.7 Possible	Mechanisms	of	Fetuin-A	Action	in	Endochondral	
Bone	Growth		To	summarize,	our	study	shows	that	the	shortening	of	femoral	bones	in	Ahsg-/-	mice	results	from	a	dysplasia	of	the	distal	femoral	growth	plates.	Newborn	Ahsg-/-,	but	not	
Ahsg+/-	mice	have	elongated	hypertrophic	zones,	which	normalize	at	an	age	of	about	three	to	four	weeks.	In	/0	days	old	Ahsg-/-	distal	femoral	growth	plates,	interferon	type	inflammatory	 gene	 expression	was	observed,	 including	 increased	 STAT!	 expression.	At	 three	 to	 four	 weeks	 of	 age,	 cellular	 infiltrates	 and	 cartilage	 degradation	 were	histologically	observed	in	prehypertrophic	zones	of	Ahsg-/-,	as	well	as	Ahsg+/-	mice.	At	four	weeks	 of	 age,	 growth	 plates	were	 disordered	 and	morphological	 changes,	 like	widening	 of	 the	 distal	 femoral	 condyles,	 were	 observed	 in	 Ahsg-/-	 but	 not	 in	
Ahsg+/-	mice.	At	eight	weeks	of	age,	Ahsg-/-	distal	 femoral	growth	plates	were	mostly	disordered.	 In	 some	 samples	 bone	 lesions	 were	 present	 or	 the	 growth	 plate	 was	partially	 replaced	 by	 bone.	 The	 severity	 of	 the	 phenotype	 was	 highly	 variable.	
Ahsg+/-	 femora	 were	 morphologically	 normal,	 and	 the	 growth	 plates	 were	 either	inconspicuous	or	showed	a	mild	to	severe	defect	in	the	prehypertrophic	region,	with	cellular	infiltrates	present.	The	increase	in	hypertrophic	zone	length	might	be	related	or	unrelated	to	the	interferon	type	inflammatory	reaction	in	the	growth	plate.	As	fetuin-A	was	shown	to	inhibit	the	autolytic	degradation	of	MMP4	!"#,	impaired	MMP+	activity	in	the	absence	of	fetuin-A	would	be	a	possible	mechanism.	Several	 diﬀerent	 mechanisms	 might	 be	 leading	 to	 the	 interferon	 type	inflammatory	reaction	and	distal	 femur	dysplasia,	which	are	schematically	shown	in	Figure	45.	Fetuin-A	might	be	an	inhibitor	for	a	protease	expressed	in	the	growth	plate.	Without	 fetuin-A,	 excessive	 degradation	 might	 lead	 to	 inflammation,	 cellular	infiltrates	and	mechanical	weakening	of	the	growth	plate,	resulting	in	dysplasia.	In	 the	 growth	 plate,	 fetuin-A	may	 exert	 its	well-known	mineral	 chaperoning	and	stabilizing	function	and	thus	decreases	cellular	mineral	stress	caused	by	the	high	amount	of	mineral	particles	present	at	the	chondro-osseous	junction	during	cartilage	
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remodeling.	 Terkeltaub	 et	 al.	 already	 suggested	 fetuin-A	 to	 be	 a	 crystal-bound	inhibitor	 of	 mineral	 stress	!"#.	 Smith	 and	 colleagues	 demonstrated	 that	“fetuin-A-containing	calciprotein	particles	reduce	mineral	stress	 in	the	macrophage”	in	 contrast	 to	 hydroxyapatite	 crystals	!"#.	 Dautova	 and	 colleagues	 showed	 similar	results	in	vascular	smooth	muscle	cells	!"".	Fetuin-A	may	act	anti-inflammatory	by	inhibiting	calcification	in	the	capillaries	at	 the	 chondro-osseous	 junction.	 We	 showed	 that	 the	 extensive	 soft	 tissue	calcifications	 observed	 in	 Ahsg-/-	 mice	 on	 a	 DBA/-	 background	 begin	 with	microcalcifications	 in	 capillaries	 (unpublished	work).	 As	 high	 quantities	 of	 calcium	and	 phosphate	 contained	 in	 the	 calcified	 cartilage	 must	 be	 transported	 through	growth	plate	capillaries	into	the	circulation,	the	absence	of	the	calcification	inhibitor	fetuin-A	may	lead	to	micro-calcifications	in	these	capillaries	leading	to	local	ischemia	and	growth	plate	inflammation.	
	
Figure	 !":	 Putative	 Role	 of	 fetuin-A	 in	 endochondral	 bone	 formation.	 #)	 Matrix	 proteinase	 regulation	!)	Stabilization	and	transport	of	mineralized	matrix	3)	Immunoregulatory	opsonization	of	mineralized	matrix.		Fetuin-A	has	an	 immunosuppressive	 function	 for	mineralized	cartilage,	and	 fetuin-A	deficiency	might	trigger	a	transient	T	cell	mediated	cartilage	antigen	response	upon	vascularization.	Several	publications	showed	anti-inflammatory	properties	of	injected	fetuin-A	in	animal	models	!",!$–!".	Particularly,	supplementation	of	fetuin-A	decreased	
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the	 release	 of	 HMGB/	 during	 endotoxemic	 sepsis	 and	 increased	 animal	 survival	rates	!".	 Interestingly,	 HMGB2	 is	 also	 involved	 in	 the	 regulation	 of	 endochondral	ossification;	 HMGB/	 is	 contained	 in	 the	 cytosol	 of	 hypertrophic	 chondrocytes	 and	
Hmgb%-/-	mice	show	a	delay	in	endochondral	bone	formation	due	to	inhibited	vascular	invasion	and	thus	osteoblast	and	osteoclast	recruitment	!"#.	As	HMGB)	expression	in	hypertrophic	 chondrocytes	 during	 is	 crucial	 for	 endochondral	 ossification,	 fetuin-A	might	 regulate	 HMGB-	 function	 in	 the	 growth	 plate,	 which	 would	 trigger	 an	inflammatory	response	in	the	absence	of	fetuin-A.			
4.2.8 Clinical	Relevance		Complete	fetuin-A	deficiency	was	never	reported	in	humans,	but	fetuin-A	is	a	negative	acute	phase	protein	with	significantly	reduced	serum	levels	during	inflammation	and	malnutrition	!",$$!,$$%.	 Thus	 endochondral	 ossification	 may	 become	 disturbed	 during	systemic	inflammation	and	during	inflammatory	bone	fracture	healing,	which	occurs	through	endochondral	ossification.	Aseptic	prosthesis	loosening	of	e.g.	hip	implants	is	likewise	 an	 inflammatory	 scenario,	 including	 mineralized	 matrix	 metabolism	 that	might	 involve	 fetuin-A	 regulation.	 Corroborating	 this	 view,	 a	 recent	 study	 by	 Max	Kauther	 and	 colleagues	 showed	 that	 fetuin-A	deficiency	 exacerbated	 bone	 loss	 in	 a	mouse	model	of	particle-induced	osteolysis	(unpublished	work).	Our	study	may	aid	our	understanding	of	certain	growth	plate	pathologies	with	unknown	etiology.	Slipped	capital	femoral	epiphysis	(SCFE)	is	a	common	hip	disorder	typically	 aﬀecting	 overweight	 adolescent	 males!"#.	 The	 proximal	 femoral	 epiphysis	fractures,	leading	to	a	displacement	of	the	femoral	head	.		Generally,	fractures	of	the	epiphysis,	so-called	Salter-Harris	fractures,	occur	in	children	and	adolescents	and	can	impair	endochondral	ossification	!"#.	It	would	be	of	high	interest	to	study	the	influence	of	fetuin-A	serum	levels	on	the	risk	for	SCFE	and	growth	plate	 fractures	 in	general.	Another	pathology	with	unknown	etiology,	where	fetuin-A	 could	 play	 a	 role,	 is	 Legg–Calvé–Perthes	 disease	 (LCPD)	!"!.	 LCPD	 results	from	 reduced	 blood	 flow	 to	 the	 femoral	 head	 during	 skeletal	 growth	 and	 leads	 to	avascular	femoral	head	necrosis,	which	causes	deformities	and	growth	impairment	of	the	 femur.	 Intriguingly,	 a	 recent	 publication	 discovered	 reduced	 fetuin-A	 levels	 in	
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broiler	chickens	with	femoral	head	necrosis	!"#.	Thus,	decreased	fetuin-A	levels	might	be	a	 risk	 factor	 for	 avascular	necrosis.	Our	 fetuin-A-deficient	mice	might	help	us	 to	better	understand	molecular	pathways	occurring	during	cartilage	 inflammation	and	epiphysiolysis.	As	there	are	currently	no	therapeutic	or	pharmacologic	interventions	to	 prevent	 bone	 bridge	 formation	 in	 children	 after	 growth	 plate	 injuries,	 the	application	 of	 fetuin-A	 in	 injured	 growth	 plates	 might	 be	 beneficial	 for	 clinical	outcomes.		
4.3 Conclusion	and	Perspective		Fetuin-A-deficient	 mice	 have	 shortened	 femoral	 bones	 due	 to	 an	 inflammatory	response	 in	 their	 growth	 plates,	 leading	 to	 the	 invasion	 of	 foreign	 cells,	 cartilage	degradation	and	disordering	and	a	movement	of	the	distal	femoral	epiphysis,	which	impairs	 proper	 femur	 development.	 Fetuin-A	 exerts	 important	 anti-inflammatory	properties	 in	 the	 growth	 plate,	 although	 the	 underlying	mechanisms	 remain	 to	 be	elucidated.	 In	 literature,	 anti-inflammatory	 properties	 have	 already	 been	 proposed	for	fetuin-A,	however	this	is	the	first	study,	which	clearly	demonstrated	that	fetuin-A	deficiency	 in	 mice	 spontaneously	 leads	 to	 inflammatory	 activity.	 As	 fetuin-A	 is	primarily	 known	 as	 calcification	 inhibitor,	 this	 novel	 anti-inflammatory	 role	would	call	 for	 a	 reevaluation	 of	 our	 current	 knowledge	 and	 understanding	 of	 fetuin-A	 in	calcification	 biology.	 Especially	 in	 cardiovascular	 calcification,	 where	 fetuin-A	concentrations	 are	 inversely	 correlated	 with	 cardiovascular	 mortality,	 an	anti-inflammatory	 role	 of	 fetuin-A	 would	 be	 of	 major	 interest.	 Also,	 in	 other	inflammatory	 diseases,	 especially	 those	 regarding	 bone	 and	 cartilage,	 such	 as	rheumatoid	arthritis,	fetuin-A	would	be	an	interesting	target	for	investigation.			 	
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! SUPPLEMENT	
5.1 Supporting	Figures		
		
Supporting	Figure	!:	Elongated	growth	plates	in	long	bones	from	56	days	old	Ahsg-/-	mice.	Paraffin	sections	from	bones	of	*+	days	old	mice	were	stained	with	safranin	O.	In	femur,	tibia,	humerus	and	ulna	from	Ahsg-/-,	but	not	
Ahsg+/-	mice,	hypertrophic	zones	(marked	with	a	dashed	line)	were	elongated.	Scale	bar	is	1!!	µm.		 	
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Supporting	 Figure	 !:	 Coronal	 !D-sections	 of	
!D-reconstructed	 µCT	 data	 of	 bones	 from	
C"#BL/'	 wildtype,	 Ahsg-/-	 (KO)	 and	
Ahsg-/-/ApoE-/-	 (DOKO)	 mice.	 The	 picture	 was	inverted.		
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Supporting	 Figure	 !:	 Frontal	 view	 of	
!D-reconstructed	 µCT	 data	 of	 bones	 from	
C!"BL/&	 wildtype,	 Ahsg-/-	 (KO)	 and	
Ahsg-/-/ApoE-/-	 (DOKO)	mice.	 The	picture	was	
inverted.	
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Supporting	 Figure	 !:	 Sagittal	!D-sections	 of	
!D-reconstructed	 µCT	 data	 of	 bones	 from	
C"#BL/'	 wildtype,	 Ahsg-/-	 (KO)	 and	
Ahsg-/-/ApoE-/-	 (DOKO)	mice.	The	picture	was	inverted.	
SUPPLEMENT	 129	
		 	
Supporting	 Figure	 !:	 Side	 view	 of	
!D-reconstructed	 µCT	 data	 of	 bones	 from	
C"#BL/'	 wildtype,	 Ahsg-/-	 (KO)	 and	
Ahsg-/-/ApoE-/-	 (DOKO)	 mice.	 The	 picture	 was	inverted.	
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Supporting	 Figure	 !:	 Coronal	 !D-sections	
of	 !D-reconstructed	 µCT	 data	 of	 bones	
from	 DBA/*	 wildtype	 and	 Ahsg-/-	 (KO)	
mice.	The	picture	was	inverted.	
Supporting	 Figure	 !:	 Frontal	 view	 of	
!D-reconstructed	 µCT	 data	 of	 bones	
from	 DBA/*	 wildtype	 and	 Ahsg-/-	 (KO)	
mice.	The	picture	was	inverted.	
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.															
			 	
Supporting	 Figure	 !:	 Sagittal	!D-sections	
of	 !D-reconstructed	 µCT	 data	 of	 bones	
from	 DBA/*	 wildtype	 and	 Ahsg-/-	 mice.	The	picture	was	inverted.	
Supporting	 Figure	 !:	 Side	 view	 of	
!D-reconstructed	 µCT	 data	 of	 bones	 from	
DBA/%	wildtype	 and	Ahsg-/-	mice.	The	picture	was	inverted.	
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5.2 Supporting	Tables		
Supporting	Table	!:	Top	%&&	significantly	differentially	regulated	genes,	when	comparing	samples	from	wildtype	to	samples	from	Ahsg-/-	mice.	Genes	were	ordered	by	fold-change.	
Gene	symbol																																																																																																																																																																																																																										Gene	description	 Fold-change P-valueCxcl9		 chemokine	(C-X-C	motif)	ligand	9		 557,52	 0,000702	Ifit1		 interferon-induced	protein	with	tetratricopeptide	repeats	1		 54,83	 0,000846	Tgtp2		 T	cell	specific	GTPase	2		 39,29	 0,00548	Usp18		 ubiquitin	specific	peptidase	18		 37,69	 0,000382	Rsad2	 radical	S-adenosyl	methionine	domain	containing	2		 33,22	 0,006103	Gbp2	 guanylate	binding	protein	2		 31,02	 0,00276	Ms4a4c		 membrane-spanning	4-domains,	subfamily	A,	member	4C		 24,1	 0,000712	Phf11b		 PHD	finger	protein	11B		 23,2	 0,000958	Gbp10		 guanylate-binding	protein	10		 22,28	 0,001607	Slfn4	 schlafen	4		 21,92	 0,001162	Ifi44		 interferon-induced	protein	44		 19,71	 0,001162	Il1b		 interleukin	1	beta		 16,33	 0,003104	Igtp		 interferon	gamma	induced	GTPase		 14,38	 0,003305	Bst2		 bone	marrow	stromal	cell	antigen	2		 14,26	 0,00094	Gm12185		 predicted	gene	12185		 13,23	 0,011681	Phf11a		 PHD	finger	protein	11A		 11,98	 0,001664	Stat1		 signal	transducer	and	activator	of	transcription	1		 11,94	 0,001149	Myh2		 myosin,	heavy	polypeptide	2,	skeletal	muscle,	adult		 11,66	 0,040529	Ckmt2		 creatine	kinase,	mitochondrial	2		 11,65	 0,017996	Clec7a	 C-type	lectin	domain	family	7,	member	a		 10,96	 0,006803	Mnda		 myeloid	cell	nuclear	differentiation	antigen		 10,45	 0,001099	Zbp1		 Z-DNA	binding	protein	1		 10,4	 0,002205	I830012O16Rik		 RIKEN	cDNA	I830012O16	gene		 10,36	 0,000713	Gbp4		 guanylate	binding	protein	4		 10,36	 0,003484	Ifi204		 interferon	activated	gene	204		 10,19	 0,000543	Gm12250		 predicted	gene	12250		 10,18	 0,004626	Rnf213		 ring	finger	protein	213		 9,76	 0,000209	Phf11d		 PHD	finger	protein	11D		 9,76	 0,002772	Irg1		 immunoresponsive	gene	1		 9,63	 0,001769	Lilrb4	 leukocyte	immunoglobulin-like	receptor,	subfamily	B,	member	4		 9,45	 0,000901	Gbp3		 guanylate	binding	protein	3		 9,16	 0,001121	Serpina3g		 serine	(or	cysteine)	peptidase	inhibitor,	clade	A,	member	3G		 9,08	 0,001982	Gm4070		 predicted	gene	4070		 9,07	 0,001981	Irf7		 interferon	regulatory	factor	7		 8,91	 0,000415	Ctss		 cathepsin	S		 8,89	 0,000952	Gm4951		 predicted	gene	4951		 8,84	 0,003288	Myoz2		 myozenin	2		 8,73	 0,02704	Clec5a		 C-type	lectin	domain	family	5,	member	a		 8,46	 0,019623	Gvin1		 GTPase,	very	large	interferon	inducible	1		 8,19	 0,002731	Trim30a	 tripartite	motif-containing	30A		 7,75	 0,004304	
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Gm4955		 predicted	gene	4955		 7,55	 0,006938	Iigp1		 interferon	inducible	GTPase	1		 7,33	 0,004049	Cybb		 cytochrome	b-245,	beta	polypeptide		 7,28	 0,035134	Ifih1		 interferon	induced	with	helicase	C	domain	1		 6,98	 0,000795	RP24-196H4.1	 GTPase,	very	large	interferon	inducible	1	(Gvin1)	pseudogene	 6,93	 0,001143	Fcgr1	 Fc	receptor,	IgG,	high	affinity	I		 6,92	 0,000054	Lgals3bp		 lectin,	galactoside-binding,	soluble,	3	binding	protein		 6,91	 0,000117	Ifit3	 interferon-induced	protein	with	tetratricopeptide	repeats	3		 6,85	 0,000227	Slfn8		 schlafen	8		 6,73	 0,000441	Oas1a	 2-5	oligoadenylate	synthetase	1A		 6,71	 0,002205	Mmp10		 matrix	metallopeptidase	10		 6,68	 0,001163	Myot	 myotilin		 6,68	 0,01771	Tceal7	 transcription	elongation	factor	A	(SII)-like	7		 6,67	 0,022555	Trim30d	 tripartite	motif-containing	30D		 6,62	 0,001987	F830016B08Rik	 RIKEN	cDNA	F830016B08	gene		 6,54	 0,020929	Gbp7	 guanylate	binding	protein	7		 6,5	 0,005029	AI607873	 expressed	sequence	AI607873		 6,4	 0,017291	Cfb	 complement	factor	B		 6,35	 0,000885	Cxcl10	 chemokine	(C-X-C	motif)	ligand	10		 6,34	 0,007232	Pyhin1	 pyrin	and	HIN	domain	family,	member	1		 6,23	 0,038584	Il1rn		 interleukin	1	receptor	antagonist		 6,22	 0,006746	Xaf1		 XIAP	associated	factor	1		 6,17	 0,000167	Cox7a1		 cytochrome	c	oxidase	subunit	VIIa	1		 6,04	 0,016898	Gbp9		 guanylate-binding	protein	9		 6,01	 0,00111	Ly6c2		 lymphocyte	antigen	6	complex,	locus	C2		 5,91	 0,026469	Pydc4		 pyrin	domain	containing	4		 5,76	 0,004868	AW112010		 expressed	sequence	AW112010		 5,75	 0,02497	Gp49a		 glycoprotein	49	A		 5,73	 0,000817	Ifi203		 interferon	activated	gene	203		 5,73	 0,007874	Oasl2	 2-5	oligoadenylate	synthetase-like	2		 5,65	 0,001712	Gbp11		 guanylate	binding	protein	11		 5,58	 0,005989	Fcgr4		 Fc	receptor,	IgG,	low	affinity	IV		 5,31	 0,001728	Tmem182		 transmembrane	protein	182		 5,22	 0,028687	Parp14		 poly	(ADP-ribose)	polymerase	family,	member	14		 5,19	 0,003235	Pydc3		 pyrin	domain	containing	3		 5,1	 0,002505	Ddx60		 DEAD	(Asp-Glu-Ala-Asp)	box	polypeptide	60		 4,97	 0,000485	Irgm1		 immunity-related	GTPase	family	M	member	1		 4,87	 0,003706	Gm21884		 predicted	gene	21884		 4,8	 0,049964	Cox6a2		 cytochrome	c	oxidase	subunit	VIa	polypeptide	2		 4,78	 0,049931	Casp4	 caspase	4,	apoptosis-related	cysteine	peptidase		 4,76	 0,006623	Ppp1r3a		 protein	phosphatase	1,	regulatory	(inhibitor)	subunit	3A		 4,75	 0,044805	Gm5431		 predicted	gene	5431		 4,68	 0,006564	Fabp3		 fatty	acid	binding	protein	3,	muscle	and	heart		 4,68	 0,036535	Ampd1		 adenosine	monophosphate	deaminase	1		 4,67	 0,007677	Actc1		 actin,	alpha,	cardiac	muscle	1		 4,66	 0,036098	
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Gm6904		 predicted	gene	6904		 4,64	 0,000867	Mybpc2		 myosin	binding	protein	C,	fast-type		 4,63	 0,038928	Irgm2		 immunity-related	GTPase	family	M	member	2		 4,61	 0,000578	Ptafr	 platelet-activating	factor	receptor		 4,59	 0,000394	H2-Q8		 histocompatibility	2,	Q	region	locus	8		 4,55	 0,000894	Ly6i		 lymphocyte	antigen	6	complex,	locus	I		 4,53	 0,006555	Oas1g		 2-5	oligoadenylate	synthetase	1G		 4,51	 0,002898	Clec4d		 C-type	lectin	domain	family	4,	member	d		 4,51	 0,012992	Ccl5		 chemokine	(C-C	motif)	ligand	5		 4,46	 0,005185	Myom2		 myomesin	2		 4,46	 0,024744	Gm8995		 predicted	gene	8995		 4,45	 0,016706	Gm14446		 predicted	gene	14446		 4,43	 0,006925	H2-K1		 histocompatibility	2,	K1,	K	region	 4,42	 0,001328	Ly6a	 lymphocyte	antigen	6	complex,	locus	A	 4,33	 0,011176	Oas1g	 2-5	oligoadenylate	synthetase	1G		 4,51	 0,002898			
Supporting	Table	!:	Results	of	pathway	enrichment	analysis.	All	genes,	which	were	significantly	differentially	regulated	more	 than	 ..01-fold	were	used	 for	 enrichment	 analysis.	 Analysis	was	 carried	 out	with	Gene	Ontology,	Wikipathways,	KEGG	and	EBI-EMBL	databases.	In	all	datbases,	we	found	indications	for	a	strong	immune-system	response.	C=	Number	of	genes	in	term,	E=	Expected	number	of	genes	in	term,	R=	Enrichment,	rawP=	raw	P	value,	adjP	=	adjusted	P-value.	
GO	Terms	Biological	process	C=812;O=158;E=23.04;R=6.86;rawP=1.35e-87;adjP=2.81e-84	 defense	response	 GO:0006952	C=1353;O=196;E=38.39;R=5.11;rawP=3.39e-86;adjP=3.53e-83	 immune	system	process	 GO:0002376	C=680;O=145;E=19.30;R=7.51;rawP=8.93e-86;adjP=6.19e-83	 immune	response	 GO:0006955	C=299;O=97;E=8.48;R=11.43;rawP=1.76e-75;adjP=9.16e-73	 innate	immune	response	 GO:0045087	C=516;O=104;E=14.64;R=7.10;rawP=2.98e-58;adjP=1.24e-55	 response	to	other	organism	 GO:0051707	C=417;O=94;E=11.83;R=7.94;rawP=3.66e-57;adjP=1.27e-54	 immune	effector	process	 GO:0002252	C=550;O=105;E=15.61;R=6.73;rawP=2.20e-56;adjP=6.54e-54	 response	to	biotic	stimulus	 GO:0009607	C=2114;O=200;E=59.98;R=3.33;rawP=1.12e-55;adjP=2.91e-53	 response	to	stress	 GO:0006950	C=777;O=114;E=22.05;R=5.17;rawP=5.49e-49;adjP=1.27e-46	 multi-organism	process	 GO:0051704	C=695;O=107;E=19.72;R=5.43;rawP=5.86e-48;adjP=1.22e-45	 regulation	of	immune	system	process	 GO:0002682	C=379;O=79;E=10.75;R=7.35;rawP=2.78e-45;adjP=5.26e-43	 regulation	of	immune	response	 GO:0050776	C=161;O=53;E=4.57;R=11.60;rawP=1.06e-41;adjP=1.84e-39	 response	to	virus	 GO:0009615	C=379;O=79;E=10.75;R=7.35;rawP=2.78e-45;adjP=5.26e-43	 regulation	of	immune	response	 GO:0050776	C=440;O=80;E=12.49;R=6.41;rawP=3.34e-41;adjP=5.35e-39	 positive	regulation	of	immune	system	process	 GO:0002684	C=132;O=47;E=3.75;R=12.55;rawP=6.51e-39;adjP=9.68e-37	 defense	response	to	virus	 GO:0051607	C=305;O=65;E=8.65;R=7.51;rawP=6.05e-38;adjP=8.39e-36	 regulation	of	defense	response	 GO:0031347	C=305;O=65;E=8.65;R=7.51;rawP=6.05e-38;adjP=8.39e-36	 regulation	of	defense	response	 GO:0031347	C=388;O=69;E=11.01;R=6.27;rawP=6.05e-35;adjP=7.41e-33b	 inflammatory	response	 GO:0006954	C=614;O=85;E=17.42;R=4.88;rawP=1.92e-34;adjP=2.22e-	 response	to	wounding	 GO:0009611	
SUPPLEMENT	136	
C=1538;O=137;E=43.64;R=3.14;rawP=4.77e-34;adjP=5.22e-32	 response	to	organic	substance	 GO:0010033	C=2194;O=168;E=62.25;R=2.70;rawP=5.44e-34;adjP=5.66e-32	 response	to	chemical	stimulus	 GO:0042221	C=130;O=42;E=3.69;R=11.39;rawP=7.25e-33;adjP=7.18e-31	 regulation	of	innate	immune	response	 GO:0045088	C=274;O=57;E=7.77;R=7.33;rawP=9.12e-33;adjP=8.63e-31	 positive	regulation	of	immune	response	 GO:0050778	C=400;O=67;E=11.35;R=5.90;rawP=2.68e-32;adjP=2.42e-30	 cytokine	production	 GO:0001816	C=269;O=56;E=7.63;R=7.34;rawP=3.18e-32;adjP=2.76e-30	 cellular	response	to	cytokine	stimulus	 GO:0071345	C=604;O=79;E=17.14;R=4.61;rawP=2.64e-30;adjP=2.20e-28	 regulation	of	response	to	stress	 GO:0080134	C=356;O=61;E=10.10;R=6.04;rawP=4.92e-30;adjP=3.94e-28	 regulation	of	cytokine	production	 GO:0001817	C=992;O=101;E=28.15;R=3.59;rawP=1.73e-29;adjP=1.33e-27	 positive	regulation	of	response	to	stimulus	 GO:0048584	C=1201;O=109;E=34.08;R=3.20;rawP=1.48e-27;adjP=1.10e-25	 cellular	response	to	chemical	stimulus	 GO:0070887	C=161;O=41;E=4.57;R=8.97;rawP=1.59e-27;adjP=1.14e-25	 positive	regulation	of	defense	response	 GO:0031349	C=2030;O=147;E=57.60;R=2.55;rawP=6.93e-27;adjP=4.81e-25	 regulation	of	response	to	stimulus	 GO:0048583	C=1201;O=109;E=34.08;R=3.20;rawP=1.48e-27;adjP=1.10e-25	 cellular	response	to	chemical	stimulus	 GO:0070887	C=2030;O=147;E=57.60;R=2.55;rawP=6.93e-27;adjP=4.81e-25	 regulation	of	response	to	stimulus	 GO:0048583	C=610;O=74;E=17.31;R=4.28;rawP=2.52e-26;adjP=1.69e-24	 cell	activation	 GO:0001775	C=7009;O=328;E=198.88;R=1.65;rawP=2.67e-26;adjP=1.74e-24	 response	to	stimulus	 GO:0050896	C=195;O=43;E=5.53;R=7.77;rawP=4.70e-26;adjP=2.96e-24	 activation	of	immune	response	 GO:0002253	C=3296;O=196;E=93.52;R=2.10;rawP=1.89e-25;adjP=1.16e-23	 positive	regulation	of	biological	process	 GO:0048518	C=538;O=68;E=15.27;R=4.45;rawP=2.80e-25;adjP=1.66e-23	 leukocyte	activation	 GO:0045321	C=154;O=37;E=4.37;R=8.47;rawP=5.49e-24;adjP=3.17e-22	 immune	response-regulating	signaling	pathway	 GO:0002764	C=207;O=42;E=5.87;R=7.15;rawP=5.79e-24;adjP=3.26e-22	 leukocyte	mediated	immunity	 GO:0002443	C=359;O=54;E=10.19;R=5.30;rawP=7.31e-24;adjP=4.00e-22	 response	to	bacterium	 GO:0009617	C=187;O=40;E=5.31;R=7.54;rawP=8.67e-24;adjP=4.63e-22	 positive	regulation	of	cytokine	production	 GO:0001819	
C=178;O=38;E=5.05;R=7.52;rawP=1.26e-22;adjP=6.50e-21	 adaptive	immune	response	based	on	somatic	recombination	of	immune	receptors	built	from	immunoglobulin	superfamily	domains	 GO:0002460	Molecular	Function	C=10881;O=441;E=309.60;R=1.42;rawP=1.78e-25;adjP=6.02e-23	 binding	 GO:0005488	C=6206;O=298;E=176.58;R=1.69;rawP=7.01e-25;adjP=1.18e-22	 protein	binding	 GO:0005515	C=45;O=15;E=1.28;R=11.72;rawP=8.68e-13;adjP=9.78e-11	 chemokine	receptor	binding	 GO:0042379	C=48;O=15;E=1.37;R=10.98;rawP=2.54e-12;adjP=2.15e-10	 double-stranded	RNA	binding	 GO:0003725	C=5115;O=221;E=145.54;R=1.52;rawP=5.27e-12;adjP=3.33e-10	 catalytic	activity	 GO:0003824	C=35;O=13;E=1.00;R=13.05;rawP=5.92e-12;adjP=3.33e-10	 chemokine	activity	 GO:0008009	C=864;O=55;E=24.58;R=2.24;rawP=2.44e-08;adjP=6.34e-07	 identical	protein	binding	 GO:0042802	C=74;O=16;E=2.11;R=7.60;rawP=2.24e-10;adjP=1.08e-08	 cytokine	receptor	activity	 GO:0004896	C=200;O=25;E=5.69;R=4.39;rawP=6.11e-10;adjP=2.58e-08	 cytokine	receptor	binding	 GO:0005126	C=11;O=7;E=0.31;R=22.37;rawP=4.37e-09;adjP=1.64e-07	 2'-5'-oligoadenylate	synthetase	activity	 GO:0001730	C=17;O=8;E=0.48;R=16.54;rawP=7.98e-09;adjP=2.70e-07	 CCR	chemokine	receptor	binding	 GO:0048020	C=82;O=15;E=2.33;R=6.43;rawP=9.46e-09;adjP=2.91e-07	 hydrogen	ion	transmembrane	transporter	activity	 GO:0015078	C=186;O=22;E=5.29;R=4.16;rawP=1.82e-08;adjP=5.13e-07	 cytokine	activity	 GO:0005125	
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C=14;O=7;E=0.40;R=17.57;rawP=4.22e-08;adjP=1.02e-06	 C-C	chemokine	receptor	activity	 GO:0016493	C=2192;O=103;E=62.37;R=1.65;rawP=2.44e-07;adjP=5.50e-06	 hydrolase	activity	 GO:0016787	C=737;O=45;E=20.97;R=2.15;rawP=1.48e-06;adjP=3.13e-05	 oxidoreductase	activity	 GO:0016491	C=5230;O=200;E=148.81;R=1.34;rawP=1.81e-06;adjP=3.31e-05	 ion	binding	 GO:0043167	C=361;O=28;E=10.27;R=2.73;rawP=1.86e-06;adjP=3.31e-05	 endopeptidase	activity	 GO:0004175	C=41;O=9;E=1.17;R=7.71;rawP=1.80e-06;adjP=3.31e-05	 transferase	activity,	transferring	pentosyl	groups	 GO:0016763	C=9;O=5;E=0.26;R=19.53;rawP=2.11e-06;adjP=3.57e-05	 hydrogen	ion	transporting	ATP	synthase	activity,	rotational	mechanism	 GO:0046933	C=23;O=7;E=0.65;R=10.70;rawP=2.41e-06;adjP=3.70e-05	 G-protein	coupled	chemoattractant	receptor	activity	 GO:0001637	C=23;O=7;E=0.65;R=10.70;rawP=2.41e-06;adjP=3.70e-05	 chemokine	receptor	activity	 GO:0004950	C=5;O=4;E=0.14;R=28.12;rawP=3.17e-06;adjP=4.66e-05	 CCR1	chemokine	receptor	binding	 GO:0031726	C=2264;O=101;E=64.42;R=1.57;rawP=3.41e-06;adjP=4.80e-05	 anion	binding	 GO:0043168	C=1173;O=61;E=33.38;R=1.83;rawP=4.32e-06;adjP=5.84e-05	 receptor	binding	 GO:0005102	C=58;O=10;E=1.65;R=6.06;rawP=4.95e-06;adjP=6.44e-05	 cytokine	binding	 GO:0019955	C=26;O=7;E=0.74;R=9.46;rawP=6.00e-06;adjP=7.24e-05	 NADH	dehydrogenase	activity	 GO:0003954	C=26;O=7;E=0.74;R=9.46;rawP=6.00e-06;adjP=7.24e-05	 adenylyltransferase	activity	 GO:0070566	C=323;O=25;E=9.19;R=2.72;rawP=6.81e-06;adjP=7.94e-05	 actin	binding	 GO:0003779	C=11;O=5;E=0.31;R=15.98;rawP=7.36e-06;adjP=8.29e-05	 proton-transporting	ATPase	activity,	rotational	mechanism	 GO:0046961	C=572;O=36;E=16.28;R=2.21;rawP=8.65e-06;adjP=9.43e-05	 peptidase	activity,	acting	on	L-amino	acid	peptides	 GO:0070011	C=2268;O=99;E=64.53;R=1.53;rawP=1.08e-05;adjP=0.0001	 nucleotide	binding	 GO:0000166	C=601;O=37;E=17.10;R=2.16;rawP=1.06e-05;adjP=0.0001	 peptidase	activity	 GO:0008233	C=581;O=36;E=16.53;R=2.18;rawP=1.21e-05;adjP=0.0001	 protein	homodimerization	activity	 GO:0042803	C=19;O=6;E=0.54;R=11.10;rawP=1.03e-05;adjP=0.0001	 peptide	antigen	binding	 GO:0042605	C=2268;O=99;E=64.53;R=1.53;rawP=1.08e-05;adjP=0.0001	 nucleoside	phosphate	binding	 GO:1901265	C=185;O=17;E=5.26;R=3.23;rawP=2.33e-05;adjP=0.0002	 G-protein	coupled	receptor	binding	 GO:0001664	C=7;O=4;E=0.20;R=20.08;rawP=2.12e-05;adjP=0.0002	 CCR5	chemokine	receptor	binding	 GO:0031730	C=44;O=8;E=1.25;R=6.39;rawP=2.95e-05;adjP=0.0002	 single-stranded	RNA	binding	 GO:0003727	C=2445;O=104;E=69.57;R=1.49;rawP=1.86e-05;adjP=0.0002	 small	molecule	binding	 GO:0036094	Cellular	Component	C=13188;O=532;E=388.68;R=1.37;rawP=3.42e-30;adjP=4.04e-28	 cell	 GO:0005623	C=13187;O=532;E=388.65;R=1.37;rawP=3.33e-30;adjP=4.04e-28	 cell	part	 GO:0044464	C=259;O=51;E=7.63;R=6.68;rawP=1.91e-27;adjP=1.50e-25	 external	side	of	plasma	membrane	 GO:0009897	C=8408;O=386;E=247.80;R=1.56;rawP=2.58e-27;adjP=1.52e-25	 cytoplasm	 GO:0005737	C=563;O=70;E=16.59;R=4.22;rawP=1.33e-24;adjP=6.28e-23	 cell	surface	 GO:0009986	C=5590;O=282;E=164.75;R=1.71;rawP=1.25e-23;adjP=4.92e-22	 cytoplasmic	part	 GO:0044444	C=1440;O=112;E=42.44;R=2.64;rawP=2.17e-21;adjP=7.32e-20	 plasma	membrane	part	 GO:0044459	C=3707;O=202;E=109.25;R=1.85;rawP=1.55e-19;adjP=4.57e-18	 cell	periphery	 GO:0071944	C=3615;O=196;E=106.54;R=1.84;rawP=1.21e-18;adjP=3.16e-17	 plasma	membrane	 GO:0005886	C=342;O=47;E=10.08;R=4.66;rawP=1.34e-18;adjP=3.16e-17	 mitochondrial	inner	membrane	 GO:0005743	C=482;O=55;E=14.21;R=3.87;rawP=8.18e-18;adjP=1.75e-16	 mitochondrial	envelope	 GO:0005740	C=361;O=47;E=10.64;R=4.42;rawP=1.21e-17;adjP=2.38e-16	 organelle	inner	membrane	 GO:0019866	
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C=11366;O=445;E=334.98;R=1.33;rawP=1.66e-17;adjP=3.01e-16	 intracellular	 GO:0005622	C=459;O=53;E=13.53;R=3.92;rawP=1.98e-17;adjP=3.34e-16	 mitochondrial	membrane	 GO:0031966	C=590;O=60;E=17.39;R=3.45;rawP=6.25e-17;adjP=9.28e-16	 mitochondrial	part	 GO:0044429	C=11126;O=436;E=327.91;R=1.33;rawP=6.29e-17;adjP=9.28e-16	 intracellular	part	 GO:0044424	C=8145;O=341;E=240.05;R=1.42;rawP=1.13e-15;adjP=1.57e-14	 membrane	 GO:0016020	C=166;O=29;E=4.89;R=5.93;rawP=1.05e-14;adjP=1.38e-13	 contractile	fiber	 GO:0043292	C=1605;O=103;E=47.30;R=2.18;rawP=5.16e-14;adjP=6.41e-13	 mitochondrion	 GO:0005739	C=153;O=27;E=4.51;R=5.99;rawP=6.80e-14;adjP=8.02e-13	 myofibril	 GO:0030016	C=142;O=26;E=4.19;R=6.21;rawP=8.02e-14;adjP=9.01e-13	 contractile	fiber	part	 GO:0044449	C=726;O=61;E=21.40;R=2.85;rawP=2.14e-13;adjP=2.30e-12	 envelope	 GO:0031975	C=714;O=60;E=21.04;R=2.85;rawP=3.38e-13;adjP=3.47e-12	 organelle	envelope	 GO:0031967	C=127;O=24;E=3.74;R=6.41;rawP=3.54e-13;adjP=3.48e-12	 mitochondrial	membrane	part	 GO:0044455	C=9753;O=377;E=287.44;R=1.31;rawP=3.08e-12;adjP=2.91e-11	 organelle	 GO:0043226	C=6473;O=273;E=190.77;R=1.43;rawP=5.20e-12;adjP=4.72e-11	 membrane	part	 GO:0044425	C=9730;O=375;E=286.77;R=1.31;rawP=6.18e-12;adjP=5.40e-11	 intracellular	organelle	 GO:0043229	C=130;O=22;E=3.83;R=5.74;rawP=3.36e-11;adjP=2.83e-10	 sarcomere	 GO:0030017	C=55;O=15;E=1.62;R=9.25;rawP=3.78e-11;adjP=3.08e-10	 mitochondrial	respiratory	chain	 GO:0005746	C=65;O=16;E=1.92;R=8.35;rawP=4.63e-11;adjP=3.64e-10	 respiratory	chain	 GO:0070469	C=1209;O=78;E=35.63;R=2.19;rawP=6.69e-11;adjP=5.09e-10	 organelle	membrane	 GO:0031090	C=24;O=10;E=0.71;R=14.14;rawP=6.26e-10;adjP=4.62e-09	 MHC	protein	complex	 GO:0042611	C=1046;O=67;E=30.83;R=2.17;rawP=2.21e-09;adjP=1.58e-08	 extracellular	region	part	 GO:0044421	C=8664;O=330;E=255.35;R=1.29;rawP=2.97e-09;adjP=2.06e-08	 membrane-bounded	organelle	 GO:0043227	C=790;O=54;E=23.28;R=2.32;rawP=1.00e-08;adjP=6.69e-08	 extracellular	space	 GO:0005615	C=324;O=31;E=9.55;R=3.25;rawP=1.02e-08;adjP=6.69e-08	 actin	cytoskeleton	 GO:0015629	C=8644;O=324;E=254.76;R=1.27;rawP=3.32e-08;adjP=2.12e-07	 intracellular	membrane-bounded	organelle	 GO:0043231	C=9;O=6;E=0.27;R=22.62;rawP=5.00e-08;adjP=3.11e-07	 symbiont-containing	vacuole	 GO:0020003	C=10;O=6;E=0.29;R=20.36;rawP=1.22e-07;adjP=6.86e-07	 host	cell	cytoplasm	 GO:0030430	C=10;O=6;E=0.29;R=20.36;rawP=1.22e-07;adjP=6.86e-07	 intracellular	region	of	host	 GO:0043656	
Wikipathways	C=102;O=26;E=1.37;R=18.98;rawP=6.83e-26;adjP=4.58e-24	 Electron	Transport	Chain	 WP295	C=186;O=28;E=2.50;R=11.21;rawP=4.40e-21;adjP=1.47e-19	 Chemokine	signaling	pathway	 WP2292	C=110;O=21;E=1.48;R=14.22;rawP=2.30e-18;adjP=5.14e-17	 Toll-like	receptor	signaling	pathway	 WP1271	C=74;O=17;E=0.99;R=17.11;rawP=1.42e-16;adjP=2.38e-15	 Type	II	interferon	signaling	(IFNG)	 WP1253	C=44;O=13;E=0.59;R=22.00;rawP=1.48e-14;adjP=1.98e-13	 Striated	Muscle	Contraction	 WP216	C=60;O=14;E=0.81;R=17.38;rawP=5.42e-14;adjP=6.05e-13	 Oxidative	phosphorylation	 WP1248	C=32;O=11;E=0.43;R=25.60;rawP=2.38e-13;adjP=2.28e-12	 TCA	Cycle	 WP434	C=202;O=20;E=2.71;R=7.37;rawP=5.80e-12;adjP=4.86e-11	 B	Cell	Receptor	Signaling	Pathway	 WP274	C=61;O=12;E=0.82;R=14.65;rawP=3.02e-11;adjP=2.25e-10	 Complement	and	Coagulation	Cascades	 WP449	C=80;O=13;E=1.07;R=12.10;rawP=5.77e-11;adjP=3.87e-10	 IL-5	Signaling	Pathway	 WP151	C=93;O=13;E=1.25;R=10.41;rawP=4.05e-10;adjP=2.47e-09	 Apoptosis	 WP1254	C=117;O=13;E=1.57;R=8.27;rawP=7.20e-09;adjP=3.82e-08	 IL-6	signaling	Pathway	 WP387	C=60;O=10;E=0.81;R=12.41;rawP=7.41e-09;adjP=3.82e-08	 Proteasome	Degradation	 WP519	
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C=92;O=11;E=1.24;R=8.90;rawP=4.79e-08;adjP=2.29e-07	 IL-2	Signaling	Pathway	 WP450	C=270;O=17;E=3.63;R=4.69;rawP=1.96e-07;adjP=8.75e-07	 Non-odorant	GPCRs	 WP1396	C=109;O=11;E=1.46;R=7.52;rawP=2.78e-07;adjP=1.16e-06	 Senescence	and	Autophagy	 WP1267	C=16;O=5;E=0.21;R=23.27;rawP=1.67e-06;adjP=6.58e-06	 Mitochondrial	LC-Fatty	Acid	Beta-Oxidation	 WP401	C=225;O=14;E=3.02;R=4.63;rawP=2.65e-06;adjP=9.18e-06	 GPCRs,	Class	A	Rhodopsin-like	 WP189	C=111;O=10;E=1.49;R=6.71;rawP=2.74e-06;adjP=9.18e-06	 IL-3	Signaling	Pathway	 WP373	C=30;O=6;E=0.40;R=14.89;rawP=2.59e-06;adjP=9.18e-06	 Inflammatory	Response	Pathway	 WP458	C=112;O=10;E=1.50;R=6.65;rawP=2.98e-06;adjP=9.51e-06	 Amino	Acid	metabolism	 WP662	C=143;O=11;E=1.92;R=5.73;rawP=4.15e-06;adjP=1.26e-05	 T	Cell	Receptor	Signaling	Pathway	 WP480	C=70;O=8;E=0.94;R=8.51;rawP=4.63e-06;adjP=1.29e-05	 Peptide	GPCRs	 WP234	C=70;O=8;E=0.94;R=8.51;rawP=4.63e-06;adjP=1.29e-05	 Kit	Receptor	Signaling	Pathway	 WP407	C=10;O=4;E=0.13;R=29.79;rawP=6.35e-06;adjP=1.70e-05	 Macrophage	markers	 WP2271	C=165;O=11;E=2.22;R=4.96;rawP=1.62e-05;adjP=4.17e-05	 MAPK	signaling	pathway	 WP493	C=69;O=7;E=0.93;R=7.55;rawP=4.02e-05;adjP=9.62e-05	 Fatty	Acid	Beta	Oxidation	 WP1269	C=215;O=12;E=2.89;R=4.16;rawP=3.96e-05;adjP=9.62e-05	 TNF-alpha	NF-kB	Signaling	Pathway	 WP246	C=75;O=7;E=1.01;R=6.95;rawP=6.89e-05;adjP=0.0001	 IL-4	signaling	Pathway	 WP93	C=186;O=11;E=2.50;R=4.40;rawP=4.88e-05;adjP=0.0001	 Focal	Adhesion	 WP85	C=17;O=4;E=0.23;R=17.52;rawP=6.68e-05;adjP=0.0001	 Complement	Activation,	Classical	Pathway	 WP200	C=51;O=6;E=0.68;R=8.76;rawP=6.20e-05;adjP=0.0001	 FAS	pathway	and	Stress	induction	of	HSP	regulation	 WP571	C=17;O=4;E=0.23;R=17.52;rawP=6.68e-05;adjP=0.0001	 Oxidative	Damage	 WP1496	C=51;O=6;E=0.68;R=8.76;rawP=6.20e-05;adjP=0.0001	 Glycolysis	and	Gluconeogenesis	 WP157	
KEGG	C=148;O=35;E=1.99;R=17.61;rawP=3.77e-33;adjP=3.36e-31	 Parkinson's	disease	 5012	C=147;O=32;E=1.97;R=16.21;rawP=3.49e-29;adjP=1.04e-27	 Oxidative	phosphorylation	 190	C=188;O=35;E=2.52;R=13.86;rawP=2.68e-29;adjP=1.04e-27	 Alzheimer's	disease	 5010	C=78;O=25;E=1.05;R=23.87;rawP=9.47e-28;adjP=2.11e-26	 Antigen	processing	and	presentation	 4612	C=245;O=37;E=3.29;R=11.25;rawP=1.77e-27;adjP=3.15e-26	 Cytokine-cytokine	receptor	interaction	 4060	C=197;O=34;E=2.65;R=12.85;rawP=2.39e-27;adjP=3.55e-26	 Huntington's	disease	 5016	C=1184;O=72;E=15.90;R=4.53;rawP=2.55e-26;adjP=3.24e-25	 Metabolic	pathways	 1100	C=176;O=31;E=2.36;R=13.12;rawP=2.47e-25;adjP=2.75e-24	 Phagosome	 4145	C=89;O=23;E=1.20;R=19.24;rawP=3.26e-23;adjP=3.22e-22	 Viral	myocarditis	 5416	C=50;O=19;E=0.67;R=28.30;rawP=4.49e-23;adjP=4.00e-22	 Staphylococcus	aureus	infection	 5150	C=185;O=28;E=2.48;R=11.27;rawP=3.78e-21;adjP=3.06e-20	 Chemokine	signaling	pathway	 4062	C=149;O=25;E=2.00;R=12.49;rawP=3.70e-20;adjP=2.74e-19	 Cell	adhesion	molecules	(CAMs)	 4514	C=101;O=21;E=1.36;R=15.48;rawP=3.52e-19;adjP=2.38e-18	 Toll-like	receptor	signaling	pathway	 4620	C=54;O=17;E=0.73;R=23.44;rawP=3.75e-19;adjP=2.38e-18	 Graft-versus-host	disease	 5332	C=81;O=19;E=1.09;R=17.47;rawP=1.52e-18;adjP=9.02e-18	 Rheumatoid	arthritis	 5323	C=52;O=15;E=0.70;R=21.48;rawP=2.06e-16;adjP=1.15e-15	 Allograft	rejection	 5330	C=59;O=15;E=0.79;R=18.93;rawP=1.68e-15;adjP=8.80e-15	 Type	I	diabetes	mellitus	 4940	C=64;O=15;E=0.86;R=17.45;rawP=6.32e-15;adjP=3.12e-14	 Leishmaniasis	 5140	C=81;O=16;E=1.09;R=14.71;rawP=1.43e-14;adjP=6.70e-14	 Cardiac	muscle	contraction	 4260	
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C=57;O=14;E=0.77;R=18.29;rawP=2.50e-14;adjP=1.11e-13	 NOD-like	receptor	signaling	pathway	 4621	C=118;O=18;E=1.58;R=11.36;rawP=3.73e-14;adjP=1.58e-13	 Osteoclast	differentiation	 4380	C=31;O=11;E=0.42;R=26.42;rawP=1.58e-13;adjP=6.39e-13	 Citrate	cycle	(TCA	cycle)	 20	C=67;O=14;E=0.90;R=15.56;rawP=2.80e-13;adjP=1.08e-12	 Autoimmune	thyroid	disease	 5320	C=56;O=13;E=0.75;R=17.29;rawP=4.65e-13;adjP=1.72e-12	 Cytosolic	DNA-sensing	pathway	 4623	C=137;O=17;E=1.84;R=9.24;rawP=5.96e-12;adjP=2.12e-11	 Hepatitis	C	 5160	C=125;O=16;E=1.68;R=9.53;rawP=1.54e-11;adjP=5.27e-11	 Natural	killer	cell	mediated	cytotoxicity	 4650	C=127;O=16;E=1.71;R=9.38;rawP=1.97e-11;adjP=6.49e-11	 Toxoplasmosis	 5145	C=76;O=13;E=1.02;R=12.74;rawP=2.94e-11;adjP=9.34e-11	 Complement	and	coagulation	cascades	 4610	C=82;O=13;E=1.10;R=11.81;rawP=7.97e-11;adjP=2.45e-10	 Hematopoietic	cell	lineage	 4640	C=83;O=13;E=1.11;R=11.66;rawP=9.34e-11;adjP=2.77e-10	 Hypertrophic	cardiomyopathy	(HCM)	 5410	C=46;O=10;E=0.62;R=16.19;rawP=4.75e-10;adjP=1.36e-09	 Malaria	 5144	C=100;O=13;E=1.34;R=9.68;rawP=1.02e-09;adjP=2.84e-09	 Chagas	disease	(American	trypanosomiasis)	 5142	C=86;O=12;E=1.15;R=10.39;rawP=1.95e-09;adjP=5.26e-09	 Apoptosis	 4210	C=89;O=12;E=1.20;R=10.04;rawP=2.92e-09;adjP=7.64e-09	 Dilated	cardiomyopathy	 5414	C=45;O=9;E=0.60;R=14.89;rawP=7.80e-09;adjP=1.98e-08	 Proteasome	 3050	C=149;O=14;E=2.00;R=7.00;rawP=1.69e-08;adjP=4.18e-08	 Systemic	lupus	erythematosus	 5322	C=153;O=14;E=2.05;R=6.81;rawP=2.37e-08;adjP=5.70e-08	 Jak-STAT	signaling	pathway	 4630	C=69;O=10;E=0.93;R=10.79;rawP=3.00e-08;adjP=7.03e-08	 RIG-I-like	receptor	signaling	pathway	 4622	C=90;O=11;E=1.21;R=9.10;rawP=3.80e-08;adjP=8.67e-08	 Fc	gamma	R-mediated	phagocytosis	 4666	C=35;O=7;E=0.47;R=14.89;rawP=3.72e-07;adjP=8.28e-07	 Prion	diseases	 5020	C=23;O=6;E=0.31;R=19.43;rawP=4.78e-07;adjP=1.04e-06	 Asthma	 5310	C=120;O=11;E=1.61;R=6.83;rawP=7.36e-07;adjP=1.56e-06	 Leukocyte	transendothelial	migration	 4670	C=43;O=7;E=0.58;R=12.12;rawP=1.62e-06;adjP=3.24e-06	 Intestinal	immune	network	for	IgA	production	 4672	C=43;O=7;E=0.58;R=12.12;rawP=1.62e-06;adjP=3.24e-06	 Pyruvate	metabolism	 620	C=216;O=14;E=2.90;R=4.83;rawP=1.64e-06;adjP=3.24e-06	 Regulation	of	actin	cytoskeleton	 4810	C=220;O=14;E=2.95;R=4.74;rawP=2.04e-06;adjP=3.95e-06	 Endocytosis	 4144	C=32;O=6;E=0.43;R=13.96;rawP=3.87e-06;adjP=7.33e-06	 African	trypanosomiasis	 5143	C=19;O=5;E=0.26;R=19.60;rawP=4.29e-06;adjP=7.95e-06	 Glyoxylate	and	dicarboxylate	metabolism	 630	C=34;O=6;E=0.46;R=13.14;rawP=5.61e-06;adjP=1.02e-05	 Primary	immunodeficiency	 5340	C=123;O=10;E=1.65;R=6.05;rawP=6.91e-06;adjP=1.23e-05	 Lysosome	 4142	C=76;O=8;E=1.02;R=7.84;rawP=8.61e-06;adjP=1.50e-05	 B	cell	receptor	signaling	pathway	 4662	C=137;O=10;E=1.84;R=5.44;rawP=1.79e-05;adjP=3.06e-05	 Tight	junction	 4530	C=27;O=5;E=0.36;R=13.79;rawP=2.72e-05;adjP=4.57e-05	 Galactose	metabolism	 52	C=48;O=6;E=0.64;R=9.31;rawP=4.37e-05;adjP=7.20e-05	 Fatty	acid	metabolism	 71	C=50;O=6;E=0.67;R=8.94;rawP=5.53e-05;adjP=8.95e-05	 Valine,	leucine	and	isoleucine	degradation	 280	C=268;O=13;E=3.60;R=3.61;rawP=8.08e-05;adjP=0.0001	 MAPK	signaling	pathway	 4010	
EMBL	C=1163;O=169;E=45.46;R=3.72;rawP=1.35e-60;adjP=1.89e-57	 abnormal	adaptive	immunity	 MP:0002420	C=1140;O=167;E=44.56;R=3.75;rawP=3.07e-60;adjP=2.15e-57	 abnormal	cell-mediated	immunity	 MP:0002421	C=1129;O=166;E=44.13;R=3.76;rawP=4.93e-60;adjP=2.30e-57	 abnormal	immune	cell	physiology	 MP:0001819	
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C=1105;O=162;E=43.20;R=3.75;rawP=4.62e-58;adjP=1.62e-55	 abnormal	leukocyte	physiology	 MP:0002442	C=868;O=141;E=33.93;R=4.16;rawP=7.48e-55;adjP=2.09e-52	 abnormal	immune	serum	protein	physiology	 MP:0002723	C=2113;O=215;E=82.60;R=2.60;rawP=4.39e-53;adjP=1.02e-50	 abnormal	immune	system	physiology	 MP:0001790	C=554;O=106;E=21.66;R=4.89;rawP=9.97e-47;adjP=1.99e-44	 abnormal	response	to	infection	 MP:0005025	C=514;O=99;E=20.09;R=4.93;rawP=1.16e-43;adjP=2.03e-41	 abnormal	cytokine	secretion	 MP:0003009	C=2645;O=227;E=103.40;R=2.20;rawP=1.55e-43;adjP=2.41e-41	 immune	system	phenotype	 MP:0005387	C=816;O=123;E=31.90;R=3.86;rawP=3.04e-43;adjP=4.26e-41	 abnormal	lymphocyte	physiology	 MP:0003945	C=519;O=97;E=20.29;R=4.78;rawP=1.65e-41;adjP=2.10e-39	 altered	susceptibility	to	infection	 MP:0001793	C=753;O=115;E=29.44;R=3.91;rawP=1.14e-40;adjP=1.33e-38	 abnormal	antigen	presenting	cell	physiology	 MP:0002452	C=388;O=83;E=15.17;R=5.47;rawP=7.74e-40;adjP=8.34e-38	 increased	susceptibility	to	infection	 MP:0002406	C=472;O=87;E=18.45;R=4.72;rawP=1.78e-36;adjP=1.78e-34	 abnormal	innate	immunity	 MP:0002419	C=1114;O=133;E=43.55;R=3.05;rawP=1.24e-35;adjP=1.16e-33	 abnormal	mononuclear	cell	morphology	 MP:0008247	C=297;O=69;E=11.61;R=5.94;rawP=2.43e-35;adjP=2.13e-33	 abnormal	cytokine	level	 MP:0008713	C=1235;O=140;E=48.28;R=2.90;rawP=2.90e-35;adjP=2.39e-33	 abnormal	leukocyte	morphology	 MP:0008246	C=302;O=69;E=11.81;R=5.84;rawP=7.61e-35;adjP=5.61e-33	 abnormal	intercellular	signaling	peptide	or	protein	level	 MP:0008835	C=1245;O=140;E=48.67;R=2.88;rawP=7.28e-35;adjP=5.61e-33	 abnormal	immune	system	cell	morphology	 MP:0000716	C=939;O=120;E=36.71;R=3.27;rawP=1.40e-34;adjP=9.80e-33	 abnormal	lymphocyte	morphology	 MP:0002619	C=494;O=84;E=19.31;R=4.35;rawP=1.92e-32;adjP=1.28e-30	 abnormal	T	cell	physiology	 MP:0002444	C=362;O=72;E=14.15;R=5.09;rawP=3.45e-32;adjP=2.20e-30	 abnormal	interleukin	secretion	 MP:0008568	C=232;O=57;E=9.07;R=6.28;rawP=1.60e-30;adjP=9.74e-29	 abnormal	interferon	secretion	 MP:0008555	C=522;O=82;E=20.41;R=4.02;rawP=4.16e-29;adjP=2.43e-27	 abnormal	protein	level	 MP:0008469	C=947;O=112;E=37.02;R=3.03;rawP=6.86e-29;adjP=3.84e-27	 abnormal	leukocyte	cell	number	 MP:0000217	C=1586;O=149;E=62.00;R=2.40;rawP=2.05e-28;adjP=1.10e-26	 abnormal	hematopoiesis	 MP:0002123	C=737;O=97;E=28.81;R=3.37;rawP=2.38e-28;adjP=1.23e-26	 abnormal	lymphocyte	cell	number	 MP:0000717	C=1563;O=147;E=61.10;R=2.41;rawP=5.39e-28;adjP=2.69e-26	 abnormal	immune	system	morphology	 MP:0000685	C=220;O=53;E=8.60;R=6.16;rawP=6.20e-28;adjP=2.99e-26	 abnormal	circulating	cytokine	level	 MP:0010210	C=1018;O=115;E=39.80;R=2.89;rawP=6.41e-28;adjP=2.99e-26	 abnormal	inflammatory	response	 MP:0001845	C=1604;O=149;E=62.70;R=2.38;rawP=7.28e-28;adjP=3.29e-26	 abnormal	blood	cell	morphology/development	 MP:0002429	C=209;O=51;E=8.17;R=6.24;rawP=3.56e-27;adjP=1.56e-25	 abnormal	interferon-gamma	secretion	 MP:0008559	C=297;O=60;E=11.61;R=5.17;rawP=3.85e-27;adjP=1.63e-25	 abnormal	macrophage	physiology	 MP:0002451	C=657;O=89;E=25.68;R=3.47;rawP=8.73e-27;adjP=3.59e-25	 decreased	leukocyte	cell	number	 MP:0000221	C=1117;O=119;E=43.67;R=2.73;rawP=1.23e-26;adjP=4.92e-25	 abnormal	hematopoietic	cell	number	 MP:0011180	C=200;O=49;E=7.82;R=6.27;rawP=3.28e-26;adjP=1.28e-24	 abnormal	interleukin	level	 MP:0008751	C=684;O=90;E=26.74;R=3.37;rawP=3.73e-26;adjP=1.41e-24	 abnormal	T	cell	morphology	 MP:0008037	C=1811;O=155;E=70.79;R=2.19;rawP=3.34e-25;adjP=1.23e-23	 abnormal	hematopoietic	system	morphology/development	 MP:0002396	C=440;O=69;E=17.20;R=4.01;rawP=2.55e-24;adjP=9.15e-23	 abnormal	circulating	protein	level	 MP:0005416	C=504;O=74;E=19.70;R=3.76;rawP=2.76e-24;adjP=9.66e-23	 abnormal	B	cell	physiology	 MP:0002459			 	
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